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The inTerTWineD ePiDeMics of DiabeTes anD obesiTy
The problem of overweight and obesity is vastly growing worldwide, with devastating 
consequences on health. For the Caucasian population, the defi nition of overweight is 
having a Body Mass Index (BMI) of 25-30 kg/m2, and with a BMI > 30 kg/m2 a person 
is considered obese (1). The World Health Organization estimated that in 2014 out of 5 
billion adults worldwide nearly 2 billion were overweight or obese (fi gure 1) (2).
In Europe, this problem is even bigger with over 50% of both men and women being 
overweight or obese, and the Netherlands are unfortunately no exception (4, 5). From 
1981 till 2015, the percentage of overweight Dutch adults increased from 33% to over 
50%, and the percentage of adults with obesity even increased threefold to 13.7% 
(fi gure 2) (4). One of the targets of the World Health Organization for 2025 is to halt the 
rise in the prevalence of obesity (6), since it’s a major risk factor for many other diseases 
such as cancers, heart diseases and in particular type 2 diabetes (T2D) (7). Persons who 
are overweight or obese have a three times and seven times greater risk of developing 
T2D, compared to those with a healthy weight (i.e. BMI 20-25 kg/m2) (8). It is estimated 
that 82-87% of all people with T2D are overweight or obese (9). Worldwide, 1 in every 
Global adult 
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8% T2D  
of whom 85% 
overweight or 
obese 
figure 1. The global prevalence of obesity and type 2 diabetes
Source: data of the Global Nutrition Report 2016 (3)
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12 adults has T2D (figure 1) (2). In the past decades, it has become more and more 
clear that the rise in prevalence of T2D goes alongside with the obesity epidemic (10).
WhaT Links obesiTy To TyPe 2 DiabeTes?
Since obesity and T2D are so closely related, the term ‘diabesity’ has been adopted 
by researchers in this field (11). There are several factors associated with both obe-
sity and T2D, including over-nutrition, lack of exercise, sleep deprivation, changes in 
gut microbiota, changes in hormones, etc. The transition from obesity to diabetes is 
characterized by a progressive augmentation in insulin resistance (a decreased tissue 
response to insulin) coupled with a deficit in insulin secretion (figure 3). It has been well 
documented that an increase in white adipose tissue results in elevated plasma free fatty 
acids (FFA) levels (12-14). Via multiple pathways, these FFAs induce hyperinsulinemia, 
which is one of the first steps towards diabetes (15). Moreover, adipose tissue excretes 
pro-inflammatory cytokines, inducing a state of chronic inflammation typical for obesity. 
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figure 2. Percentage of adults with overweight and obesity in The Netherlands from 1981-2015 (Source: 
RIVM) (4).
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This chronic inflammation and the accompanied oxidative stress also contribute to the 
development of insulin resistance (12-14). Moreover, oxidative stress and chronic inflam-
mation may cause beta cell dysfunction (16). The beta cells of the pancreas will initially 
respond to the state of insulin resistance by increasing the production of insulin. When 
ultimately this compensation fails because of beta cell dysfunction, insulin insufficiency 
and consequently hyperglycemia will occur and the person will be diagnosed with T2D. 
Importantly, insulin resistance can locally induce endothelial dysfunction, eventually lead-
ing to vascular complications (figure 4) (17).
WhaT are The consequences of obesiTy?
BMI is associated with coronary heart disease and stroke: for each 5 kg/m2 increase 
in BMI (above a BMI of 20 kg/m2), the risk of developing coronary heart disease is 
1.27 times higher and the risk of stroke is 1.18 times higher. These increased risks are 
largely mediated by high levels of cholesterol, glucose, and blood pressure (19). Obe-
sity increases mortality and reduces healthy life years, a finding which is consistent over 
Central Obesity  
Increased FFA flux 
Oxidative stress 
Hyperglycemia 
Insulin resistance β cell dysfunction 
Type 2 diabetes 
Dyslipidemia 
Hypercaloric diet  
Inflammation 
figure 3. The effects of obesity on metabolism, leading to type 2 diabetes
Visceral adipose tissue (‘central obesity’) releases free fatty acids (FFA) easily into the bloodstream. A hyper 
caloric diet also leads to an increase in FFA. This increased FFA flux into liver and muscle promotes insulin 
resistance, leading to hyperglycemia and dyslipidemia, and stimulates the production of radical oxygen spe-
cies inducing cell damage (‘oxidative stress’), leading to a chronic low-grade inflammation. This low-grade 
inflammation, typical for obesity, also induces insulin resistance. Oxidative stress and chronic inflammation 
may cause β cell dysfunction which together with increasing insulin resistance contributes to the development 
of type 2 diabetes.
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four continents (20). It has been estimated that in obese people aged 20-39 years, 6 
years of life are lost from diabetes and cardiovascular disease (CVD), with smaller losses 
in the elderly. The loss of healthy life years has been estimated as 2 to 4 times higher 
than the total life years lost (21). Moreover, adults with diabetes with an increased BMI 
have more vascular complications and increased mortality than those with a normal BMI 
(22-24). In the Swedish National Diabetes Register, 81% of the obese individuals with 
T2D had hyperlipidemia and 88% hypertension, both independent CVD risk factors. BMI 
is an independent predictor of these risk factors (25). In a large Japanese cohort study, 
persons with T2D and obesity were 2.2 times more likely to have diabetic nephropathy 
(chronic kidney disease) compared to normal weight T2D individuals, and even past 
obesity almost doubled the risk of nephropathy (22, 23). 
Apart from health problems and the accompanied loss of quality of life, obesity and 
diabetes also induce loss of income for the affected individual (26, 27). For society, 
the economic effects of obesity and its related diseases are detrimental: in the US, 
direct medical costs associated with obesity were estimated to have reached 114 billion 
Arterial lumen 
Arterial wall 
(endothelium) 
Muscle cells 
figure 4. The effects of obesity on vascular function. Adapted from: Potenza et al. (18)
Central obesity induces insulin resistance. Local insulin resistance of the endothelium decreases the produc-
tion of nitric oxide (NO) and stimulates the secretion of endothelin-1 (ET-1) from endothelial cells. As a result, 
the endothelium produces more adhesion molecules (for example soluble vascular cell adhesion molecule 1 
(sVCAM-1) and soluble intercellular adhesion molecule 1 (sICAM-1)) and molecules enhancing platelet ag-
gregation, like von Willebrand Factor (vWF), leading to an enhanced permeability of the endothelium, and 
more vasoconstriction and platelet aggregation. These changes can eventually lead to vascular complications 
and cardiovascular disease.
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dollars annually in 2008 (28). For the Netherlands in 2016, the direct medical costs of 
overweight, obesity and related diseases were estimated to be 1.7 billion euro (29). The 
largest part of this amount was spent on cardiovascular diseases and diabetes (29, 30).
Taken together, it is utterly important to reduce the global burden of obesity as well as 
diabetes. Unfortunately, recent global reports show that the rise in BMI still continues and 
that ‘the probability of meeting the global obesity target is virtually zero’ (31).
WhaT can be Done abouT obesiTy anD obesiTy-reLaTeD TyPe 
2 DiabeTes?
Lifestyle interventions
Since obesity and overweight are caused by an energy imbalance due to an increase 
in food intake and a decrease in physical activity, it seems logical to search for interven-
tions in nutrition and exercise. There is strong and consistent evidence that weight loss 
via diet and/or exercise can delay the onset of T2D (32, 33). In obesity-related T2D, 
lifestyle interventions aimed at weight loss have been shown to improve hyperglycemia, 
hyperlipidemia, hypertension, proteinuria, obstructive sleep apnea and quality of life, 
and to reduce the need for medications (34-41). In a prospective study in 4970 over-
weight individuals with diabetes, intentional weight loss was associated with a 25% 
reduction in overall mortality compared with weight stable individuals (42). However, 
in the only RCT conducted investigating the effect of an intensive lifestyle intervention on 
cardiovascular events (the Look AHEAD trial), no effect has been shown (43). This study 
has several limitations, potentially diminishing the effect, such as the non-blinded design, 
the higher use of cardio protective drugs in the control arm and the modest weight 
loss difference between the study arms because of weight regain. Behavioral lifestyle 
interventions typically include a diet with an energy-deficit of at least 500 kcal a day, 
daily exercise and behavioral interventions. Effective weight loss diets include low-fat 
diets, low-carbohydrate diets, high-protein diets and Mediterranean diets (43-47). In 
the guideline ‘obesity management for the treatment of T2D’ of the American Diabetes 
Association (48) it is stated that all these diets are equally effective if they create the 
same energy deficit. It was also stated that very low-calorie diets (VLCDs; a diet with an 
energy-intake limited to 450-800 kcal per day (49)) produce the greatest energy deficit, 
and thus the most weight loss, and are safe to use in T2D with close medical monitoring 
(48). These VLCDs normally consist of 2 or 3 meal replacements per day and at least 50 
grams of protein and daily requirements of vitamins and minerals. A VLCD is typically low 
in carbohydrates as well as in fat content. In a recent meta-analysis, the authors found 
that VLCDs induce more weight loss in obese people with T2D compared to usual care 
or compared to low calorie diets, with similar levels of adherence (50). Remarkably, a 
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VLCD has been shown to normalize both beta cell function and hepatic insulin sensitivity, 
hereby reversing the abnormalities underlying T2D (51).
anti-obesity drugs and bariatric surgery
Over the past decades, researchers have tried to find a pharmaceutical treatment for 
obesity and diabetes. Long term interventions with anti-obesity medications showed that 
they are modestly effective in reducing weight and CVD risk factors, at the expense of 
side effects such as gastro-intestinal complaints, raised blood pressure and pulse rate, 
and mood disorders (52, 53). Many of these drugs have already been withdrawn from 
the market because of safety concerns. New anti-diabetes treatments as glucagon-like 
peptide-1 (GLP-1) receptor agonists, dipeptidylpeptidase IV (DPP-4) inhibitors and sodium 
glucose cotransporter-2 (SGLT-2) inhibitors are very promising, achieving positive effects 
on both weight and glucose control in adults with diabetes (54). But also in obese indi-
viduals without T2D, GLP-1 receptor agonists have been shown to effectively decrease 
weight and reverse the pre-diabetes state (55).
Bariatric surgery is a therapeutic option for individuals with obesity and obesity-related 
T2D, resulting in favorable long-term outcomes on weight, diabetes remission and CVD 
risk profile (56-58). The gastric bypass procedure shows better results on weight and 
blood glucose levels than the gastric sleeve and gastric banding procedure (59, 60). 
Long-term data on survival, mental health and complications are currently lacking, mak-
ing gastric surgery not the first treatment option for obese persons. For persons with T2D 
in the Netherlands, bariatric surgery is only reimbursed by the health insurers in case of 
severe obesity (BMI > 35).
inDiviDuaL Differences in The effecTiveness of WeiGhT Loss 
DieTs
Although energy restricted diets are successful in reducing weight in obesity-related T2D, 
not all individuals equally benefit. There is a tremendous intra-individual variability in the 
effect of weight loss interventions: a substantial percentage of individuals is unsuccess-
ful in reducing weight via lifestyle interventions (61). Although the exact mechanisms 
underlying this variance are unknown, a number of predictors of weight loss have been 
identified over the past decades. However, these predictors only explain 20-30% of 
the variance in weight loss (62). Moreover, these predictors have been studied in the 
obese non-diabetic population, and obviously without including variables specific for 
diabetes. Since obesity-related T2D is a complex multifactorial disorder, a combination 
of psychological and physiological predictors of weight loss is hypothetically needed to 
explain a larger part of the variance of the efficacy of weight loss programs.
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The effecT of WeiGhT Loss DieTinG on carDiovascuLar 
Disease risk facTors
Classical cardiovascular disease (CVD) risk factors, such as high blood pressure, high 
blood glucose levels and an unfavorable lipid profile, are independently associated with 
both obesity and CVD, but they do not fully explain the association between overweight 
or obesity and cardiovascular disease (19). In addition to these classic CVD risk factors, 
atherosclerosis may be aggravated by other factors, such as systemic inflammation and 
endothelial dysfunction, which are typical for overweight and obese individuals (17, 
63). Visceral fat mass secretes pro-inflammatory cytokines and induces a free fatty acid 
(FFA) flux, subsequently leading to oxidative stress, insulin resistance and endothelial dys-
function (figure 3 and 4) (12). Impaired vascular function is an independent predictor of 
adverse cardiovascular outcomes (64, 65). In T2D, endothelial dysfunction and systemic 
inflammation have been linked to vascular complications and mortality (17, 66-72).
Diet-induced weight loss improves the classical CVD risk factors in overweight and 
obese adults with and without T2D (35-38). Moreover, weight loss improves vascular 
function and alleviates the inflammatory state (44, 63, 73-79). Individuals with T2D often 
receive multiple cardio-protective agents, such as metformin, statins and ACE-inhibitors, 
which also have been shown to improve endothelial function and chronic inflammation 
(17). It is unknown whether diet-induced weight loss still has an effect on endothelial 
function in T2D adults, who are on (maximum) cardio-protective medical treatment. 
Moreover, it is unknown if weight loss still has beneficial effects on endothelial function 
and inflammation at progressed stages of the disease.
A number of new candidate biomarkers for CVD risk have emerged and the effect of 
weight loss on these markers is fully unknown. Among them is lipoprotein(a) [lp(a)], an 
LDL-like particle with an additional apolipoprotein(a) molecule attached to it. High plasma 
Lp(a) concentration is an independent CVD risk factor, especially in individuals with T2D 
(80-85). Another example of a new biomarker for vascular impairment is low density 
lipoprotein receptor-relative with 11 ligand-binding repeats (LR11, also called SorLA or 
SORL1). LR11 is a type I membrane protein, which after proteolytic cleavage sheds a 
large soluble extracellular part called sLR11 into the circulation. LR11 and sLR11 have 
been shown to play a role in energy metabolism, atherosclerosis, and plaque formation 
(86-90). Increased plasma levels of sLR11 correlate with BMI and overall adipose tissue 
mass. In T2D, sLR11 correlates with coronary artery disease and retinopathy (91-93). 
The effect of weight loss on plasma levels of sLR11 has not been investigated before.
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The ProbLeM of WeiGhT reGain
As abovementioned, diet-induced weight loss improves CVD risk factors in overweight 
and obese individuals with T2D. However, in the Look AHEAD trial an intensive lifestyle 
intervention did not result in any effect on CVD events after 10 years of follow-up in adults 
with T2D, despite short-term favorable effects on CVD risk factors. Possible explanations 
of this lack of effect might have been the gradual regain of weight during follow-up or 
the use of cardio protective medication (43).
Weight regain after successful weight loss is a substantial problem in the treatment of 
obesity (94, 95). Almost anyone who has ever lost weight can confirm that it is more 
difficult to maintain weight loss than to lose weight. After a successful weight loss diet, 
only 20-50% of the dieters manages to maintain a clinically relevant weight loss of 
5-10% for more than 1 year (96, 97). Physiological reasons for weight regain include 
a decline in resting energy expenditure (98), increase of specific neural signals in the 
brain, leading to increased appetite and decreased non-resting energy expenditure (99-
101), and changes in hormones like leptin, ghrelin and insulin, increasing hunger signals 
and promoting energy storage (95, 97).
Apart from these physiological explanations for the difficulty of weight loss main-
tenance, also environmental and behavioral barriers have been identified (61, 95). 
We live in an ‘obesogenic’ environment, in which overconsumption of energy-dense 
foods is encouraged by their abundant availability, oversized portions and aggressive 
marketing (102). Above this, inactivity has become the standard due to our sedentary 
jobs, mechanized labor and motorized transportation (103). Successful weight loss 
maintainers have been shown to continue exercising on a daily basis and consuming 
an energy-balanced diet, even after they have reached their weight loss goal (104). 
Personal motivation, self-efficacy (the belief that one is able to successfully change one’s 
behavior) and behavioral techniques as self-monitoring and planning have been shown 
very important in that respect (105, 106). In the conventional treatment of obesity, 
dietitians personalize a weight loss diet to the individual needs and wishes, while ap-
plying different kinds of behavioral techniques, such as self-monitoring, planning, peer 
support, goal setting, etc. (107). Nonetheless, the adherence to the prescribed lifestyle 
regimen often decreases over time, possibly because the perceived ‘costs’ eventually 
outweigh the perceived ‘benefits’ of the lifestyle change (61). A permanent behavioral 
change is needed, and therefore, behavioral therapy is an important part of long-term 
weight management programs.
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coGniTive behavioraL TheraPy in WeiGhT Loss anD 
MainTenance
In this thesis, I focus on Cognitive Behavioral Therapy (CBT). CBT is a psychological 
approach to behavior change, aimed at identifying and changing aversive thinking 
patterns and mood states using behavioral experiments and challenges. It is widely 
used in the treatment of psychological disorders including eating disorders (108-110). 
Cognitive approaches to weight loss and maintenance focus on identifying dysfunctional 
cognitions and beliefs that affect lifestyle, like thoughts regarding self-image, diet, exer-
cise, unrealistic goal-setting and prior relapses. In cognitive behavioral (group) therapy 
(CB(G)T), these thoughts are identified and modified in order to facilitate behavioral 
change and subsequently weight loss and maintenance. For example, all-or-nothing 
thinking (‘I ate one cookie, so my diet is ruined for today. I might as well eat the whole 
lot’) is a common dysfunctional thinking pattern of unsuccessful dieters (111, 112). With 
cognitive restructuring, these thoughts can be challenged and replaced by more realistic 
ones, ultimately facilitating behavior leading to weight loss. CB(G)T has been shown to 
effectively reduce weight in obese individuals without diabetes, mostly when combined 
with diet and/or exercise (36, 111, 113-121). In international clinical guidelines for the 
management of obesity, CBT or ‘cognitive restructuring’ is recommended as a behavioral 
treatment option to facilitate weight loss (122, 123). Also in adults with type 2 diabetes, 
one prospective and one retrospective cohort study showed favorable effects of CBGT 
on long-term weight loss, when combined with other lifestyle interventions (124, 125). 
Other specific cognitive behavioral strategies as Proactive Coping and Problem Solving 
Therapy have also been shown to enable weight loss (126, 127). CBT can be provided 
one-on-one or in a group. The advantages of individual therapy are more personal 
attention and possibly less drop-out, while group therapy provides social support and is 
less costly. In obesity research, individual CBT has been shown equally or less effective 
than CBGT (128-131).
Apart from promoting weight loss, there is some evidence that CBGT is effective 
in maintaining weight, or reducing weight regain, after losing weight via diet (116, 
117). Sbrocco et al. (117) showed that in 24 obese women, who lost weight via an 
intervention focusing on diet and exercise, weight regain occurred in the group random-
ized to traditional behavioral treatment (control condition), while in the group with a 
CBGT-based intervention, a continued slow weight loss was seen during follow-up. In 
the study of Werrij et al. (116), 204 overweight and obese participants lost on average 
5% of their bodyweight via diet. Subsequently, they were randomly assigned to diet plus 
CBGT or diet plus exercise (control). After a 1-year follow-up, CBGT was effective in 
maintaining diet-induced weight loss, while exercise alone was not. Abovementioned 
studies were conducted in non-diabetic obese participants only, so whether a CBGT 
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intervention is effective in reducing weight regain after weight loss dieting in adults with 
T2D is unknown. 
The currenT Thesis: LonG-TerM effecTiveness of cbGT on 
WeiGhT MainTenance in T2D
In this thesis, I studied whether CBGT is effective in preventing weight regain during 2 
years after VLCD-induced weight loss in overweight and obese adults with T2D. Further, I 
determined which physiological and psychological factors predict successful diet-induced 
weight loss in overweight and obese T2D individuals, and the effect of short-term weight 
loss on specific CVD risk markers and the interaction with cardio-protective medication.
aims of this thesis
The primary aim of the current thesis is:
– To determine the effect of cognitive behavioral group therapy on maintaining 
weight during 2 years of follow-up after weight loss via a very low-calorie diet 
in overweight and obese adults with type 2 diabetes.
The secondary aims are:
– To evaluate the effects of cognitive behavioral group therapy on cardiovascular 
risk factors and psychological wellbeing during 2 years of follow-up after 
weight loss via a very low-calorie diet.
– To determine which individuals benefit most from a very low-calorie diet.
– To determine the short-term effect of diet-induced weight loss on glycemic 
parameters and cardiovascular disease risk factors.
To this end, we set up the Prevention Of Weight Regain (POWER) trial, which is a 
2-phase study in overweight and obese adults with T2D from a single tertiary center, the 
Erasmus Medical Center, Rotterdam, the Netherlands. During the first phase, participants 
followed a very low-calorie diet (VLCD) for 8 weeks. The participants, who successfully 
lost weight via the VLCD, entered the second phase with a duration of 2 years. At the 
start of the second phase, the participants were randomized to CBGT or usual care. 
After the first phase, all participants continued with a low-calorie diet (LCD) for 12 weeks, 
and thereafter a diet aiming at weight maintenance was advised. At the end of the first 
phase, we examined which characteristics best predicted successful weight loss, and 
assessed the effect of the diet-induced weight loss on glycemic parameters and CVD risk 
factors. During and at the end of the second phase, we determined the effect of CBGT 
on weight regain.
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outline of this thesis
Chapter 2 examines which physiological and psychological variables predict short term 
diet-induced weight loss, and whether a prediction model of VLCD-induced weight loss 
in T2D can be developed.
In chapter 3, I report the effect of diet-induced weight loss on classical cardiovascular 
risk factors and biomarkers of endothelial dysfunction and inflammation in overweight 
and obese adults with T2D. In addition, we investigated whether this effect was influ-
enced by the use of cardio-protective drugs (statins, ACE inhibitors, metformin) and the 
duration of T2D.
The effects of diet-induced weight loss on sLR11 and Lp(a) in T2D are unknown. 
Chapter 4 focusses on the effect of diet-induced weight loss on plasma sLR11 levels in 
overweight and obese individuals with T2D.
In chapter 5, we examine the effect of weight loss via diet or bariatric surgery on Lp(a) 
levels in overweight and obese individuals with and without T2D. The effect of diet was 
assessed in the participants of the POWER trial, in an independent cohort of overweight 
and obese subjects with T2D, and in a cohort of obese subjects without T2D. The effect 
of bariatric surgery was assessed in a cohort of obese subjects without T2D.
Chapter 6 is the protocol of the Prevention Of Weight Regain (POWER) trial, in which 
we describe the rationale of the study, the interventions, sample size calculations, ran-
domization, methods of statistical analyzation and pilot data.
In chapter 7, I report the results of the POWER trial, in which we investigated the 
2-years efficacy of CBGT compared to usual care, in preventing weight regain after a 
VLCD in overweight and obese adults with T2D.
In chapter 8, I discuss the main findings of this thesis and place them in a broader 
perspective: methodological considerations, potential clinical implications, including the 
results of an implementation study of VLCD, and future research are the main topics.
Chapter 1
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absTracT
background and aims
A very low calorie diet improves the metabolic regulation of obesity related type 2 
diabetes, but not for all patients, which leads to frustration in patients and professionals 
alike. The aim of this study was to develop a prediction model of diet-induced weight 
loss in type 2 diabetes.
Methods
192 patients with type 2 diabetes and BMI>27 kg/m2 from the outpatient diabetes 
clinic of the Erasmus Medical Center underwent an 8-week very low calorie diet. 
Baseline demographic, psychological and physiological parameters were measured 
and the C-index was calculated of the model with the largest explained variance of 
relative weight loss using backward linear regression analysis. The model was internally 
validated using bootstrapping techniques.
results
Weight loss after the diet was 7.8±4.6 kg (95%CI 7.2-8.5; p<0.001) and was inde-
pendently associated with the baseline variables fasting glucose (B=-0.33 (95%CI -0.49, 
-0.18), p=0.001), anxiety (HADS; B=-0.22 (95%CI -0.34, -0.11), p=0.001), numb 
feeling in extremities (B=1.86 (95%CI 0.85, 2.87), p=0.002), insulin dose (B=0.01 
(95%CI 0.00, 0.02), p=0.014) and waist-to-hip ratio (B=6.79 (95%CI 2.10, 11.78), 
p=0.003). This model explained 25% of the variance in weight loss. The C-index of 
this model to predict successful (≥5%) weight loss was 0.74 (95%CI 0.67-0.82), with 
a sensitivity of 0.93 (95% CI 0.89-0.97) and specificity of 0.29 (95% CI 0.16-0.42). 
When only the obese T2D patients (BMI>30 kg/m2; n = 181) were considered, age 
also contributed to the model (B=0.06 (95%CI 0.02, 0.11), p=0.008), whereas waist-
to-hip ratio did not.
conclusions
Diet-induced weight loss in overweight adults with T2D was predicted by five baseline 
parameters, which were predominantly diabetes related. However, failure seems difficult 
to predict. We propose to test this prediction model in future prospective diet intervention 
studies in patients with type 2 diabetes.
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inTroDucTion
The metabolic regulation of obesity-related type 2 diabetes improves with diet-induced 
weight loss. A very low calorie diet is successful in that respect, but unfortunately not in 
all patients, which leads to feelings of failure and reduction of cost-effectiveness of the 
treatment. A prediction model of weight loss can assist selecting those individuals that 
will benefit most.
The dramatic rise in the world-wide prevalence of obesity has led to a rising prevalence 
of T2D. It is estimated that 82-87% of the T2D population are overweight or obese (1). 
In patients with T2D, a high BMI and waist circumference are associated with increased 
mortality (2, 3). Conversely, moderate weight loss improves glycaemic control, lipid 
profile and blood pressure in these individuals and has been associated with reduced 
mortality (4-6). Therefore, weight loss is an important aspect of treatment of T2D. Weight 
loss of more than 5% results in important health benefits and reduces health care costs 
(7, 8). However, not all individuals that are overweight or obese achieve and maintain 
5% weight loss or more with lifestyle interventions (6, 9). Predictors of weight loss may 
be very helpful in optimizing individualized weight loss strategies and in selecting those 
individuals who will benefit most from a diet, ultimately improving treatment outcome 
and reducing health care costs. In adults with obesity, a number of physiological and 
psychological predictors of weight loss have been identified. These include sex, previous 
dieting for weight loss, initial weight, motivation, self-efficacy, self-esteem and exercise 
(10, 11). However, these predictors of weight loss have not been studied in subjects with 
T2D, and diabetes-specific variables have not been included in previous research in this 
field. Both psychological and physiological factors are most probably of importance, as 
obesity-related T2D is a complex multifactorial disease.
Therefore, the purpose of the present study was to identify which factors predict diet-
induced weight loss in overweight and obese adults with T2D, using psychological, 
physiological as well as diabetes-related variables.
MaTeriaLs anD MeThoDs
We enrolled participants of the run-in phase of the Prevention Of Weight Regain (POWER) 
trial of which the protocol has been published previously (12). This study was approved 
by the Medical Ethics Committee of the Erasmus Medical Center in Rotterdam (reference 
number MEC-2009-143/NL26508.078.09), in compliance with the Helsinki Declara-
tion. All participants provided written informed consent before participating in this study.
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study population
Patients with T2D having BMI>27 kg/m², whose age was 18-75 years, were recruited 
from the outpatient diabetes clinic of the Erasmus Medical Center, Rotterdam from 
2010-2013. Exclusion criteria were pregnancy, lactation, severe psychiatric problems, 
significant cardiac arrhythmias, unstable angina, decompensated congestive heart fail-
ure, major organ system failure, untreated hypothyroidism, and end-stage renal disease. 
Patients who had a myocardial infarction, cerebrovascular accident or major surgery 
during the previous 3 months were also excluded.
Diet intervention and data collection
Intervention
After signing informed consent, participants followed a Very Low Calorie Diet (VLCD) for 
a period of 8 weeks. The VLCD consisted of 2 commercially available meal replacements 
per day (Glucerna SR®, Abbott Nutrition BV), plus 75 grams of lean meat, one skimmed 
milk product and vegetables. Daily intake was approximately 750 kcal. Participants 
received oral and written instructions on how to follow this diet at home. Before the 
start of the diet the anti-diabetes medication was lowered to prevent hypoglycaemia: 
oral anti-diabetic agents (except metformin) and short-acting insulin analogues were 
discontinued, while the doses of long-acting insulin analogues and biphasic mixtures 
were halved. GLP-1 analogues and DPP-4 inhibitors were continued. One week after 
starting the diet, participants received a phone call of the research team. A structured 
discussion about blood glucose measurements, questions about the diet, problems with 
adherence to the diet, and complaints was performed. Participants were encouraged to 
follow the dietary recommendations of the study and to weekly email their blood glucose 
measurements. The insulin dose was adjusted during the diet period based on these daily 
glucose measurements.
Measures and outcomes
The primary outcome was weight loss, expressed as a percentage of baseline body-
weight. At baseline and at the end of the diet intervention bodyweight was measured. 
Weight loss was considered ‘successful’ if ≥5% reduction of baseline body weight 
was achieved. Moderate weight loss of ≥5% is considered by the American Diabetes 
Association and the European Association of the Study of Diabetes to produce significant 
health benefits (13, 14).
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Besides age and sex, the baseline variables were as follows:
1. Weight and BMI
 Weight was measured to the nearest 0.1 kg using the same Seca 888 compact 
digital flat scale after removal of shoes. Height was measured to the nearest 0.5 cm 
without shoes using a Seca stadiometer.
2. Waist circumference and waist-to-hip ratio
 Waist circumference (cm) was measured at the level midway between the lowest 
rib margin and the aliac crest. Hip circumference was measured at the widest point 
over the buttocks. Both waist- and hip circumference were measured by the nearest 
0,5 cm, using a tape-measure. Subsequently, waist-hip ratio (WHR) was calculated.
3. Glycemic control
 a.  Fasting glucose, measured using standard laboratory techniques
 b.  Hemoglobin A1c (HbA1c), measured using standard laboratory techniques
 c.  Total daily insulin dose (IU/day)
 d.  Total daily metformin dose (mg/day)
4. Physical complaints related to diabetes
 a.  Polyuria (yes/no)
 b.  Pruritus (yes/no)
 c.  Eye problems (yes/no)
 d.  Numbness in extremities (yes/no)
5. Exercise
 Days per week ≥30 minutes of exercise
6. History of dieting for weight loss
 Number of weight loss attempts
7. Fatigue
 Measured by the Checklist Individual Strength (CIS) (15), which consists of 20 state-
ments for which the respondent has to indicate on a 7-point scale (from true to false) 
to what extent the particular statement applies to him or her. The statements refer to 
four fatigue aspects: (1) subjective fatigue (2) reduced motivation (3) reduced activ-
ity and (4) reduced concentration. People with a score above 76 are at increased 
risk of long-term sickness absence.
8. Depression and anxiety
 Measured by the Hospital Anxiety and Depression scale (HADS). The HADS consists 
of a 7-item Anxiety scale and a 7-item Depression Scale. Each item is scored from 
0 to 3. A total score on either scale below 8 excludes anxiety or depression, re-
spectively. A score of 8–10 and 11-21 indicates a possible and probable anxiety/
depression, respectively (16).
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9. Quality of life
 Measured by the EQ-5D VAS score, ranging from 0 (death) to 100 (perfect health) 
(17, 18)
10. Self-esteem
 Measured by the Rosenberg Self-esteem Scale (RSE), which is a 10-item question-
naire that measures global self-esteem. Items are scored on a 4-point scale. A 
higher score indicates a more positive self-esteem. Scores below 21 indicate low 
self-esteem (19)
11. Eating disorders
 a.  Measured by the Eating Disorder Examination-Questionnaire (EDE-Q), a 36 
item questionnaire that measures concerns about shape, weight and eating, 
restraint and binge eating. Total EDE-Q score range between 0–6. A higher 
score indicates more severe eating psychopathology (20).
 b.  Binge eating disorder (BED), measured by use of the DSM-V criteria (yes/no)
All data were filed in a database using a trial management system (OpenClinica®).
statistical analysis
Variables at baseline were expressed as number with percentage or mean with standard 
deviation. Prior to analysis, missing data were imputed using regression imputation. 
Participants with more than 50% missing data were excluded. For 7 participants, whose 
body weight at the end of the diet intervention was not available due to attrition, we 
assumed 0% weight loss. We analysed the data according to the intention-to-treat as well 
as the per-protocol principle, leaving those 7 patients out of the analysis. The average 
weight loss was analysed using a paired samples t-test. The difference between groups 
at baseline was tested with a Chi-Square test, an independent samples t-test or a Mann-
Whitney U test, depending on normality of the data. Potential predictors were identified 
by univariate regression analyses with percentage weight loss as dependent variable. 
Subsequently, all variables were entered into a multiple regression analysis. The least in-
formative covariates were successively removed from the model in a backward stepwise 
elimination procedure based on the Akaike information criterion (AIC)(21). We accepted 
a maximum Variance Inflation Factor of 5 to exclude multicollinearity problems. Each step 
of the backward regression analysis was internally validated using bootstrapping (22). 
In short, 1000 bootstrap cohorts (of equal size as the original dataset) were randomly 
drawn, with replacement, from the cases in the original dataset. Logistic regression was 
applied to predict successful (≥ 5% = 1) and unsuccessful (< 5% = 0) weight loss. The 
relationship between false positives (1 - specificity) and true positives (sensitivity) of this 
prediction was presented in a ROC (Receiving Operating Characteristic) curve. For the 
dichotomized prediction, the sensitivity, specificity and positive predictive value were 
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calculated. Statistical significance was set at p < 0.05. All data processing and analyses 
were carried out in SPSS (version 21).
resuLTs
From March 2010 to May 2013, we assessed 296 patients with BMI>27 kg/m2 and 
T2D from our out-patient diabetes clinic, of whom 276 were eligible and 206 were 
willing to participate in this study (Fig 1). Individuals who declined to participate were 
older (58.0 (49.8-64.0) years vs. 53.5 (47.0-61.8) years, p=0.04) and more often 
male (61% vs. 42%, p=0.005) than the individuals who were willing to participate in 
this study. Ethnicity did not differ. The main reasons for the declined participation were 
work related and lack of time. Fourteen participants did not fill out the questionnaires and 
did not provide blood samples, hence we collected data from 192 participants.
Table 1 shows baseline characteristics of our study population, of which 58% were 
female. Of the participants, 181 (94.3%) had a BMI>30 kg/m2, thus qualified as 
obese. Mean HbA1c and fasting glucose levels were well above target levels despite 
antidiabetic medication. Sixty-two percent of the participants used insulin (62.0±63.9 
IU/day). According to the HADS norm, 18% had a clinical depression and 20% a 
clinical anxiety disorder. Twelve participants (6.3%) used antidepressants (self-reported).
296 patients with type 2 
diabetes and BMI>27 kg/m2 
assessed for inclusion 
90 patients excluded: 
20 not eligible after 
reassessement 
70 declined to participate 
206 patients started the 
diet intervention 
Data incomplete for 14 
patients 
192 patients included 
 
8 weeks of VLCD 
 
figure 1. Study flow chart
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After 8 weeks of VLCD, participants had lost 7.8±4.6 kg (95%CI 7.2-8.5; p<0.001). 
Twenty-five percent of the participants lost less than 5%, 28% lost 5-7.5%, 21% lost 
7.5-10% and 26% lost more than 10% of their bodyweight. Compared with the suc-
cessful weight loss group, the unsuccessful weight loss group (i.e. <5%) showed higher 
levels of HbA1c and fasting glucose, and were more likely to have pruritus and a lower 
self-esteem (p<0.01).
Table 1. General baseline characteristics (n = 192)
Characteristics Value, mean ± SD (range)
  Age (y) 54.2 ± 10.6 (26-75)
  Sex, female (n (%)) 112 (58%)
  Exercise (weekly days ≥30 min. exercise) 5.3 ± 2.3 (0-7)
Physiological variables:  
  Weight (kg) 106.0 ± 19.0 (69.4-169.2)
  BMI (kg/m2) 37.0 ± 5.6 (27.3-62.6)
  Waist circumference (cm) 120.2 ± 13.3 (90-163) 
  Waist-to-hip ratio 1.0 ± 0.1 (0.8 -1.3)
  HbA1c (mmol/mol) 63.9 ± 15.2 (32-126)
  HbA1c (%) 8.0 ± 1.4 (5.1-13.7) 
  Fasting glucose (mmol/l) 9.5 ± 3.2 (3.2-21.1)
  Insulin dose (IU)*
    and users (n (%))
100.1 ± 52.7 (8-248)
119 (62%)
  Metformin dose (mg)* 1774.8 ±754.2 (500-3000)
    and users (n (%)) 154 (80%) 
  Numb feeling in extremities (n (%)) 96 (50%)
  Polyuria (n (%)) 57 (30%)
  Pruritus (n (%)) 37 (19%)
  Diabetes-related eye problems (n (%)) 45 (23%)
Psychological variables:  
  Depression score (HADS 0-20);
  Clinical depression (n (%))
7.0 ± 4.0 (0-20)
35 (18%)
  Anxiety score (HADS 0-20); 6.6 ± 4.3 (0-20)
  Clinical anxiety disorder (n (%)) 38 (20%) 
  Self-esteem (RSE 0-40) 30.6 ± 5.6 (13-40)
  Quality of life (EQ5D VAS 1-100) 58.8 ± 21.0 (10-100)
  Fatigue (CIS total score 20-140) 80.9 ± 23.8 (25-133)
  Eating disorders (EDE-Q total score 0-6) 2.2 ± 1.2 (0-5.4)
  Binge eating disorder (DSM V, n (%)) 11 (6%)
  Diet history (no. of weight loss attempts) 1.0 ± 1.1 (0-5)
*dose only in users
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In univariate regression analyses (table 2), age, waist-to-hip ratio, numb feeling in 
extremities, and self-esteem were all positively associated with relative weight loss, while 
female sex, fasting glucose, HbA1c, pruritus and anxiety were negatively associated 
with relative weight loss.
Table 3 shows the results of the multiple linear regression analysis. Since both fasting 
glucose and HbA1c, and waist circumference and waist-to-hip ratio were strongly cor-
related (p<0.001), we included only fasting glucose and waist-to-hip ratio in the multi-
variate analysis to avoid multicollinearity problems. In the backward stepwise elimination 
multiple regression analysis (using bootstrapping), the final model contained 5 baseline 
variables which were independently associated with relative weight loss: the higher the 
Table 2. Univariate linear regression analysis of relative weight loss with baseline variables
Covariate B SE β p
  Age (y) 0.086 0.026 0.237 0.001
  Sex (female) -1.908 0.547 -0.246 0.001
  Exercise (weekly days ≥ 30 min. exercise) 0.137 0.119 0.083 0.251
     
Physiological variables:     
  Weight (kg) 0.014 0.015 0.071 0.325
  Waist circumference (cm) 0.040 0.021 0.137 0.058
  Waist-to-hip ratio 10.160 2.927 0.244 0.001
  Fasting glucose (mmol/l) -0.311 0.085 -0.257 <0.001
  HbA1c (mmol/mol) -0.046 0.018 -0.181 0.012
  Insulin dose (IU) 0.008 0.004 0.131 0.070
  Insulin dose change during diet (IU) -0.019 0.006 -0.245 0.001
  Metformin dose (mg) <0.0001 <0.0001 0.007 0.922
  Numbness in extremities (n=0/y=1) 1.792 0.540 0.234 0.001
  Polyuria (n=0/y=1) 0.019 0.608 0.002 0.976
  Pruritus (n=0/y=1) -1.732 0.693 -0.178 0.013
  Diabetes-related eye problems (n=0/y=1) -0.648 0.654 -0.072 0.324
     
Psychological variables:     
  Depression score (HADS 0-20) -0.132 0.070 -0.136 0.060
  Anxiety score (HADS 0-20) -0.223 0.062 -0.252 <0.001
  Self-esteem (RSE 0-40) 0.126 0.049 0.184 0.011
  Quality of life (EQ5D VAS 1-100) 0.024 0.013 0.131 0.071
  Fatigue (CIS total score 20-140) -0.011 0.012 -0.065 0.371
  Eating disorders (EDE-Q total score 0-6) -0.276 0.238 -0.084 0.247
  Binge eating disorder (DSM V, n=0/y=1) 0.049 1.189 0.003 0.967
  Diet history (no. of weight loss attempts) -0.111 0.248 -0.032 0.656
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reported numb feeling in extremities (B=1.86 (95%CI 0.85, 2.87), p=0.002), insulin 
dose (B=0.01 (95%CI 0.00, 0.02), p=0.014) and waist-to-hip ratio (B=6.79 (95%CI 
2.10, 11.78), p=0.003), and the lower the fasting glucose level (B=-0.33 (95%CI 
-0.49, -0.18), p=0.001) and anxiety score (HADS; B=-0.22 (95%CI -0.34, -0.11), 
p=0.001), the greater the relative weight loss. These five parameters together explained 
25% of the variance of relative weight loss (R2 = 0.25, F(5) = 12.54, p<0.001). In 
Fig 2, we show the ROC curve of our intention-to-treat model in discriminating unsuc-
cessful (<5%) from successful (≥5%) weight loss, which had a C-index of 0.74 (95%CI 
0.67-0.82). The logistic model had 0.80 (95% CI 0.74-0.86) post-test likelihood of 
predicting successful weight loss and 0.58 (95% CI 0.39-0.78) post-test likelihood 
of predicting unsuccessful weight loss. The model yielded 134 true positive, 34 false 
positive, 10 false negative and 14 true negative predictions. Hence, the sensitivity 
of this model was 0.93 (95% CI 0.89-0.97) and the specificity was 0.29 (95% CI 
0.16-0.42). When we corrected this model for change in insulin dose during the diet, 
the five baseline variables remained significantly associated with relative weight loss; 
the model now explained 30% of the variance of weight loss (R2 = 0.30, F(6) = 13.31, 
p<0.001) and discriminated successful from unsuccessful weight loss with a C-index of 
0.75. However, the VIF statistics for insulin dose and insulin change was 7, indicating 
possible multicollinearity problems.
We conducted the multivariate regression analysis in a backward stepwise manner, to 
obtain the optimal model. Alternatively, putting all the univariately associated variables 
(p<0.1) in the multivariate regression model only marginally affected the performance of 
the model (R2 = 0.29, F(11) = 6.53, p<0.001; C-index = 0.77).
Variables entered into the model: age; sex; weight; waist-to-hip ratio; fasting glucose; 
total daily insulin dose; total daily metformin dose; physical complaints related to diabetes 
(polyuria, pruritus, eye problems, numbness in extremities, all yes/no); exercise (days per 
week ≥30 minutes of exercise); history of weight loss dieting (number of different diets); 
fatigue (Checklist Individual Strength); depression and anxiety (Hospital Anxiety and 
Depression scale); quality of life (EQ-5D VAS score); self-esteem (Rosenberg self-esteem); 
eating disorders (EDE-Q); and binge eating disorder (DSM-V criteria, yes/no).
When we excluded the 7 participants who did not finish the diet intervention (per 
protocol analysis), the model slightly improved, as indicated by the additional contribution 
of the variables pruritus and quality of life (EQ5D VAS). The lower the reported pruritus 
and the higher the perceived quality of life, the greater was the weight loss. This model 
explained 30% of the variance of relative weight loss (R2 = 0.30, F(8) = 9.29, p<0.001) 
and discriminated successful from unsuccessful weight loss with a C-index of 0.79.
We also performed the analysis for the obese subgroup (BMI>30 kg/m2; n=181) 
only. Compared to the entire study population, age now also contributed to the model 
(B=0.06 (95%CI 0.02, 0.11), p=0.008), whereas waist-to-hip ratio was removed from 
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the model in the backward elimination procedure. The model containing fasting glucose, 
insulin dose, age, numb feeling in extremities and anxiety score explained 25% of the 
variance of relative weight loss (R2 = 0.25, F(5) = 11.84, p<0.001), and discriminated 
successful from unsuccessful weight loss with a C-index of 0.73.
figure 2. ROC Curve of multiple logistic regression model of successful relative weight loss (≥5%)
Variables included in the multiple linear regression model: fasting glucose level, insulin dose, waist-to-hip ratio, 
numb feeling in extremities and anxiety score.
Table 3. Multiple linear regression model (backward stepwise elimination using bootstrapping) of relative 
weight loss with baseline variables
Variable B 95%CI
Lower
95%CI
Upper
R2 p
Fasting glucose (mmol/l) -0.332 -0.485 -0.180 0.078 0.001
Insulin dose (IU) 0.010 0.002 0.018 0.032 0.014
Waist-to-hip ratio 6.790 2.096 11.775 0.025 0.003
Numbness in extremities 1.860 0.853 2.874 0.065 0.002
Anxiety (HADS) -0.219 -0.344 -0.111 0.056 0.001
Explained variance in this model R2 = 0.25, F(5) = 12.54, p<0.001; C-index = 0.74
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Discussion
In this pragmatic explorative study, we found that successful diet-induced weight loss can 
be predicted in overweight adults with T2D by the baseline variables fasting glucose, 
anxiety, numb feeling in extremities, insulin dose and waist-to-hip ratio. However, failure 
seems more difficult to predict. Surprisingly, the ‘usual suspects’ in predicting weight loss 
in individuals with obesity but without T2D, such as initial weight, diet history, self-esteem 
and exercise, did not contribute to the model. Remarkably, 3 out of 5 predictors in 
the model were related to diabetes. This suggests that diabetes control is of major 
importance for overweight and obese patients with T2D, who aim at losing weight, more 
than factors that are most relevant in non-diabetic persons with obesity.
Our data showed that participants with a higher baseline fasting glucose and, hence, 
worse diabetes control were less successful in achieving weight reduction. One could 
speculate that controlling diabetes might require skills that are also important in control-
ling weight. A recent review by Ahola, et al. found that factors associated with good 
management of diabetes included individual issues such as self-efficacy, motivation, 
coping and problem-solving skills, as well as issues related to the environment such as 
social support and socio-economic factors (23). All of these factors have been linked with 
successful weight loss as well (10). Alternatively, participants with a high fasting glucose 
may lose energy through glycosuria. Losing weight reduces blood glucose levels in T2D 
(6) and subsequently the energy deficit due to glycosuria may disappear, leading to a 
disadvantage in weight loss for participants with a very high fasting glucose at baseline.
We identified anxiety as an unexpected negative predictor for weight loss. Among 
our participants with T2D, the prevalence of anxiety disorder was as high as 20%. 
This is higher than the prevalence of anxiety disorder in the Dutch population (7.7% for 
males and 12.5% for females (24)), and in line with previous studies in T2D (25). While 
anxiety has not been extensively studied in the context of weight control, it has been cor-
related with a defensive coping style: avoiding problems rather than solving them (26). 
In diabetes, an anxious, defensive coping style has been associated with decreased 
adherence to therapy (27). Similarly, in our study anxiety could have led to a decreased 
adherence to the diet. A more autonomous coping strategy has been shown to correlate 
better with the capability to lose weight than a defensive coping style (11, 28). It would 
be interesting to test whether treating anxiety prior to the diet intervention would improve 
the success rate of a weight loss diet.
Baseline insulin dose was positively associated with weight loss. Before starting with 
the VLCD, we reduced the insulin dose by more than 50% to avoid hypoglycaemic 
events. Insulin use has been associated with weight gain due to the stimulation of li-
pogenesis and a reduction of lipolysis and glycosuria (29). Lowering the insulin dose 
could have had the opposite effect, where participants on a high baseline dose could 
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have had more benefit from the greater absolute reduction of insulin dose. Reducing the 
insulin dose before a weight loss attempt is important to prevent hypoglycaemia, but it 
may also enhance weight loss. Indeed, baseline insulin dose and change in insulin dose 
were highly correlated (r=-0.929, p<0.001), so the association of baseline insulin with 
weight loss could very well have been the effect of lowering the insulin dose. However, 
when we corrected the model for change in insulin dose, baseline insulin dose was still 
significantly associated with relative weight loss.
Experiencing a numb feeling in extremities was positively associated with the rela-
tive weight loss. Of the participants who lost less than 5% weight, 35% reported this 
complaint, compared with 55% in the successful weight loss group. A numb feeling 
in extremities could be associated with diabetic neuropathy. Indeed, numbness was 
significantly correlated with a history of diabetic neuropathy (data not shown) and 
therefore probably with the severity of complications. Complications or perceiving more 
complaints could be a motivational trigger for patients to adhere to the diet regimen, 
although this has not been studied previously.
Participants with a higher waist-to-hip ratio and to a lesser extent waist circumference, 
i.e. more abdominal fat, were more prone to lose weight in our study population. Moder-
ate weight loss, particularly by a VLCD, has been shown to result in preferential loss of 
visceral fat mass (30). Visceral fat mass is associated with reduced insulin sensitivity and 
increased systemic low-grade inflammation (2, 31). Men tend to have a higher waist-to-
hip ratio than women, as was the case in our population (1.07±0.07 vs. 0.94±0.06, 
p<0.001). Since males have a higher energy expenditure compared to women, and 
the diet intervention was the same for both men and women, the association we found 
could be explained by the higher energy deficit for the male participants. Accordingly, 
the univariate analysis showed that women lost significantly less weight than men, sug-
gesting that men will benefit most from weight reduction and preferential abdominal fat 
mass loss. However, in the multiple linear regression analysis, sex no longer contributed 
significantly to weight loss while waist-to-hip ratio remained an independent contributor. 
Waist-to-hip ratio is a stronger predictor for weight loss success than sex.
A number of covariates, such as baseline bodyweight, self-motivation, diet history and 
self-esteem have previously been associated with diet-induced weight loss in individuals 
with obesity (10, 11). However, they did not predict relative weight loss in the present 
study. Self-esteem was positively associated with weight loss in the univariate analysis, 
but no longer in the multiple analysis. In concordance with most other studies on predic-
tors of weight loss in subjects with obesity (10, 32), binge eating disorders and baseline 
exercise behaviour were not associated with weight loss. In previous studies, depression 
or other measures of psychological well-being were not predictive for weight loss (33), 
as was the case in the present study, or were negatively associated with weight loss (34).
Chapter 2
42
Limitations and strengths
The present study is a pragmatic and explorative before-after study in the run-in phase 
of a trial. We internally validated our results using statistical techniques (bootstrapping), 
however, future prospective replication studies are required in order to confirm our find-
ings. With the baseline variables that were included in our study, 25% of the variance of 
weight loss could be explained, leaving a large part unexplained. Future studies could 
build further on the model presented here in an independent patient cohort, including 
other possible predictors like plasma hormone levels or genomic profiles. A limitation 
of this study is the relatively low number of participants with unsuccessful weight loss, 
diminishing the discriminating power of the model. Due to the academic hospital setting, 
our study population may not be representative of the general population with T2D and 
overweight. However, a substantial percentage of our population had been referred 
to us by the general practitioner with participation in our study as exclusive purpose, 
leading to a relatively heterogeneous patient cohort in a ‘real life’ clinical setting. Finally, 
we studied the short-term effect of the diet intervention only. However, a relatively quick 
success of the intervention in terms of weight loss and improved glycemic control may 
motivate the patients with obesity and diabetes to change lifestyle necessary to achieve 
long term health benefit. Additional studies are required to determine whether the model 
also predicts long-term maintenance of weight loss. Strengths of the current study are the 
prospective design, the relative large cohort of patients with T2D, the low attrition rate 
(3%) and the consideration of psychological as well as physiological variables.
conclusion and clinical implications
The current study suggests that diet-induced weight loss can be predicted by five easily 
measurable psychological and physiological variables, with a positive post-test probabil-
ity of 80%. Diabetes specific variables were better at predicting successful weight loss 
during a VLCD than the predictors known from non-T2D obese cohorts. Future prospective 
studies in the T2D population are needed in order to replicate these findings. Restricting 
a VLCD to individuals with a high post-test likelihood of successful weight loss seems 
attractive as it might increase efficacy and improve the cost-effectiveness. Such screening 
of patients and predicting their treatment success will bring us one step closer to personal-
ized treatment of diabetes.
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absTracT
background and aims
Overweight and obesity increase cardiovascular mortality in patients with type 2 diabetes 
(T2D). In a recent trial, however, diet-induced weight loss did not reduce the cardiovas-
cular risk of patients with T2D, possibly due to the parallel intensive medical treatment. 
We investigated the effect of diet-induced weight loss on cardiovascular risk factors in 
overweight and obese patients with T2D, and whether this effect was influenced by the 
use of statins, ACE inhibitors, metformin and duration of T2D.
Methods
Patients with T2D and BMI > 27 were subjected to an energy-restricted diet during 4 
months. Before and after intervention, plasma levels of sICAM-1, sVCAM-1, hsCRP, vWF 
and classical biomarkers were measured. The association of the change in biomarker 
levels with medication use and T2D history, corrected for age, sex and change in insulin 
dose, was tested by matched linear regression analyses.
results
In 131 patients, the diet resulted in weight loss of 10.2 kg (95%CI 9.2, 11.3; p<0.001), 
improved median levels of HbA1c (-7.0 mmol/mol (95%CI -8.5, -5.0); p<0.001), LDL 
cholesterol (-0.2 mmol/L (95%CI -0.4, -0.1); p<0.001), sICAM-1 (-22.4 ng/mL (95%CI 
-37.1, -8.7); p=0.001), vWF (-3.9 IU/mL (95%CI -6.4, -1.4); p=0.003) and hs-CRP 
(-0.6 mg/L (95%CI -1.2, -0.2); p=0.007), but did not affect sVCAM-1 levels (1.6 
ng/mL (95%CI -41.5, 48.6); p=0.949). Duration of T2D and medical treatment were 
not associated with these effects, except for an association between statin use and 
change in sVCAM-1, where statin users improved more.
conclusion
Diet-induced weight loss reduced the levels of biomarkers of endothelial dysfunction and 
inflammation in overweight and obese patients with T2D independently of medication 
use and T2D duration. Even on intensive medical drug treatment as well as after a long 
history of T2D, patients may still profit from diet-induced weight reduction.
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inTroDucTion
Cardiovascular disease is a feared complication of type 2 diabetes (T2D), as it is often 
fatal in persons with T2D (1). Overweight and obesity enhance cardiovascular mortality 
in T2D (2). In early asymptomatic stages, the insulin resistance typical for T2D has already 
detrimental effects on endothelial function (3). This endothelial dysfunction is character-
ized by decreased vasodilation, increased vasoconstriction, insufficient or excessive 
angiogenesis, reduced barrier function, pro-coagulant activity, and a pro-inflammatory 
status, which are all associated with cardiovascular disease (4). The soluble vascular cell 
adhesion molecule 1 (sVCAM-1), soluble intercellular adhesion molecule 1 (sICAM-1) 
and von Willebrand factor (vWF) are biomarkers of endothelial function. These markers 
are elevated in patients with T2D and have been linked to vascular complications and 
mortality in T2D (3, 5-9). The systemic inflammation marker high-sensitivity C-reactive 
protein (hs-CRP) is also associated with endothelial dysfunction, atherosclerosis as well 
as visceral adipose tissue mass (10, 11). The hs-CRP levels are clinically used to stratify 
cardiovascular risk (12).
Moderate intentional weight loss in overweight persons with and without T2D improves 
insulin sensitivity, blood pressure, lipid profile, endothelial function, and alleviates the 
pro-inflammatory state (13-19). However, weight loss resulting from a lifestyle interven-
tion did not reduce the cardiovascular risk of patients with T2D in the Look AHEAD trial 
(20). The use of well-established, cardio-protective drugs such as statins, angiotensin-
converting enzyme (ACE) inhibitors and metformin, which are commonly prescribed in 
T2D, might have reduced the contrast between the groups in this study. Alternatively, 
pathological changes might have become irreversible after a long history of T2D.
In this study, we have investigated the effect of diet-induced weight loss on biomarkers 
of endothelial dysfunction and inflammation in overweight and obese patients with T2D. 
Subsequently, we determined the associations between the change in biomarkers and 
the use of cardio-protective medication and the time since diagnosis of T2D.
MaTeriaLs anD MeThoDs
The present study is a pragmatic before-after study in the run-in phase of the Prevention 
Of Weight Regain (POWER) trial of which the protocol has been published previously 
(21). This study was approved by the Medical Ethics Committee of the Erasmus Medical 
Center in Rotterdam (reference number MEC-2009-143/NL26508.078.09), in compli-
ance with the Helsinki Declaration. All participants provided informed consent.
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study population
Overweight and obese T2D patients (BMI>27 kg/m²) aged 18-75 years were recruited 
from the outpatient diabetes clinic of the Erasmus Medical Center, Rotterdam from 2010-
2013. Exclusion criteria were pregnancy, lactation, severe psychiatric problems, sig-
nificant cardiac arrhythmias, unstable angina, decompensated congestive heart failure, 
major organ system failure, untreated hypothyroidism, and end-stage renal disease, and 
a myocardial infarction, cerebrovascular accident or major surgery during the previous 
3 months. For all participants in the present study, antidiabetic and cardio protective 
medication was constant for at least 3 months prior to the intervention.
Diet intervention and data collection
The participants started with a very low-calorie diet (VLCD) of 750 kcal per day for a 
period of 8 weeks. The VLCD consisted of 2 commercially available meal replacements 
(Glucerna SR, Abbott Nutrition B.V.) per day plus 75 grams of lean meat, 150 ml of 
skimmed milk, and low-carbohydrate vegetables ad libitum. Subsequently, participants 
followed a low calorie diet of 1100-1300 kcal/day for another 12 weeks. After 20 
weeks, the participants used a 1300 kcal/day diet based on national health recom-
mendations. During the diet program, 60 minutes of daily exercise was encouraged. To 
reduce the risk of hypoglycemia, the doses of sulfonylurea-derivatives and insulin were 
lowered before start of the dietary intervention but after baseline measurements. During 
the dietary intervention, insulin dose was adjusted based on glucose levels. Since insulin 
was adjusted during the intervention, we did not analyze the interaction of insulin use 
with the diet-effect, but in all the analyses diet-induced effects were corrected for the 
insulin change during the intervention. The doses of metformin, statins and ACE inhibitors 
were maintained during the intervention.
Plasma samples were obtained after an overnight fast, and samples were stored at 
-80°C until further analysis. Of the 206 patients, who followed the dietary intervention, 
blood samples were obtained before as well as immediately after the dietary intervention 
of 131 patients. To enable participants to serve as their own control, only these 131 pa-
tients were enrolled in the current study. The other 75 patients did not differ significantly 
from the enrolled patients with respect to age, sex, baseline weight, baseline HbA1c or 
diabetes complications (data not shown). We recorded demographic variables, dura-
tion of diabetes, smoking status and medication use, and measured weight (kg), waist 
circumference (cm) and blood pressure of all participants before and after the dietary 
intervention. The combined use of statins, ACE inhibitors and metformin was defined 
as ‘maximum treatment’. Glycated hemoglobin (HbA1c (mmol/mol)), fasting glucose 
(mmol/l) and plasma lipids (mmol/l) were measured using routine lab techniques. 
Physical activity was measured using the Short Questionnaire to Assess Health Enhancing 
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Physical Activity (SQUASH) (22). The study was monitored and documented with the trial 
management system OpenClinica (Waltham, MA).
Measurement of biomarkers of endothelial dysfunction and inflammation
Biomarker levels were measured in plasma by enzyme-linked immunosorbent assays 
(ELISA). sICAM-1, sVCAM-1 and hs-CRP were measured using DuoSet ELISA Develop-
ment Systems (R&D Systems, Minneapolis, MN) and vWF was measured using Von 
Willebrand Factor BioAssay ELISA (USBiological Life Sciences, Salem, MA). All assays 
were performed according to the manufacturer’s instructions. For each patient, samples 
collected before and after intervention were analyzed on the same ELISA plate.
statistical analysis
We calculated that a sample size of 120 patients would give a power of 80% to 
detect a small effect (Cohen’s d=0.20) with an alpha of 0.05 and an inter-correlation 
of 0.70 between the two measurements. Normality of the data and homogeneity of 
variances were tested using the Shapiro-Wilks test and Levene’s test. Variables before 
and after the dietary intervention were expressed as mean with standard deviation or 
median with inter-quartile range and tested for statistical significance using a two-sided 
paired samples t-test or a Wilcoxon ranking test plus Hodges-Lehman median difference 
test, depending on presence or absence of normality of data. Wilcoxon ranking tests 
were used to compare the distribution of participants across CRP based CVD-risk groups 
before and after the intervention. Matched linear regression analyses were performed 
to test the association of the change in biomarkers with medication use and T2D history, 
corrected for age, sex and change in insulin dose. To analyze the interaction between the 
biomarkers before and after dietary intervention and medication use, we used repeated 
measurements MANOVA analyses. The variables used in the regression analyses and 
repeated measurements MANOVA were Blom-transformed to meet with the assumption 
of normally distributed residuals. Statistical significance was considered at p-values of 
<0.05. All statistical analyses were carried out using IBM SPSS statistics version 21.
resuLTs
baseline characteristics
Table 1 summarizes the characteristics of our study population. At baseline, the BMI 
was 36.8±5.6 kg/m2. The median period after T2D diagnosis was 10.0 years and 
ranged from 0.4 to 39.0 years. Of the 131 participants, 62.6% were treated with 
insulin, 75.6% with metformin and 20.6% with a sulfonylurea-derivative, while only two 
participants were treated with incretins and none with thiazolidinediones. 72.5% of 
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the participants used statins, whereas 58.8% of the participants used ACE inhibitors, 
35.9% beta blockers, 21.4% calcium antagonists, 48.1% diuretics and 3.1% alpha-2 
antagonists. Microvascular and macrovascular complications were evident in 60.3% 
and 27.6% of the participants. While on medication, the median baseline HbA1c level 
was 61.0 mmol/mol and the median baseline LDL cholesterol level was 2.5 mmol/l. 
Nineteen participants (15.4%) were current smokers; during the intervention period three 
started and two stopped smoking.
Table 1. Characteristics of the study population (n=131) before and after dietary intervention
 Variables* Before After p-value**
Age (y, range) 54 (26-74)   
Sex (% female) 57.3   
Years after diagnose T2D 10.0 (3.0, 15.0)   
Insulin users (%) 62.6 57.6  
Insulin dose among users (IU/day) 108.0 (68.0, 136.0) 31.0 (16.8, 52.5) <0.001
Metformin users (%) 75.6 unchanged  
Metformin dose among users (mg/day) 1700 (1000, 2550) unchanged  
Statin users (%) 72.5 unchanged  
ACE inhibitor users (%) 58.8 unchanged  
Microvascular disease (%) 60.3 unchanged  
Macrovascular disease (%) 27.6 unchanged  
Physical Activity (SQUASH score) 3360 (1440, 6270) 3960 (1800, 7680) 0.395
Weight (kg) 105.0±19.1 94.5±17.3 <0.001
BMI (kg/m²) 36.8±5.6 33.1±5.2 <0.001
Waist circumference (cm) 119.8±12.9 110.8±11.9 <0.001
Systolic blood pressure (mmHg) 138.0 (127.8, 157.3) 139.0 (128.0, 150.0) 0.405
HbA1c (mmol/mol) 61.0 (52.0, 71.0) 53.0 (43.0, 66.0) <0.001
Fasting glucose (mmol/l) 8.8 (6.9, 10.8) 7.3 (6.1, 9.3) <0.001
Total cholesterol (mmol/l) 4.4 (3.7, 5.1) 4.1 (3.5, 4.8) <0.001
LDL cholesterol (mmol/l) 2.5 (2.1, 3.1) 2.4 (1.8, 2.9) <0.001
HDL cholesterol (mmol/l) 1.1 (1.0, 1.3) 1.2 (1.0, 1.4) 0.002
Triglycerides (mmol/l) 1.8 (1.2, 2.6) 1.4 (1.0, 2.0) <0.001
sICAM-1 (ng/ml) 175.0 (133.1, 257.5) 158.2 (113.4, 222.5) 0.001
sVCAM-1 (ng/ml) 451.3 (324.3, 636.5) 432.5 (292.0, 682.1) 0.949
hs-CRP (mg/l) 3.9 (1.6, 13.0) 3.4 (1.1, 8.5) 0.007
vWF (IU/ml) 31.3 (24.1, 43.6) 30.2 (20.5, 40.7) 0.003
*Mean±SD or median (interquartile range), **Paired samples T-test or Wilcoxon ranking test
At baseline, the statin users had a lower median LDL cholesterol (2.4 mmol/L (2.0, 3.0) 
vs. 2.9 mmol/L (2.3, 3.6), p=0.007), lower hs-CRP (3.3 g/mL (1.3, 10.0) vs. 6.9 g/mL 
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(1.8, 18.9), p=0.035) and lower vWF levels (30.6 IU/mL (23.1, 41.3) vs. 36.2 IU/mL 
(27.5, 57.7), p=0.028) than the non-statin users. Compared to participants not using ACE 
inhibitors, users were older (56.0 y (50.0, 63.0) vs. 53.0 y (42.5, 59.0), p=0.018) and 
had a higher systolic blood pressure (141.0 mmHg (130.0, 162.5) vs. 132.0 mmHg 
(122.5, 148.5), p=0.009). Participants on metformin treatment did not differ at baseline 
from those not using metformin. Participants on ‘maximum treatment’ using the combination 
of statins, ACE inhibitors and metformin (n=48) showed a lower hs-CRP level than the other 
participants (2.7 g/mL (1.1, 7.1) vs. 4.8 g/mL (2.3, 16.6), p=0.015).
effect of the dietary intervention
The effects of the dietary intervention on metabolic and endothelial markers are shown in 
table 1. During the 4-month dietary intervention, participants lost 10.2 kg (95%CI 9.2, 
11.3; p <0.001), which is 9.8±5.2% of their initial bodyweight. The median plasma 
levels of HbA1c (-7.0 mmol/mol (95%CI -8.5, -5.0); p<0.001), LDL cholesterol (-0.2 
mmol/L (95%CI -0.4, -0.1); p<0.001) and other plasma lipids (p<0.01) improved, 
while systolic blood pressure did not change (p=0.405). The median plasma levels 
of sICAM-1 (-22.4 ng/mL (95%CI -37.1, -8.7); p=0.001), vWF (-3.9 IU/mL (95%CI 
-6.4, -1.4); p=0.003) and hs-CRP (-0.6 mg/L (95%CI -1.2, -0.2); p=0.007) decreased 
during the weight loss intervention, while sVCAM-1 levels were unchanged (1.6 ng/mL 
(95%CI -41.5, 48.6); p=0.949). The change in these biomarkers was not correlated 
with change in physical activity nor with the prevalence of microvascular and macrovas-
cular disease (data not shown).
Only for CRP levels, a cut-off point for high CVD risk has been defined as equal 
to or above 3 mg/L, while CRP levels <1 mg/L reflect a low risk for CVD (12). The 
distribution of patients over the three risk categories shifted significantly towards the lower 
CVD-risk categories during the diet intervention (p<0.001): at baseline, 58.3% of our 
population had a CRP level above 3 mg/ml, which decreased to 50.8% after the dietary 
intervention (p=0.033). The proportion of patients with a low-risk CRP level increased 
from 12.1% to 23.5% during the diet intervention (p<0.001).
associations of the change in biomarkers with duration of T2D
To determine whether the diet-induced changes in biomarkers were associated with the 
time since diagnosis of T2D, we conducted univariate linear regression analyses, cor-
rected for age, sex and change in insulin dose. At baseline, sVCAM-1 levels were posi-
tively associated with duration of T2D (β=0.245, p=0.005), while sICAM-1 (β=0.104, 
p=0.237), vWF (β=0.065, p=0.460) and hs-CRP levels (β=-0.021, p=0.811) were 
not. The diet-induced changes in sICAM-1 (β=-0.044, p=0.621), sVCAM-1 (β=0.013, 
p=0.886), vWF (β=-0.005, p=0.952) and hs-CRP (β=-0.012, p=0.887) were not 
related to the duration of T2D.
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associations of the change in biomarkers with cardio-protective 
medication
Firstly, we studied the association of medication with the diet-induced change in the 
vascular biomarker levels via a matched linear regression analysis corrected for age, sex 
and change in insulin dose. Changes in the biomarkers were not associated with the use 
of statins, ACE inhibitors or metformin, except for a negative association between statin 
use and change in sVCAM-1 (β=-0.23, p=0.020).
We also performed a formal interaction study. In table 2 we present the difference 
in effect of the dietary intervention on the measured vascular biomarkers, according to 
medication use. There were no significant interactions between the vascular biomarker 
levels before and after diet and the use of statins, ACE inhibitors and metformin. We 
found a borderline significant interaction between sVCAM-1 before and after diet with 
maximum medical treatment (statin plus ACE inhibitor plus metformin). Participants on 
maximum medical treatment showed a decrease in sVCAM-1 while the other participants 
showed an increase in sVCAM-1 (between-group difference p=0.047). Similar results 
were obtained after adjusting for age, sex, weight change and insulin use.
Discussion
We found that diet-induced weight loss not only improved glycemic state and lipid 
parameters, but also reduced biomarkers of endothelial dysfunction and inflammation in 
overweight and obese patients with T2D. These effects of weight loss were not associ-
ated with the duration of T2D or with the use of statins, ACE inhibitors, and metformin.
The beneficial effect of diet-induced weight loss on classical cardiovascular risk fac-
tors such as hypercholesterolemia and hyperglycemia in obese T2D patients is well 
established (20, 23) and confirmed in this study. Our results on biomarkers of endothelial 
function and inflammation are in concordance with previous studies on weight loss dieting 
in obese subjects with and without T2D (16, 19, 24-27). The biomarkers for endothelial 
function used in this study play an important role in the adhesion of leukocytes to the 
endothelium, coagulation processes and vascular inflammation (28, 29). In subjects with 
T2D, each of these biomarkers is strongly associated with cardiovascular outcome (3, 
7-11), and a lowering of sICAM-1, vWF and hs-CRP may therefore reduce the risk of 
vascular complications. To illustrate, the proportion of patients shifting from the medium 
or high CVD risk group to the low CVD risk group, according to their hs-CRP level, was 
almost doubled. However, the changes in biomarker levels induced by our short term 
diet-induced weight loss program are relatively small, and follow-up studies are required 
to determine the clinical relevance.
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We found that statin use and diet-induced weight loss are additive in reducing hs-
CRP levels in T2D patients, which is in line with the results of the Look AHEAD trial 
(24). Although the dietary intervention in our study was of shorter duration, the same 
magnitude of weight loss was observed as in the Intensive Lifestyle Intervention arm 
of the Look AHEAD trial after 1 year (20). Unlike the Look AHEAD group, we directly 
compared the statin-treated with the non-statin treated participants. Adjustments of the 
statin doses made during the dietary intervention period were a limitation of the Look 
Ahead study. In our study, medication doses were maintained during the intervention. 
We found no interaction of statin use with improvements in hs-CRP levels, nor in sICAM-1 
and vWF levels. The only interaction between diet and medication was observed in 
patients receiving the combination of a statin, ACE inhibitor and metformin versus the 
other patients, which showed a diet-induced improvement of sVCAM1 levels when on 
maximal treatment. The lack of effect on cardiovascular endpoints in the Look AHEAD 
trial (20) may therefore not be the result of the increasingly intensive medical treatment of 
the participants, but possibly of the gradual regain of weight during the follow-up period. 
Taken together, lifestyle interventions aimed at long-term weight reduction may still be a 
therapeutic option on top of medication in overweight and obese T2D patients.
The wide range of T2D history in our study group (0.4-39.0 years since T2D was 
diagnosed) gave us a good opportunity to study the influence of duration of T2D on 
the effect of a weight loss intervention. One could argue that in a late stage of disease 
many pathological changes have become irreversible and therefore the vasculature may 
not benefit from weight loss anymore (30). However, we found that the effect of weight 
loss on surrogate vascular endpoints was independent of T2D duration, suggesting that 
patients with a long history of T2D still benefit from a weight loss intervention similar 
to newly diagnosed patients. Our results are in line with results from patients with a 
relatively short history of T2D. In the ACTID trial (26) the levels of sICAM-1, CRP and IL-6 
decreased significantly during diet and in another small trial brachial flow-mediated dila-
tation (FMD) improved, although the microvascular reactivity and vWF did not change 
significantly in this latter trial (19).
strengths and limitations of the study
The present study is a pragmatic before-after study in the run-in phase of a randomized 
trial. As a consequence, we cannot fully exclude that other factors than the dietary 
intervention have contributed to the described effects. Physical activity did not change 
significantly and did not correlate with the change in biomarkers (data not shown), 
medication use was tightly monitored and no major changes in medical status are to 
be expected during the 4-month intervention period. However, patient compliance to 
medication or dietary treatment could not be checked. Future randomized controlled 
replication studies are required in order to confirm our findings. One could argue that the 
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medication subgroups were small and that the chance of a type 2 error was considerable 
for the interaction analysis. However, the linear regression analyses are more robust and 
were in concordance with the interaction study. Another limitation is the use of change 
scores in the regression analyses, which may be sensitive to regression toward the mean. 
Finally, our study was limited to the endothelial role in inflammation and thrombosis using 
surrogate markers. We have no data available for vasomotor, barrier and angiogenic 
function. The effect of diet-induced weight loss on long-term endothelial function and 
cardiovascular endpoints in this patient population awaits further study. Strengths of the 
present study were the prospective design, structured information about medication use 
and a strict medication protocol during the intervention. Furthermore, we were able to 
collect a cohort with a wide range of T2D history, making the results generalizable to the 
overweight and obese T2D population.
concLusions
Our findings support a beneficial effect of diet-induced weight reduction on biomarkers 
of endothelial dysfunction and inflammation irrespective of intensive medical drug treat-
ment and a long history of T2D. Replication in long term follow-up studies is needed in 
order to establish the effect of diet-induced weight loss and the interaction with cardio 
protective medication on cardiovascular endpoints.
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absTracT
background and aims
Cardiovascular disease (CVD) is a major complication in patients with type 2 diabetes 
(T2D), especially in those with obesity. Plasma soluble low density lipoprotein receptor-
relative with 11 ligand-binding repeats (sLR11) plays a role in the development of 
atherosclerosis and has been linked with the metabolism of triglyceride-rich lipoproteins, 
adiposity, and vascular complications in T2D. We aimed to determine the effect of 
diet-induced weight loss on plasma sLR11 levels in overweight and obese individuals 
with T2D.
Methods
Plasma sLR11 levels were determined in 64 individuals with T2D and BMI > 27 kg/m² 
before and after a 20-week weight loss diet. As a reference, sLR11 levels were also 
determined in 64 healthy, non-obese controls, matched as a group for age and sex.
results
Median plasma sLR11 levels of the T2D study-group at baseline (15.4 ng/mL (IQR 
12.9-19.5)) were higher than in the controls (10.2 (IQR: 8.7-12.2) ng/mL; p=0.001). 
The diet resulted in a weight loss of 9.7±5.2% (p=0.001) and improved CVD risk fac-
tors. sLR11 levels were reduced to 13.3 ng/mL (IQR 11.0-17.1; p=0.001). Changes 
in sLR11 levels positively associated with changes in non-HDL cholesterol (B=1.54, 
R2=0.17, p=0.001) and HbA1c (B=0.07, R2=0.11, p=0.007), but not with weight 
loss (B=0.04, R2=0.05, p=0.076). The changes in non-HDL cholesterol and HbA1c 
together explained 24% of the variance of sLR11 reduction (p=0.001).
conclusions
Weight loss dieting in overweight and obese individuals with T2D resulted in a reduc-
tion in plasma sLR11 levels, that was associated with improvements in lipid-profile and 
glycemic state.
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inTroDucTion
Type 2 diabetes (T2D) and obesity are major risk factors for cardiovascular disease 
(CVD) (1-4). The risk of cardiovascular disease (CVD) is higher in obese than in lean 
individuals with T2D (1). Weight loss has been shown to improve multiple cardiovascular 
risk factors in obese patients with T2D, e.g. lipid profile, glycemic control, blood pres-
sure and systemic inflammation (5-9).
Low density lipoprotein receptor-relative with 11 ligand-binding repeats (LR11, also 
called SorLA or SORL1) is a type I membrane protein, which after proteolytic cleavage 
sheds a large soluble extracellular part called sLR11 into the circulation (10, 11). LR11 
is highly expressed in intimal smooth muscle cells of atheromatous lesions in experimental 
animal models (12-14). LR11 and sLR11 have been shown to play a role in the develop-
ment of atherosclerosis and plaque formation by increasing vascular smooth muscle cell 
proliferation and migration from media to intima layer, and by causing macrophage 
infiltration of the arterial wall (10, 11, 15, 16). In mouse models, LR11 expression 
in adipose tissue and sLR11 plasma levels are upregulated by a high-fat diet (17). 
In HepG2 and smooth muscle cell cultures, LR11 expression and sLR11 release are 
stimulated by triglyceride-rich lipoproteins (TGRL) (18), which typically are increased in 
subjects with T2D (19, 20). Compared to healthy controls, levels of sLR11 are higher in 
individuals with T2D (21, 22) and are correlated with hemoglobin A1c (HbA1c) levels 
(21, 23, 24). Individuals with T2D complicated by coronary stenosis, acute coronary 
syndrome, or retinopathy display increased plasma sLR11 levels, suggesting a link with 
the severity of vascular complications in these patients (21, 23, 25). In humans, LR11 
expression in white adipose tissue (WAT) positively correlated with BMI (26), and plasma 
levels of sLR11 correlated with BMI and overall adipose tissue mass (17). In mouse 
models, sLR11 has been shown to act as a negative regulator of adipose tissue energy 
expenditure (17), and LR11 expression in WAT exacerbated diet-induced adiposity and 
decreased lipolysis in WAT by promoting cell surface recycling of internalized insulin 
receptors (26). The decrease in BMI and visceral and subcutaneous fat tissue induced by 
bariatric surgery in obese subjects was accompanied by a marked reduction in sLR11 
levels (17). We therefore hypothesized that diet-induced weight loss will reduce sLR11 
levels in patients with T2D.
The aim of the current study was to determine whether diet-induced weight loss affects 
sLR11 levels in a cohort of overweight and obese patients with T2D. In addition, we 
investigated the association between plasma sLR11 levels and other CVD risk factors in 
relation with diet-induced weight loss.
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MaTeriaLs anD MeThoDs
study Population and Design
In this study, we enrolled the first 64 participants of the run-in phase of the Prevention 
of Weight Regain (POWER)-trial (27). The latter study was aimed at studying long term 
weight maintenance after the run-in diet phase. Participants were overweight and obese 
subjects (BMI > 27 kg/m2) with established T2D from the outpatient clinic of the Erasmus 
Medical Center, Rotterdam, the Netherlands. Exclusion criteria were pregnancy (or 
lactating), severe psychiatric problems, significant cardiac arrhythmias, unstable angina, 
decompensated congestive heart failure, major organ system failure, untreated hypothy-
roidism, end-stage renal disease, or a cerebrovascular event, myocardial infarction or 
major surgery in the last 3 months.
The participants were subjected to a very low calorie diet for 8 weeks, using a diabetes-
specific meal replacement (Glucerna SR, Abbott Nutrition BV) for breakfast and lunch 
combined with a light dinner, providing approximately 750 kcal/day in total, including 
67 g carbohydrates, 54 g protein and 32 g fat (of which 16 g was monounsaturated 
fatty acid), and micronutrients as recommended by the national nutritional guidelines 
(27). In the next 12 weeks, a low calorie diet according to the national nutritional 
guidelines (approx. 1300 kcal/day), was gradually reintroduced.
At baseline and after the diet intervention, outcome parameters were measured and 
filed in a database using the OpenClinica® trial management system. We recorded de-
mographic variables, exercise (days per week with minimum of 30 minutes of exercise), 
diabetes complications and medication use. Statin medication was converted into statin 
equivalent score (scale 0-7) (28). We measured bodyweight, height, waist circumference 
and blood pressure, and determined glycated hemoglobin (HbA1c), fasting glucose, 
fasting insulin, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides and hs-CRP 
by standard clinical laboratory assays. Non-HDL cholesterol was calculated as the dif-
ference between total and HDL cholesterol. HOMA-IR was calculated using the formula: 
HOMA-IR = [glucose (mmol/L) * insulin (µU/mL)/22.5] (29), but analyzed separately 
for insulin users and non-insulin users.
A healthy control group was used as a reference for the sRL11 level. The controls were 
matched as a group for age and sex to the T2D group but did not undergo dieting. The 
healthy controls (n = 64) were recruited via an advertisement in the Rotterdam region.
All participants provided written informed consent. This research was approved by the 
Medical Ethics Committee of the Erasmus Medical Centre, Rotterdam, the Netherlands 
(reference number MEC-2009-143/NL26508.078.09), in compliance with the Hel-
sinki Declaration.
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blood sample analysis
Fasting blood samples were obtained from the patients with T2D before and after the 20-week 
dieting period, and from the healthy controls. After centrifugation, plasma samples were stored 
at -80oC until analysis. Lipid and glycemic parameters were measured by standard biochemi-
cal techniques. Soluble LR11 was measured using a sandwich enzyme-linked immunosorbent 
assay (ELISA) with two specific monoclonal antibodies against human LR11 (Sekiaui Medical, 
Ryugasaki Japan) as previously described (30). In brief, 50 ml of plasma diluted with sample 
buffer were incubated with the capture monoclonal antibody M3 and then incubated with 
biotinylated reporter monoclonal antibody R14. The LR11-antibody complex was quantitated 
with horseradish-peroxidase-conjugated streptavidin. A standard curve was constructed using 
purified LR11 protein. The lower detection limit for sLR11 was 0.1 ng/mL.
statistical analysis
This was a post hoc analysis of data obtained in the run-in phase of a randomized trial, 
with long term weight loss as the primary endpoint (27). Normality of the data and 
homogeneity of variances were tested using the Shapiro-Wilks test and Levene’s test. 
Variables before and after the diet intervention period were expressed as ratio (%), mean 
± standard deviation or median (inter-quartile range). Differences were tested for statistical 
significance using a two-sided paired samples t-test or a Wilcoxon ranking test, depend-
ing on the normality of data. Changes were calculated as value after intervention minus 
baseline value. Differences between two (sub)groups were tested for significance using 
either a two-sided t-test or a Mann-Whitney U test. Potential outliers were identified using 
Cook’s Distance statistics (31). Correlations at baseline were determined using Spearman 
correlation analysis. We performed univariate linear regression analyses to identify po-
tential contributors to the diet-induced changes in sLR11 levels. The change in sLR11 was 
log transformed to obtain a normal distribution of the residuals of the regression analyses 
and perform statistical testing. Subsequently, all significant co-variables were included in 
multivariate analysis. All data were analyzed using IBM SPSS v 21.0 software.
resuLTs
baseline measurements
The general characteristics of the 64 patients with T2D are shown in Table 1. Sixty-
two (96.9%) out of the 64 patients were obese (BMI> 30 kg/m2). At inclusion, 43 
(67%) of the participants presented with microvascular complications and 16 (25%) had 
experienced macrovascular complications. Forty-five patients (70%) used insulin. The 
median HOMA-IR for insulin-users and non-insulin-users was 80.6 (39.7-225.9) and 
42.6 (23.9-73.0), respectively (p=0.016).
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Table 1. Characteristics of the participants before and after diet (n=64)
 Baseline After diet p
Male sex N (%) 28 (44)   
Age (y) 53.0 (46.3-62.0)   
Ethnicity (cau) N (%) 39 (61)   
Microvascular complications N (%) 43 (67)   
Macrovascular complications N (%) 16 (25)   
30 minutes of exercise (days/week) 7.0 (4.0-7.0) 7.0 (5.0-7.0) 0.583
Weight (kg) 106.7±19.5 96.3±17.7 <0.001
BMI (kg/m2) 37.2±5.3 33.6+5.0 <0.001
Waist circumference (cm) 121.7±12.6 112.2+11.9 <0.001
Systolic blood pressure (mmHg) 141.6±18.1 139.8±21.2 0.509
Diastolic blood pressure (mmHg) 80.1±10.7 79.5±9.4 0.637
sLR11 (ng/mL) 15.4 (12.9-19.5) 13.3 (11.0-17.1) <0.001
Total cholesterol (mmol/L) 4.5 (3.9-5.5) 4.3 (3.6-5.0) 0.003
HDL cholesterol (mmol/L) 1.1 (1.0-1.3) 1.2 (1.0-1.4) 0.003
LDL cholesterol (mmol/L) 2.5 (2.1-3.1) 2.5 (1.8-2.9) 0.035
Non-HDL cholesterol (mmol/L) 3.3 (2.7-4.1) 3.0 (2.5-3.8) <0.001
Triglyceride (mmol/L) 1.9 (1.3-2.9) 1.5 (1.0-2.2) <0.001
hs-CRP (mg/L) 2.8 (1.3-17.7) 2.3 (1.0-10.6) 0.055
HbA1c (%) 7.8 (7.2-8.6) 7.2 (6.3-8.3) <0.001
HbA1c (mmol/mol) 62.0 (55.0-70.0) 55.0 (45.3-67.8) <0.001
Fasting glucose (mmol/L) 8.8 (7.2-10.4) 7.2 (6.0-9.4) <0.001
Insulin users N (%) 45 (70) 41 (64) 0.046
Insulin dose among users (IU/day) 100.0 (57.0-136.0) 34.0 (19.0-50.0) <0.001
Metformin users N (%) 46 (72) 48 (75) 0.157
Metformin dose among users (mg/day) 1700 (1375-2550) 1700 (1000-2550) 0.602
Statin users N (%) 47 (73) 45 (70) 0.705
Statin equivalent dose (scale 0-7) 4.0 (3.0-4.0) 4.0 (3.0-4.0) 0.839
ACE inhibitor users N (%) 38 (59) 34 (53) 0.637
aData are mean±SD or median (IQR)
The healthy controls had a significantly lower BMI (25.7±3.8 kg/m2) compared to the 
T2D patients (p<0.001). The median sLR11 level at baseline was 15.4 (IQR: 12.9-
19.5) ng/mL for the T2D group, which was significantly higher than the median sLR11 
level of the healthy controls (10.2 (IQR: 8.7-12.2) ng/mL, p<0.001).
In the T2D group, baseline levels of sLR11 correlated with levels of HDL choles-
terol (r=-0.269, p=0.034), non-HDL cholesterol (r=0.274, p=0.031), ApoB (r=0.324, 
p=0.010), triglycerides (r=0.303, p=0.016), HbA1c (r=0.254, p=0.045) and fasting 
glucose (r=0.319, p=0.012). sLR11 levels correlated with HOMA-IR in the non-insulin-
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users (r=0.511, p=0.030), but not in the insulin-users (r=0.131, p=0.402). sLR11 was 
not significantly correlated with weight (r=0.054, p=0.672), BMI (r=0.196, p=0.120), 
waist circumference (r=0.232, p=0.065) or statin dose (r=-0.219, p=0.082). Similar 
results were found after exclusion of the two non-obese T2D patients. In the combined 
T2D and healthy control group, sLR11 levels were significantly correlated with BMI at 
baseline (r=0.602, p<0.001), but no longer after correcting for fasting glucose levels 
(r=0.113, p=0.210).
effect of diet-induced weight loss
After a 20-week dietary intervention, the participants lost 10.5 ± 6.1 kg body weight, 
which was 9.7% (range +1.7% to -20.7%) of the initial body weight (p<0.001, Table 1). 
Waist circumference, HDL cholesterol, non-HDL cholesterol, triglyceride, HbA1c, fasting 
glucose and HOMA-IR all improved significantly (p<0.001). At the end of the diet inter-
vention, the number of participants using insulin was reduced from 45 (70%) to 41 (64%; 
p=0.046), and among insulin users, the median dose was significantly reduced by 66 
units per day (p<0.001). The number of patients on metformin, statin and ACE inhibitors, 
and prescribed doses, did not change significantly during the intervention period.
After the diet intervention, median plasma sLR11 levels were 13.3 (IQR 11.0-17.1) 
ng/mL, which was significantly lower than baseline levels (p<0.001). The effect of the 
diet on plasma sLR11 levels varied markedly among the participants, as shown in Figure 
1. Of the 64 participants, 44 exhibited decreased plasma sLR11 levels, 7 remained 
stable (defined as a change below the intra-assay coefficient of variation of 3%), and 
the other 13 participants displayed increased plasma sLR11 levels. The participants with 
decreased sLR11 levels had lost significantly more weight than the other 20 participants 
(-11.7 kg vs. -7.7 kg, p=0.009).
In Table 2, the results of the univariate regression analyses with the change in sLR11 
are shown. The change in sLR11 was not associated with sex, age and weight loss. 
Significant associations were observed with change in non-HDL cholesterol (B=0.59, 
R2=0.17, p=0.001) and HbA1c (B=0.03, R2=0.11, p=0.007). The change in HbA1c 
strongly correlated with weight loss (r=0.456, p<0.001), while non-HDL cholesterol 
levels did not (r=0.209, p=0.105).
In a multiple linear regression model, the change in non-HDL cholesterol and HbA1c 
remained independently associated with sLR11 change (p=0.003 and p=0.023, Table 
3). The model with changes in non-HDL cholesterol and HbA1c explained 24% of the 
variance of sLR11 change (p<0.001). Adding baseline sLR11 to this model did not 
affect the point estimates, p-value and the explained variance.
Using Cook’s distance analysis (31), we identified four possible outliers with strongly 
increased sLR11 levels. These four cases showed a moderate influence on the outcomes 
(Cook’s distance 0.08-0.19). Excluding these participants from the analysis yielded the 
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same independent contributors to the change in sLR11, where the change in non-HDL 
cholesterol (B=1.48, p=0.001) and HbA1c (B=0.08, p=0.002) explained 35% of 
the variance of sLR11 reduction (17% and 18% for change in non-HDL cholesterol and 
HbA1c, respectively).
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figure 1. Baseline sLR11 levels and change (%) in plasma sLR11 levels during 20 weeks of diet in indi-
vidual participants.
(A) Baseline sLR11 levels and (B) change (%) in plasma sLR11 levels during 20 weeks of diet in individual 
participants 1 till 64. Participants were arranged according to relative change in plasma sLR11 levels.
Table 2. Univariate regression analysis of (log-transformed) change in plasma sLR11 levels and age, sex, 
baseline sLR11 and changes in other co-variables.
 Univariate B 95%CI R2 p
    Age 0.01 -0.01-0.04 0.02 0.292
    Sex 0.13 -0.43-0.69 0.00 0.644
    Baseline sLR11 0.02 -0.03-0.07 0.01 0.413
    ΔWeight 0.04 -0.01-0.09 0.05 0.076
    ΔWaist circumference 0.03 -0.02-0.09 0.02 0.243
    ΔHDL cholesterol 0.32 -1.03-1.66 0.00 0.639
    Δnon-HDL cholesterol 0.59 0.25-0.93 0.17 0.001
    ΔTriglyceride 0.01 -0.14-0.15 0.00 0.917
    ΔCRP -0.02 -0.04-0.01 0.02 0.245
    ΔHbA1c 0.03 0.01-0.05 0.11 0.007
    ΔFasting glucose 0.10 -0.01-0.22 0.05 0.082
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Discussion
The present study shows that plasma sLR11 levels were significantly reduced in over-
weight and obese individuals with T2D upon a 20-week weight loss diet. The reduction 
in plasma sLR11 was independently associated with reductions in non-HDL cholesterol 
and HbA1c, but not with weight loss or the reduction in waist circumference or BMI. The 
observed reduction in sLR11 during weight loss may have clinical relevance as it is in 
the same order of magnitude as the previously reported increase in sLR11 upon coronary 
stenting in response to vascular injury (32). Since patients with T2D are prone to develop 
atherosclerosis, and sLR11 has been shown to facilitate the atherosclerotic process (10, 
11, 15, 16), the reduction in sLR11 may be beneficial in delaying the development of 
vascular complications.
A decrease of sLR11 levels after weight loss has also been described in morbidly 
obese individuals, who underwent bariatric surgery (17). At 12 months post-surgery, the 
decrease in sLR11 and BMI was 37 % and 28%, respectively. In our study, 20 weeks 
of weight loss dieting resulted in a more modest decrease in sLR11 and BMI of 9% 
and 10%, but the decrease in sLR11 relative to that in BMI was similar in both studies. 
In the bariatric surgery study, the decrease in sLR11 was strongly associated with the 
loss of adipose tissue mass, but not with the reduction in BMI. In our study, the change 
in sLR11 levels was also not related to change in BMI, nor with change in weight or 
waist circumference. However, we did not include measurements of adipose tissue mass. 
Obviously, the effects of bariatric surgery go beyond weight reduction, and include 
changes in peptide hormones (like GLP-1 and leptin), bile acid flow and gut bacteria, 
all potentially affecting sLR11 levels (33). Whether these factors are also affected by 
diet-induced weight loss is unknown. Nonetheless, we show for the first time that the 
potentially beneficial reduction in sLR11 levels seen after bariatric surgery can also be 
achieved through weight loss dieting.
The average baseline sLR11 level in the overweight and obese subjects with T2D 
was significantly higher than in healthy, non-obese controls. Comparable high sLR11 
levels (mean: 16.8 ng/ml) have been reported in morbidly obese individuals (17), 
suggesting that the high sLR11 level in our participants is related to their prominent 
obesity. However, in our T2D study group sLR11 levels were not correlated with baseline 
Table 3. Matched multiple regression analysis of (log-transformed) changes in plasma sLR11 levels and 
changes in co-variables.
 Multivariate B 95%CI Partial R2 p
    ΔNon-HDL cholesterol 0.53 0.19-0.86 0.15 0.003
    ΔHbA1C 0.02 0.003-0.04 0.09 0.023
    Explained variance   0.24  
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BMI, weight and waist circumference. Whittle et al. found that circulating sLR11 levels 
were positively correlated with BMI in 156 subjects with sleep apnea and in 25 subjects 
with type 2 diabetes or glucose intolerance (17). The participants in their sleep apnea 
study group were mostly non-obese, and also in their glucose-intolerant study group half 
of the participants were non-obese, resulting in a BMI ranging from morbidly obese to 
underweight values. When we included our healthy, mostly normal weight controls in 
the analysis, we indeed found a strong correlation between BMI and sLR11. Since this 
correlation disappeared after correcting for baseline fasting glucose levels, it could be 
argued that the increase of sLR11 with BMI is secondary to decreased glucose tolerance. 
In line with this, sLR11 levels have previously been shown to be associated with HbA1c 
levels in diabetic as well as the non-diabetic patient groups (21, 23, 24).
The mechanism by which sLR11 decreases during weight loss-dieting or bariatric 
surgery remains to be clarified. There is evidence that circulating sLR11 originates from 
the vasculature (34); however, brown and white adipose tissue highly express LR11 and 
therefore may also contribute (17). High-fat feeding significantly increased and fasting 
decreased LR11 mRNA expression in adipose tissue of mice (17). Similarly, we have 
previously reported that high-fat feeding upregulates liver LR11 expression and circulat-
ing sLR11 levels in mice (18). We have also shown that postprandial TGRL enhance the 
expression of LR11 in hepatocytes (18), as it does in endothelial cells (35). Consequently, 
the decline in sLR11 levels in the overweight subjects with T2D upon dieting may also 
be due to reduced levels of TGRL during the dieting period. Accordingly, our data show 
that changes in sLR11 levels associated with changes in non-HDL cholesterol. These 
changes in non-HDL cholesterol predominantly reflect altered levels of TGRL, because 
LDL-C levels were hardly affected by the diet (Table 1). Non-HDL cholesterol level is a 
known CVD risk factor and a strong predictor of CVD and death in patients with T2D 
(36, 37). Modulation of sLR11 levels may contribute to the mechanisms by which non-
HDL cholesterol affects CVD risk.
sLR11 has recently been identified as a negative regulator of brown adipose tissue 
(BAT) activity (17). It is tempting to speculate that BAT activity increased, possibly contrib-
uting to weight loss and improved metabolic profile, as a result of the decreased sLR11 
levels in our study population. The association of sLR11 levels with the glycemic state of 
the participants, as reflected by HbA1c, has been reported previously for the diabetic 
as well as the non-diabetic population (21, 23, 24). In mouse models, the increased 
thermogenic activity in brown and white adipose tissue that is associated with decreased 
sLR11 levels, has been shown to improve insulin sensitivity and the glycemic state (17). 
Interestingly, in a recent study mice lacking LR11 expression showed improved insulin 
sensitivity when fed a high-fat diet, although LR11 was shown to augment insulin receptor 
signaling in adipocytes by recycling internalized receptor molecules to the cell surface 
(26). Possibly, the plasma sLR11 levels are only remotely related to LR11 expression in 
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adipose tissue, or the effects of LR11 on systemic glucose tolerance are mainly mediated 
by circulating sLR11. Alternatively, glucose transporter type 4 (GLUT4)-storage vesicles 
were found to be enriched in LR11 (38) suggesting a possible role for LR11 in GLUT4 
trafficking. Whether sLR11 has a direct effect on glucose metabolism needs further study.
study limitations and strengths
Diet-induced weight loss induces a wide range of metabolic changes, making it difficult 
to pinpoint the precise mechanisms responsible for the observed effect on sLR11 levels. 
Therefore, it remains to be established to which aspect of the dietary intervention the 
reduction of sLR11 and its associations can be attributed. We did not study the effect on 
visceral and subcutaneous fat mass, which in part may account for the unexplained vari-
ance in sLR11 change. Moreover, we have conducted a before-after study in which we 
analyzed weight loss in a continuous way. As a consequence, we cannot fully exclude 
that lifestyle changes other than the dietary intervention have contributed to the weight 
reduction. Physical activity, however, did not change significantly. Another limitation is 
the use of change scores in the regression analyses, which may be sensitive to regression 
toward the mean, although adding baseline levels to the regression analyses did not 
change our results. Strengths of this study are the prospective design, the relatively large 
study population of overweight and obese subjects with T2D, and the relatively long 
duration of the diet intervention.
In conclusion, circulating sLR11 levels were significantly reduced during weight loss 
dieting. The reduction in sLR11 was associated with reduction in HbA1c and non-HDL 
cholesterol levels, and respectively pointing at improved glycemic control and reduced 
cardiovascular risk. The reduced sLR11 levels may contribute to the mechanism by which 
diet modulates CVD risk. Further research is warranted to elucidate the direct interactions 
between sLR11 and glucose, cholesterol and triglyceride metabolism in patients with 
T2D.
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absTracT
background and aims
Elevated levels of lipoprotein(a) [Lp(a)] are an independent risk factor for cardiovascular 
disease (CVD), particularly in individuals with type 2 diabetes. Although weight loss 
improves conventional risk factors for CVD in type 2 diabetes, the effects on Lp(a) are 
unknown and may influence the long-term outcome of CVD after diet-induced weight loss. 
The aim of this clinical study was to determine the effect of diet-induced weight loss on 
Lp(a) levels in obese individuals with type 2 diabetes.
Methods
Plasma Lp(a) levels were determined by immunoturbidimetry in plasma obtained before 
and after 3-4 months of an energy-restricted diet in four independent study cohorts. The 
primary cohort consisted of 131 predominantly obese patients with type 2 diabetes (co-
hort 1), all participants of the Prevention Of Weight Regain in diabetes type 2 (POWER) 
trial. The secondary cohorts consisted of 30 obese patients with type 2 diabetes (cohort 
2), 37 obese individuals without type 2 diabetes (cohort 3) and 26 obese individuals 
without type 2 diabetes who underwent bariatric surgery (cohort 4).
results
In the primary cohort, the energy-restricted diet resulted in a weight loss of 9.9% (95% 
CI 8.9, 10.8) and improved conventional CVD risk factors such as LDL-cholesterol levels. 
Lp(a) levels increased by 14.8 nmol/l (95% CI 10.2, 20.6). In univariate analysis, the 
change in Lp(a) correlated with baseline Lp(a) levels (r=0.38, p<0.001) and change in 
LDL-cholesterol (r=0.19, p=0.033). In cohorts 2 and 3, the weight loss of 8.5% (95% 
CI 6.5, 10.6) and 6.5% (95% CI 5.7, 7.2) was accompanied by a median increase 
in Lp(a) of 13.5 nmol/l (95% CI 2.3, 30.0) and 11.9 nmol/l (95% CI 5.7, 19.0), 
respectively (all p<0.05). When cohorts 1-3 were combined, the diet-induced increase 
in Lp(a) correlated with weight loss (r=0.178, p=0.012). In cohort 4, no significant 
change in Lp(a) was found (-7.0 nmol/l; 95% CI -18.8, 5.3) despite considerable 
weight loss (14.0%; 95% CI 12.2, 15.7).
conclusions
Diet-induced weight loss was accompanied by an increase in Lp(a) levels in obese 
individuals with and without type 2 diabetes while conventional CVD risk factors for 
CVD improved. This increase in Lp(a) levels may potentially antagonise the beneficial 
cardiometabolic effects of diet-induced weight reduction.
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inTroDucTion
Cardiovascular disease (CVD) is the main cause of morbidity and mortality in obese 
individuals with and without type 2 diabetes [1-3]. The risk of CVD in obese patients with 
type 2 diabetes has been attributed to age, smoking, hyperglycaemia, hypertension and 
dyslipidaemia [2]. Weight loss via lifestyle programmes, consisting of diet and physical 
activity, results in an improvement in conventional CVD risk factors and is first-line therapy 
to slow down the development of type 2 diabetes and the progression of its complica-
tions in overweight or obese individuals [4, 5].
Lipoprotein (a) [Lp(a)] is an independent risk factor for CVD [6-12]. Lp(a) consists of an 
LDL-like particle with an additional apolipoprotein (a) [apo(a)] attached to it. Plasma Lp(a) 
concentrations vary highly between individuals and are largely genetically determined 
by the number of copies of kringle-IV type 2 (KIV-2) in the Apo(a) protein (apo(a) isoform) 
[13-16]. A low number of copies of KIV-2, associated with elevated levels of Lp(a), has 
been shown to increase the risk of CVD [17]. A recent prospective population-based 
cohort of 56,367 participants showed a significantly higher contribution of Lp(a) levels 
to CVD and risk of myocardial infarction in patients with type 2 diabetes than in control 
participants without type 2 diabetes [18]. About 25% of the variance in Lp(a) levels has 
been attributed to lifestyle [19]. Weight loss in obese individuals has been reported to 
affect Lp(a) levels, but the results are controversial [20-23]. The effect of weight loss on 
plasma Lp(a) levels in type 2 diabetes has not yet been determined.
The aim of the current study was to determine the effect of diet-induced weight loss on 
Lp(a) levels in obese patients with type 2 diabetes. In order to confirm our findings we 
also examined the effect of weight loss on Lp(a) levels in three independent cohorts of 
obese patients with or without type 2 diabetes. As a secondary aim, we assessed the 
influence of Apo(a) isoforms on diet-induced changes in Lp(a) level in individuals with 
type 2 diabetes.
MeThoDs
Participants and interventions
The effect of weight loss was examined in four independent cohorts. The primary cohort 
(cohort 1, n=131) consisted of overweight and obese individuals (BMI >27 kg/m², 
93% obese) with type 2 diabetes who participated in the run-in phase of the Prevention 
Of Weight Regain (POWER) trial (trial registration no. NTR2264) [24]. This trial aimed 
to study long-term weight maintenance after the run-in diet phase. The sample size of 
131 patients was sufficient to find a difference of 10.6 nmol/l (5 mg/dl) in Lp(a) level 
with a baseline-to-end correlation of 0.95 between the measurements, an α of 0.05 
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and a power of 0.90. The diet started with 8 weeks of a diet very low in energy (very 
low calorie diet [VLCD]) of approximately 3000 kJ (750 kcal) per day, consisting of 
two meal replacements (Glucerna SR, Abbott Nutrition, Lake Forest, Illinois, USA) and a 
small dinner daily. Thereafter, energy intake was slowly increased up to approximately 
5500 kJ (1300 kcal) per day (a low-energy diet) over 12 weeks. Some of the baseline 
characteristics and effect of the diet on body weight in cohort 1 have previously been 
reported [25].
Cohort 2 (n=30) also consisted of overweight and obese patients (80% obese) with 
type 2 diabetes, who were recruited after the POWER trial had finished, to study the 
implementation of a VLCD for weight loss in type 2 diabetes. The participants underwent 
the same dietary intervention as the patients in the primary cohort. Cohorts 1 and 2 were 
both recruited from the outpatient diabetes clinic of the Erasmus Medical Center, Rotter-
dam, the Netherlands. To reduce risk of hypoglycaemia, doses of insulin and sulfonylurea 
derivates were lowered before the start of the diet but after baseline measurements had 
been made. During the diet, the insulin dose was regularly adjusted to achieve optimal 
glycaemic control. Metformin use was continued. Only two participants were taking 
glucagon-like peptide 1 (GLP-1) receptor agonist treatment, which was continued during 
the intervention period. Statin treatment was kept unchanged during the study.
Cohort 3 consisted of 37 obese individuals without type 2 diabetes, who were re-
cruited at the Obesity Center ‘Centrum voor Gezond Gewicht’ of the Erasmus Medical 
Center. They underwent a 3 month dietary intervention consisting of a 2000 kJ (500 
kcal) per day reduction in intake relative to baseline (low-energy diet), with macronutrient 
and micronutrient content in line with national dietary guidelines, while exercise was 
encouraged.
Cohort 4 consisted of 26 obese individuals without type 2 diabetes who underwent 
gastric banding (n=10) or a gastric bypass procedure (n=16). These participants were 
recruited at the Leiden University Medical Center, Leiden, the Netherlands. No specific 
diet was recommended beyond a staged meal progression during the first 3 months after 
surgery. Analyses were performed at baseline and 3 months after surgery.
The dietary intervention studies and Lp(a) analysis of previously collected clinical 
samples were approved by the Medical Ethics Committee of the Erasmus Medical 
Center (reference numbers MEC-2009-143, MEC-2014-090 and MEC 2016-604). 
The bariatric surgery study and use of the samples was approved by the Medical Ethics 
Committee of the Leiden University Medical Center (reference number MEC P08.215). 
All investigations were carried out in accordance with the principles of the declaration of 
Helsinki (2008). All participants provided written informed consent.
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Measurements
Blood samples were obtained after an overnight fast and were stored at -80°C until 
further analysis. Demographic variables were recorded, and weight, height and waist 
circumference (except for cohort 4) were measured. Ethnicity was expressed as white or 
non-white. HbA1c, fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol and 
triacylglycerol were measured using standard laboratory techniques.
Lp(a) measurement
Plasma Lp(a) concentrations were measured using a particle-enhanced immunoturbidi-
metric assay, which was largely independent of Apo(a) KIV repeat number (Diagnostic 
System #171399910930; DiaSys Diagnostic System, GmbH, Holzheim, Germany) 
[26]. Plasma samples were stored at -80°C for 0.5-5 years and thawed for the first time 
prior to this analysis. For each individual, levels at baseline and after intervention were 
measured in the same run. The detection limit of the assay was 6 nmol/l, and the mean 
intra-assay variability was 2.8%. Interference of triacylglycerol with Lp(a) measurements 
was minimal, as measured Lp(a) levels were less than 5% affected by the addition 
of plasma containing different concentrations of triacylglycerol (ranging from 0 to 12 
mmol/l) to plasma with a relatively high Lp(a) concentration (169 or 338 nmol/l). 
Repeated sampling in 27 healthy control individuals at an interval of 2-6 months did 
not reveal significant differences in median Lp(a): 29.3 nmol/l (interquartile range [IQR] 
17.5-87.8) vs 26.4 nmol/l (IQR 12.4-60.3), p=0.087, for day 0 and after 2-6 months, 
respectively.
In the primary cohort (cohort 1), the Apo(a) KIV repeat number was determined by im-
munoblotting, as previously described [27, 28]. When two distinct Apo(a) isoforms were 
present, the band representing the smaller isoform showed the strongest intensity in most 
cases and was used as a continuous variable. Apo(a) KIV repeat numbers were stratified 
in two groups as previously described [28]: low molecular weight (mass) (LMW) when at 
least one isoform with 22 or fewer KIV repeats was present, and high molecular weight 
(mass) (HMW) when only isoforms with more than 22 repeats were present.
statistical analysis
Normality of the data and homogeneity of variances were tested using the Shapiro–Wilk 
test and Levene’s test. Variables were expressed as mean ± SD or as median with IQR, 
and were tested for statistical significance using a two-sided paired-sample t test or a 
Wilcoxon ranking test, depending on the normality of the data. Medians and 95% CIs 
were calculated using ratio statistics, and median differences were analysed using a 
related-samples Hodges–Lehman test. Owing to the low numbers in cohorts 2, 3 and 4, 
in-depth analyses were performed only for cohort 1. We determined Spearman correla-
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tions of both baseline Lp(a) levels and change in Lp(a) with different variables of weight 
loss and glycaemic control.
Mann–Whitney U tests were used to analyse the difference in baseline Lp(a) levels 
between the LMW and HMW subgroups. Repeated-measurements multivariate ANOVA 
(MANOVA) analysis (on Blom-transformed outcome variables) was used to analyse 
the difference in change in Lp(a) between subgroups. SPSS version 21.0 (IBM corp., 
Armonk, New York, USA) and GraphPad Prism version 5 (GraphPad Software, La Jolla, 
California, USA) were used for the statistical analyses.
resuLTs
effect of diet on obese patients with type 2 diabetes (cohort 1)
The characteristics of the primary cohort (cohort 1) at baseline and after intervention are 
shown in Table 1. The 131 individuals were predominantly obese, as 93% had a BMI 
greater than 30 kg/m2. The remainder had a BMI >27 and ≤30 kg/m2. This cohort had 
a mixed ethnic background (56% white, and 44% non-white: South-Asian and African). 
Baseline Lp(a) levels correlated negatively with Apo(a) KIV repeat number (r=-0.53, 
p<0.001), baseline weight (r=-0.18, p=0.046), HbA1c (r=-0.20, p=0.022), fasting 
triacylglycerol (r=-0.19, p=0.032) and ethnicity (r=-0.34, p<0.001), and positively 
with LDL-cholesterol (r=0.18, p=0.038). We found no correlation of baseline Lp(a) levels 
with sex (r=0.08, p=0.389), fasting glucose (r=-0.17, p=0.057) or fasting insulin levels 
(r=-0.06, p=0.494). Participants of white origin had lower baseline Lp(a) levels than 
non-white participants: median 25.7 nmol/l (IQR 5.7-120.1) vs 122.0 nmol/l (IQR 
34.0-214.6) (p<0.001).
The diet resulted in a weight loss of 10.2 kg (95% CI 9.2, 11.3), which was equivalent 
to 9.9% (95% CI 8.9, 10.8) of initial body weight. Both BMI and waist circumference 
decreased significantly (p<0.001 for all). HbA1c and fasting glucose levels decreased 
(p<0.001 for both), indicating improved glycaemic control. Lipid variables also im-
proved during the dietary intervention (p<0.01 for all, Table 1).
Lp(a) levels increased significantly from 40.9 nmol/l (IQR 13.9-159.5) to 55.9 nmol/l 
(IQR 23.0-201.1) (p<0.001, Table 1). Figure 1 shows a waterfall plot of the changes 
in Lp(a) per individual. Of the 131 participants, 49 showed an increase of over 21 
nmol/l (10 mg/dl), and only six showed a decrease of 21 nmol/l or more (10 mg/dl). 
The median increase in Lp(a) levels in cohort 1 was 14.8 nmol/l (95% CI 10.2, 20.6).
The change in Lp(a) correlated with baseline Lp(a) levels (r=0.38, p<0.001) and 
with the change in fasting glucose (r=-0.17, p=0.049) and LDL-cholesterol (r=0.19, 
p=0.033). The correlations with change in fasting glucose and LDL-cholesterol disap-
peared after correction for baseline Lp(a) levels. The change in Lp(a) did not correlate 
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with sex (r=-0.04, p=0.543) or change in weight (r=-0.14, p=0.116). The change in 
Lp(a) also correlated with ethnicity (white vs non-white: r=-0.17, p=0.048), although 
this did not happen after correction for baseline Lp(a) levels. The Lp(a) response to the 
diet did not differ between white and non-white individuals in a repeated-measurements 
MANOVA (F(1;129)=0.199, p=0.656). In cohort 1, 95 out of the 131 (73%) participants 
used statins; the diet-induced change in Lp(a) levels was similar whether or not statins 
were used (F(1;129)=0.669, p=0.415).
Excluding two possible outliers, who had an increase in Lp(a) level of ≥211 nmol/l, 
did not alter the outcome.
effect of apo(a) isoform on diet-induced changes in Lp(a) levels in 
cohort 1
Forty-three participants had an LMW and 88 an HMW Apo(a) isoform. As expected, 
baseline Lp(a) levels were significantly higher in the LMW than the HMW subgroup 
(148.8 nmol/l [IQR 26.6-297.9] vs 30.6 nmol/l [IQR 6.5-119.4]; p<0.001). Lp(a) 
levels increased during the dietary intervention to 182.7 nmol/l (IQR 37.3-327.5; 
p<0.001) in the LMW subgroup and to 41.6 nmol/l (IQR 15.4-139.9; p<0.001) in 
the HMW subgroup (Fig. 2). The diet-induced effect on Lp(a) did not significantly differ 
between the LMW and the HMW subgroup (F(1;129)=1.68, p=0.197). The alteration in 
Lp(a) levels correlated strongly with baseline Lp(a) level in the HMW subgroup (r=0.43, 
p<0.001) but not in the LMW subgroup (r=0.24, p=0.118).
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figure 1. Diet-induced changes in Lp(a) level per individual in cohort 1 (n=131)
Individual participants (x-axis) are arranged according to the diet-induced change in Lp(a) level. Grey bars, 
white participants; black bars, non-white participants
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Long-term effect
Of the 131 participants in cohort 1, 69 consented to provide an additional blood 
sample 20 months after finishing the dietary intervention. This subgroup was older (55.6 
vs 51.8 years, p=0.016), had a longer history of type 2 diabetes (12.2 vs 8.8 years, 
p=0.017) and had lost more weight during the intervention (12.1 vs 8.6 kg, p=0.001), 
but did not differ from the other participants in sex distribution, ethnicity, baseline Lp(a), 
BMI, HbA1c and LDL-cholesterol, nor in change in Lp(a) during the diet. In this sub-
group, Lp(a) levels increased from 40.9 nmol/l (IQR 15.6-151.7) to 55.1 nmol/l (IQR 
24.7-200.2) during the dietary intervention. Twenty months after the diet, patients had 
regained an average of 6.8±5.5 kg of body weight but were still 5.2±6.0 kg below 
baseline weight. Lp(a) levels decreased to 43.9 nmol/l (IQR 12.2-157.8), which was 
no longer statistically different from baseline levels (p=0.050). Weight regain was not 
correlated with the decrease in Lp(a) levels from the end of the intervention to 20 months 
after the intervention (r=-0.06, p=0.626).
effect of weight loss on Lp(a) levels in secondary cohorts
The characteristics of the cohorts 2–4 at baseline and after the intervention are shown 
in Table 1. Cohort 2, consisting predominantly of obese patients with type 2 diabetes, 
showed effects of the diet similar to the primary cohort. Weight loss was 9.0 kg (95% 
CI 6.7, 11.3), or 8.5% (95% CI 6.5, 10.6) of initial body weight, and both BMI and 
waist circumference decreased significantly (p<0.01 for all). HbA1c level also decreased 
(p=0.001), but changes in fasting glucose and lipid variables (total cholesterol, triac-
ylglycerol, LDL-cholesterol and HDL-cholesterol) did not reach statistical significance in 
this small group (Table 1). During dieting, Lp(a) increased from 56.9 nmol/l (IQR 12.4-
148.9) to 61.5 nmol/l (IQR 20.4-185.9) (p=0.018; Table 1). The median increase in 
Lp(a) was 13.5 nmol/l (95% CI 2.3, 30.0).
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figure 2. The effect of the dietary intervention on Lp(a) level in the Apo(a) isoform subgroups in cohort 1.
Medians and 95% CIs of Lp(a) levels before and after the dietary intervention for the LMW Apo(a) isoform 
group (circles, n=43) and the HMW Apo(a) isoform group (squares, n=88)
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In cohort 3, which consisted of obese individuals without type 2 diabetes, the dietary 
intervention led to a weight loss of 7.1 kg (95% CI 6.3, 8.0), or 6.5% (95% CI 5.7, 
7.2) of initial body weight, and to significant reductions in BMI and waist circumference 
(p<0.001 for all). Although these participants did not have type 2 diabetes, HbA1c and 
fasting glucose levels improved in this group (p=0.002 and p=0.003, respectively). In 
addition, lipid variables improved significantly (p<0.05 for all). Lp(a) levels increased 
from 27.0 nmol/l (IQR 2.1-75.2) to 45.2 nmol/l (IQR 22.7-94.5) (p=0.001; Table 1). 
The median increase in Lp(a) was 11.9 nmol/l (95% CI 5.7, 19.0).
Cohort 4 consisted of obese individuals without type 2 diabetes who underwent bar-
iatric surgery and were followed up for 3 months. This intervention resulted in a weight 
loss of 17.4 kg (95% CI 15.0, 19.8), or 14.0% (95% CI 12.2, 15.7) of initial body 
weight (p<0.001). During this period, most lipid variables improved significantly (Table 
1). Lp(a) levels were lower after the intervention than before (falling from 36.4 nmol/l 
[IQR 17.2-91.5] to 20.6 nmol/l [IQR 6.3-104.1]), but this result did not reach statistical 
significance in this small group (Table 1). The median difference in Lp(a) level was -7.0 
nmol/l (95% CI -18.8, 5.3).
Figure 3 summarises the results obtained for the four independent cohorts. The relation-
ship between weight loss and increase in Lp(a) levels was similar for the first three 
cohorts. When cohorts 1-3 were considered together, the increase in Lp(a) correlated 
with the diet-induced weight loss (n=198, r=-0.18, p=0.012). This relationship was 
not observed for cohort 4, which consisted of individuals who lost weight after bariatric 
surgery.
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figure 3. ΔLp(a) and Δweight in the four independent study cohorts.
Means and 95% CI for Δweight (white circles) and medians with 95% CIs for ΔLp(a) (black circles) in the four 
cohorts. The size of the symbols reflects the number of participants
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Discussion
Our data show that diet-induced weight loss increased Lp(a) levels in overweight and 
obese individuals irrespective of the presence or absence of type 2 diabetes. Repeated 
sampling in healthy control participants at an interval of 2-6 months showed that the 
increase in Lp(a) levels was not explained by general environmental changes over time 
or by assay artefacts. In patients with type 2 diabetes, the extent of the increase in Lp(a) 
was mainly determined by baseline Lp(a) level, with the highest increase seen in individu-
als with the highest baseline levels. This effect on Lp(a) was independent of the Apo(a) 
isoform. Such an increase in Lp(a) levels was not observed in individuals who underwent 
bariatric surgery, suggesting that weight loss per se does not increase Lp(a) levels.
Previous studies have not shown a change in Lp(a) levels in obese adults after various 
dietary interventions aimed at weight loss [21-23]. In these studies, weight-reducing 
drugs and diets different from ours were tested, and patients with type 2 diabetes were 
not included. One study reported a decrease in Lp(a) levels in obese children [20]. This 
discrepancy in relation to our study may be explained by different age-related hormonal 
states or by differences in dietary composition. The type and content of fat in the diet may 
be an important determinant of the dietary effect on Lp(a) levels. An increased intake of 
total and saturated fat has been found to decrease Lp(a) levels, while an increased intake 
of monounsaturated fatty acids tended to increase Lp(a) levels in healthy individuals 
and those with metabolic dysregulation [29-31]. Faghihnia et al [30] have suggested 
that a low-fat diet results in an increase in Lp(a) levels that may be due to an altered 
metabolism of Lp(a) particles. The dietary interventions used in our cohorts 1-3 were all 
based on a low intake of total and saturated fat, while no specific dietary restrictions 
were prescribed for the participants in the cohort who underwent bariatric surgery. We 
previously reported that, in a random subset of participants in cohort 1, our dietary inter-
vention lowered plasma levels of the soluble form of the LDL receptor relative sLR11 [32]. 
However, diet-induced changes in sLR11 and Lp(a) levels did not correlate with each 
other (r=-0.07, p=0.635). In participants in cohort 1 from whom blood samples were 
available at 20 months of follow-up, Lp(a) levels had almost returned to baseline values, 
whereas the initial weight reduction was only partially reversed by weight regain. This 
suggests that the increase in Lp(a) levels was an acute effect of the diet. Unfortunately, 
we do not have information about the diet during the prolonged follow-up. Future studies 
on the effect on Lp(a) of weight-reducing diets with different fat contents in obese patients 
with and without type 2 diabetes are warranted.
High Lp(a) levels have consistently been associated with an increased risk of coronary 
heart disease [6, 9], and results from genetic studies indicate a causal association 
between high Lp(a) levels and CVD [17, 33, 34]. The risk of CVD associated with high 
Lp(a) levels is notably higher in individuals with than without type 2 diabetes [18]. The 
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dose–response relationship of Lp(a) levels with CVD risk has been shown to be curvilinear 
in shape, with no evidence of a threshold [35]. This suggests that the increase in Lp(a) 
levels induced by weight loss dieting observed in our study might increase the risk of 
CVD. This could potentially reduce the beneficial cardiometabolic effects that result from 
the improvement in conventional CVD risk factors after diet-induced weight loss. In the 
Look AHEAD (Action for Health in Diabetes) study (NCT00017953), the incidence of 
CVD was not reduced by a low-energy, low-fat diet and physical activity in patients with 
type 2 diabetes after 10 years of follow-up, despite an improvement in conventional risk 
factors for CVD [5]. Hypothetically, a parallel increase in Lp(a) levels could be one of 
the explanations why CVD events were not reduced by this lifestyle change. However, 
effects on Lp(a) levels were not reported in the Look AHEAD trial. Randomised clinical tri-
als addressing the effect of alterations in Lp(a) levels with lifestyle changes or medication 
on hard clinical endpoints or CVD risk are needed. Recently, the short-term efficacy and 
safety of two specific Lp(a)-lowering agents has been reported [36]. Long-term effects on 
cardiovascular endpoints are awaited.
In participants who underwent bariatric surgery, weight loss was not accompanied by 
an increase in Lp(a) level. Two previous studies have shown that bariatric surgery-induced 
weight loss in obese individuals was accompanied by a decrease in Lp(a) levels [37, 
38], whereas another study found no significant effect [39]. The effects of bariatric sur-
gery on bile acid flow and signalling, inflammation, release of gastrointestinal hormones, 
the gut microbiome and the wound healing processes may all have had an impact on 
Lp(a), resulting in the absence of a weight loss-induced increase in Lp(a) levels [40-44].
The baseline Lp(a) levels in our two cohorts with type 2 diabetes (cohorts 1 and 2) were 
relatively high compared with the two cohorts without type 2 diabetes (cohorts 3 and 
4), whereas in the Women’s Health Study and Copenhagen City Heart Study the Lp(a) 
levels in participants with diabetes were significantly lower than the Lp(a) levels in the 
control participants [45, 46]. Non-white individuals, in particular those of South-Asian 
ancestry, display markedly higher Lp(a) levels than white individuals [47-49], and are 
over-represented in our cohorts with type 2 diabetes. The change in Lp(a) during the diet 
was correlated with ethnicity. However, in the repeated-measurements analysis we found 
no difference between the white and non-white populations in ΔLp(a). This suggests that 
non-white individuals have higher baseline Lp(a) levels, and therefore show the highest 
absolute change in Lp(a) levels on dieting, but that the relative change is similar to that 
in white individuals.
The strengths of this study are its prospective design and the use of four independent 
cohorts for investigating the effect of weight loss on Lp(a), which more than doubled the 
total number of participants who have so far been studied in relation to this topic. Our 
study is descriptive in nature. Future studies should clarify the mechanisms underlying the 
increase in Lp(a) levels on diet-induced weight loss, as well as the consequence of weight 
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loss for the functionality of Lp(a). As all the participants had been referred to a tertiary 
centre, our findings may not be applicable to the entire population of overweight and 
obese patients with or without type 2 diabetes. We found that the effect of diet-induced 
weight loss on Lp(a) levels occurred irrespective of the presence or absence of type 2 
diabetes. However, some of the individuals in cohorts 3 and 4 may have had impaired 
glucose tolerance, since the classification was based on fasting glucose level and not on 
an oral glucose tolerance test. Finally, a long-term follow-up study is required to determine 
whether elevated Lp(a) levels after weight loss dieting affect the incidence of CVD in 
obese patients with and without type 2 diabetes.
In conclusion, Lp(a) levels increased significantly in obese individuals with and without 
type 2 diabetes during diet-induced weight loss, but not in individuals who underwent 
bariatric surgery. This may hypothetically reduce the beneficial cardiometabolic effects 
of a diet-induced weight loss. Therefore, Lp(a) may be an additional target in overweight 
and obese individuals on a energy-restricted diet to reduce the risk of CVD. Long-term 
follow-up studies are required to establish whether adding a specific Lp(a)-lowering agent 
to a dietary intervention will improve long-term CVD outcome in obese individuals with 
and without type 2 diabetes.
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absTracT
background and aims
Obesity is of major pathogenic importance to type 2 diabetes, it contributes to poor 
glycaemic control and increases the risk of cardiovascular disease. Over 80% of patients 
with diabetes type 2 are overweight. To achieve a more favourable risk profile, changes 
in diet and lifestyle are needed. However, current treatment programs for obese DM 
type 2 patients are not effective in the long term. In this RCT, we compare the effective-
ness of a Combined Psychological Intervention (CPI) and usual care in maintaining the 
favourable effects on weight and risk profile during 2 years of follow-up after a Very Low 
Calorie Diet (VLCD).
Methods
In a randomised parallel group intervention study, 140 patients with type 2 diabetes 
and overweight (BMI>27 kg/m2) will be recruited from the outpatient department of the 
Erasmus Medical Centre. After obtaining ≥5% of weight loss with a VLCD, participants 
will be randomly assigned to CPI or usual care for 10 weeks. CPI consists of cognitive 
behaviour therapy, problem solving therapy and proactive coping. Primary outcome 
measure is weight change (kg). Other outcome measures are Body Mass Index (BMI 
= weight (kg)/length (m)2), waist circumference (cm), systolic blood pressure (mmHg), 
HbA1c (mmol/mol), lipid levels (LDL, HDL, TG (mmol/l) and chol/HDL-ratio), antidia-
betic agents and doses, cardiovascular risk profile (UKPDS), lifestyle and quality of life 
(EuroQol EQ-5D). Psychosocial parameters are also studied, as secondary outcomes as 
well as determinants for weight loss. When successful, we want to conduct an analysis 
of the cost effectiveness of the intervention as compared to usual care.
Discussion
We expect that a CPI after a VLCD will be effective in maintaining weight loss and 
improving cardiovascular risk and glycaemic control, while being cost-effective and 
improving quality of life in patients with type 2 diabetes.
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inTroDucTion
Diabetes has become a worldwide epidemic: the estimated global prevalence was 2.8% 
in 2000 and is expected to rise up to 4.4% in 2030. In the year 2000 the excess global 
mortality attributable to diabetes was 5.2% making diabetes the fifth leading cause of 
death (1). The increase in prevalence is associated with aging of the population, the 
increasing prevalence of obesity in combination with physical inactivity. Cardiovascular 
disease is the major cause of death among patients with diabetes. An intensive phar-
maceutical and behavioural therapy treatment has been estimated to reduce the risk of 
cardiovascular and micro vascular events by approximately 50% (2). Approximately 
80% of the people with type 2 diabetes are overweight. Losing weight is the cornerstone 
of prevention and treatment of type 2 diabetes: it decreases the resistance to insulin, 
improves glycaemic control and reduces hypertension and lipid abnormalities (3-5). 
Weight loss interventions thus may contribute to a reduction of cardiovascular risk and is 
shown to reduce mortality in patients with type 2 diabetes and obesity (6). Unfortunately, 
interventions aimed at weight reduction have only a limited effect in the long run because 
of regain of the initial weight loss. The required long-term lifestyle change seems difficult 
to achieve (7). A meta-analysis of weight loss interventions in adults with type 2 diabetes 
showed that multi-component interventions including Very Low Calorie Diets may hold 
promise for achieving weight loss (7,8). However, trials with long follow-up periods are 
lacking and the most effective type of psychological intervention remains unclear.
In the present study, we determine the effect of an integrated multi-model cognitive 
group therapy, in obtaining and maintaining favourable effects on weight and cardiovas-
cular risk profile during 2 years of follow-up after a Very Low Calorie Diet.
very Low-calorie Diet
A Very Low Calorie Diet (VLCD) is a diet of less than 800 kilocalories (kcal) daily [4). The 
very low intake of fat and carbohydrates, but normal amount of proteins (0.8 g/kg ideal 
bodyweight per day) enhances lipolysis and ketosis while preventing a negative nitrogen 
balance, sparing lean body mass (9). The most commonly used VLCD’s are commercially 
available mixed-formula diets, containing various amounts of carbohydrate, fat and high 
quality protein, and have proven safety for use in patients with type 2 diabetes (9,10). 
The short-term effects (i.e. < 6 months) of a VLCD in overweight patients with type 2 
diabetes are favourable on weight, glycaemic control, hypertension and dyslipidaemia 
(11-15). However, study outcomes are less positive in the long term (i.e. > 1 year follow-
up): patients regain most of the lost weight and HbA1c returns to the same value as 
prior to the intervention. Nonetheless, participants often needed less anti-diabetic agents 
(16-18). The study of Jazet, et al (19) seems to be a positive exception: 18 months after 
a 30-day VLCD period, favourable effects on weight, blood pressure and dyslipidaemia 
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were maintained in 18 obese patients with diabetes type 2, but with no effect on 
HbA1c. The authors indicated that the success was based on the strong motivation of the 
patients to prevent a need for insulin and a slow reintroduction of normal diet. Limitations 
of this study, however, were the small intervention group and the lack of a control group.
Taken together, randomized controlled trials of sufficient duration focused on preven-
tion of weight gain after a VLCD in DM type 2 patients are required to improve the 
effectiveness of VLCDs.
Weight maintenance
To achieve weight maintenance after successful weight loss, a permanent behaviour 
change is needed. For this purpose, a variety of psychological interventions have been 
implemented in weight reduction programmes. Behaviour therapy and cognitive behaviour 
therapy (CBT) are potential psychological interventions facilitating better maintenance of 
weight loss (20). CBT is used to describe a wide range of techniques to change thinking 
patterns and behaviours. As a result, interventions are heterogeneous and the findings 
are difficult to compare. We identified three promising psychological interventions to 
attain better results in sustaining weight loss: cognitive (behaviour) therapy, problem 
solving therapy and proactive coping. In the current study, we propose to combine them 
into an integrated weight maintenance programme.
cognitive behavioural therapy
Within cognitive psychology, humans are regarded as information processing systems, 
where knowledge is organized in so-called schemas. Cognitive schemas are activated 
by incoming information, leading to cognitions (thoughts), emotions and subsequently 
to behaviour. According to the founding father of the cognitive therapy, Aaron Beck, 
emotional disorders such as depression and anxiety disorders result from dysfunctional 
schemas. Cognitive therapy focuses on changing dysfunctional schemas and cognitions, 
using behavioural experiments and challenges (21). In eating disorders, the cognitive 
model was first used to treat bulimia nervosa by adjusting overvaluation of weight 
and shape based on low self-esteem (22,23). In the treatment of obesity, this model is 
combined with the cognitive model for addiction, which is based on the assumption that 
addictive behaviour is enhanced by dysfunctional cognitions during exposure to external 
stimuli like the smell or sight of food (24). In a Cochrane review (20) concerning the effect 
of psychological interventions in the treatment of overweight and obese patients, positive 
effects of cognitive behaviour treatment on weight loss were described, particularly when 
combined with diet and/or physical activity. In a number of studies, weight loss was 
enhanced significantly by the addition of the cognitive component to an intervention 
of diet and/or exercise (25-28). Moreover, it was found that a longer duration of the 
intervention and more frequent clinical contact was associated with an increased effect. 
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However, studies with substantial follow-up (i.e. > 1 year) are lacking. In patients with 
type 2 diabetes, psychotherapy (especially CBT) improves glycaemic control (HbA1c 
−1.0%) and psychological well-being (29). Surprisingly, CBT did not appear to affect 
weight control in this patient group. Perhaps this was caused by too short duration of 
the studies (i.e. <6 months), as CBT may encourage long-term behavioral changes (29).
Problem solving therapy
Problem Solving Therapy (PST) is defined as the self-directed cognitive-behavioural process 
by which a person attempts to identify effective or adaptive solutions for specific problems 
encountered in everyday living (30,31) PST is recognized as an effective treatment of 
depression (32,33). The problem-solving model for obesity treatment was first described 
by Perri, Nezu and Viegener in 1992 (34). and proposes that active problem solving 
efforts by a health care provider can help the obese person encounter everyday problems 
in their weight management. Perri, et al. found significantly greater long-term weight 
reductions in participants, who completed a PST-intervention, compared to participants 
receiving behavioural therapy (35). Moreover, a recent study showed that people with 
better problem-solving skills lost more weight and were more compliant to therapy (36).
Proactive coping
Proactive coping (PC), directed at an upcoming instead of an ongoing stressor, is a new 
focus in positive psychology research. PC consists of efforts undertaken in advance of a 
potentially stressful event to prevent it or modify its form before it occurs. The theory de-
scribed by Aspinwall and Taylor consists of five stages: PC starts with the ‘accumulation 
of resources’ such as time, money, planning or organizational skills and social support, 
so that one is prepared as much as possible to deal with future threats. ‘Recognition’ 
refers to the ability to see a potential stressful event coming, followed by ‘initial appraisal’ 
(what is this and should I be worried about this?). The next stage consists of ‘initial 
coping efforts’: activities undertaken to prevent or minimize a recognized or suspected 
stressor. Finally, the ‘use of feedback’ involves the evaluation of the stressful event itself 
and the effects of one’s preliminary efforts (37). Schwarzer and Taubert described PC as 
a way of aspiring a positive future by accumulating resources and realistic goal setting 
(38). A recent publication has shown that the pursuit of goals was related to improved 
wellbeing, while preventing a negative future was not (39). A study of the effects of PC 
on the self-care behaviours of newly diagnosed DM patients revealed that the treatment 
was highly appreciated and even after 9 months improvements in eating and exercising 
habits were seen. In addition, the intervention was effective in reducing both weight and 
blood pressure after 9 months, but had no effect on HbA1c or lipid profile (40).
In the current randomized study, we compare the effect of a Combined Psychological 
Intervention (CPI) with usual care on weight maintenance after a Very Low Calorie Diet. 
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Hence, we do not compare the effectiveness of Cognitive Behaviour Therapy with neither 
Problem Solving Therapy nor Proactive Coping, but combine these three therapies into 
an integrated multi-model program.
objectives
The primary objective of this study is to determine if an integrated multi-model cognitive 
group therapy, is more effective in preventing weight regain after a Very Low Calorie 
Diet compared to usual care.
The secondary objectives are to investigate whether an integrated multi-model cogni-
tive group therapy following a VLCD has an effect on glycaemic control, cardiovascular 
risk profile, psychological variables and quality of life, and subsequently to determine 
which patient group benefits most of the intervention.
The tertiary objective is to determine whether the intervention is cost-effective.
ethical approval
This research is approved by the Medical Ethics Committee of the Erasmus Medical 
Centre in Rotterdam (reference number MEC-2009-143/NL26508.078.09), in compli-
ance with the Helsinki Declaration.
MeThoDs/DesiGn
Design of the study
This study is a randomized controlled parallel group intervention trial. When patients 
lose equally or more than 5% of their bodyweight in the first 8 weeks of the VLCD, they 
are included in the intervention trial testing CPI. This arbitrary cut-off value was chosen 
because of its relatively large effect on the risk profile (3). Moreover, we need a relevant 
weight loss to investigate weight maintenance after weight reduction. After randomiza-
tion, stratified to the achieved weight loss at 8 weeks, participants are assigned to one 
of the following conditions:
1. VLCD + conventional treatment
2. VLCD + conventional treatment + CPI
The duration of the diet period will be 20 weeks: 8 weeks of VLCD (<800 kcal/day) 
followed by 12 weeks of slowly reintroducing a normal, mildly energy-restricted diet (1300 
kcal/day). During week 10 of the diet, the intervention group starts with a total of 17 ses-
sions of CPI. The first 10 sessions are weekly sessions; followed by two 2-weekly sessions, 
two monthly sessions, two 3-monthly sessions and 1 session with an interval of 6 months.
Outcome measurements are assessed at baseline, after finishing the intensive CPI-period 
at 4 months and subsequently at 1 year, 1.5 years and 2 years after randomization. At 8 
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weeks (randomization after VLCD), only the primary outcome (weight) will be measured. 
Figure 1 shows the design of the study.
The study started in May 2010 with a pilot and inclusion will be completed in 2013. 
The follow-up will continue until 2015.
 
Assessment of eligibility 
based on inclusion- 
(BMI  27 kg/m2) and 
exclusion criteria 
 
Recruitment of patients 
(age 18-75, diagnosed DM 
type 2) from the outpatient 
diabetes clinic of the 
Erasmus Medical Centre 
Rotterdam. 
Written informed consent 
Baseline measurements 
Very Low Calorie Diet for 8 
weeks 
 
Randomization 
stratified to % weight loss 
in 8 weeks VLCD: 
1: 5-7,5% 
2: 7,5-10% 
3: >10% 
 
Control group: 
Diet for 12 weeks 
Usual care 
 
Intervention group: 
Diet for 12 weeks 
Usual care plus CPI 
 
Follow-up 1: 
4 months after start diet 
(directly after finishing diet) 
 
Follow-up 1: 
4 months after start diet 
(directly after finishing diet 
and 10 weekly sessions 
CPI) 
 
Follow-up 2: 
12 months after 
randomization 
 
Follow-up 3: 
18 months after 
randomization 
 
Follow-up 2: 
12 months after 
randomization 
Follow-up 3: 
18 months after 
randomization 
 
Follow-up 4: 
24 months after 
randomization 
 
Follow-up 4: 
24 months after 
randomization 
 
Loss to follow-up 
 
Loss to follow-up 
 
Loss to follow-up 
 
Loss to follow-up 
 
Not eligible 
No informed consent 
< 5% weight loss after 8 
weeks VLCD 
 
figure 1. flow-chart of the study
VLCD = Very low-calorie diet, CPI = Combined Psychological Intervention
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study population
Patients are recruited from the outpatient diabetes clinic of the Erasmus Medical Centre 
in Rotterdam by the medical team, based on the in- and exclusion criteria shown in 
Table 1. In our hospital, a tertiary referral centre, we see both patients with only oral 
antidiabetic agents and patients treated with one or more insulin doses daily. In general, 
our patients will have more complex disease and more comorbidity compared to the 
average diabetic patient referred to a GP. However, GP’s can also directly refer their 
eligible patients to our trial. Patients interested in participating in the study will receive an 
information letter and a questionnaire to be filled in at home. Two weeks later they will 
visit the outpatient clinic for an intake interview with the researcher (KACB). Eligibility will 
be checked again. After signing the informed consent form by the patient, the baseline 
measurements will be performed.
Patients with psychiatric disorders or major psychological disturbances are excluded 
from the trial. Patients with eating disorders (bulimia nervosa and binge eating disorder) 
or depression are not excluded, since it is expected that these conditions are common 
among patients with type 2 diabetes and previous research has shown that cognitive 
behaviour therapy can have beneficial effects in these patient groups (28,41-43). We 
will analyse the effect of these background variables on the outcome of the intervention.
randomization
Groups of 20 patients will start with a VLCD concomitantly. After 8 weeks of VLCD, the 
patients who lost ≥5% of bodyweight are randomly assigned to either or the intervention 
group (usual care + CPI) or the control group (usual care) with an allocation ratio of 
1:1. The stratified randomization is computer controlled, carried out by a secretary and 
supervised by a statistician, who are both not involved in the trial. The reason for a strati-
Table 1. eligibility
Inclusion criteria:
1 Diagnosed diabetes mellitus type 2
2 Age 18–75 years
3 BMI ≥ 27 kg/m2
Exclusion criteria:
6 Pregnancy or lactation during the study
7 Inadequate expression of the Dutch language (spoken and written)
8 Inability to lose ≥ 5% of bodyweight during the first 8 weeks of VLCD
9 Severe psychiatric problems
10 Significant cardiac arrhythmias, unstable angina, decompensated congestive heart failure, major 
organ system failure, untreated hypothyroidism and/or myocardial infarction, end-stage renal disease, 
cerebrovascular accident or major surgery in the last 3 months.
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fied randomization is to avoid an unsuccessful randomization with regard to weight loss 
during the VLCD. It is not possible to correct afterwards in the analysis, as it is the primary 
outcome measurement. We defined the following strata (based on clinical experience):
1. 5% - 7.5%
2. 7.5% - 10%
3. >10% weight loss after 8 weeks of VLCD.
The statistician generates the allocation sequence and hands it over to the secretary of 
the department of Medical Psychology and Psychotherapy, who is not involved in the 
study, to guarantee allocation concealment. The secretary assigns the participants to their 
group and makes a list for KACB, who will plan their study appointments.
sample size calculation
After randomization of 75 participants, the sample size calculation was carried out by 
an independent statistician to base it on realistic data. Sample size was calculated with 
SPSS 17.0, using the mixed-model ANOVA procedure described by Aberson (44). 
Alpha was set at 0.05, power at 0.80 and the baseline-end correlation at 0.90. A 
clinically relevant difference between the treatment groups is 5% weight loss (3). Mean 
weight at the start of the treatment is about 110 kg, with a standard deviation of 22, 
this equals an effect size of d = 0.25 (45). With this power calculation we estimate that 
we need 52 patients in each group. Anticipating a dropout rate of 25%, we aim for a 
total sample size of 140.
For the most important secondary outcomes we calculated the detectable difference 
with the sample size of n=104, alpha 0.05 and power 0.80 (Table 2). The detectable 
differences are quite small, so the aimed sample size seems adequate to analyse at least 
these secondary outcomes.
blinding
Given the nature of the intervention, it is impossible to blind the participants, CPI-therapist 
and researcher (KACB). Nevertheless, we will try to keep the intervention as separate as 
possible from the diabetes treatment, by giving participants strict instructions not to com-
municate about the intervention with their medical team. Patients are given the possibility 
to discuss problems related to the study with an independent medical doctor. The CPI 
group sessions will take place in another part of the hospital, outside the diabetes clinic, 
to ensure that patients and medical team will not run into each other. The VLCD is not a 
part of the intervention and can therefore be guided by the diabetes medical team. To 
avoid bias, measurements will be conducted by blinded medical assistants and analyses 
will be done by two analysts, independent of each other. The allocation sequence will be 
revealed to the researchers once recruitment, data collection and analyses are complete.
Chapter 6
104
interventions
Phase 0: very Low calorie diet
The first part of the study (before randomization) is the same for all participants and 
consists of a Very Low Calorie Diet (VLCD) for the duration of 8 weeks, with a phase-out 
of 12 weeks. When after 8 weeks of VLCD a loss of 5% or more of the initial bodyweight 
is reached, random allocation to the intervention- and control group will take place. 
Patients losing less than 5% of bodyweight in the first 8 weeks are excluded from the 
study and will receive usual care, including dietary advice. The use of a VLCD is an 
integrated part of the dietary treatment at our outpatient diabetes clinic. Normally, the 
patients are free to choose between the different types of weight reduction strategies. 
In the present study however, only one type of weight reduction therapy is used (VLCD). 
The product we use for this study is Glucerna SR®, a product specifically developed for 
patients with diabetes and based on a combination of slow released carbohydrates, a 
low-fat, high monounsaturated fatty acid content and the addition of dietary fibre. Various 
studies indicate that this product decreases the postprandial blood glucose levels, which 
may have a lowering effect on HbA1c. This diabetes-specific diet product is also used as 
a meal replacement for achieving weight reduction in people with type 2 diabetes, with 
positive effects on weight control, glycaemic control and lipid profile (46-48).We have 
chosen to use a twice a day regimen of meal replacements, together with a small dinner, 
Table 2. Power calculation secondary outcomes
Secondary outcome: SD: Detectable difference:(n = 104, β=0.8 α=0.05)
Waist circumference 11 2.75 cm
Blood pressure sys/dias 20/20 5/5 mmHg
Total cholesterol 1.4 0.35 mmol/l
LDL cholesterol 1.0 0.25 mmol/l
HDL cholesterol 0.7 0.2 mmol/l
Triglyceride 3.0 0.75 mmol/l
HbA1c 12 3 mmol/mol
Insulin 50 12.5 IU
Depression (HADS score 0–21) 3 0.75
Anxiety (HADS score 0–21) 4 1.0
Self-esteem (RSE score 10–40) 5 1.25
Fatigue (CIS score 8–56) 13 3.25
Concentration (CIS score 5–35) 8.5 2.1
Motivation (CIS score 4–28) 6 1.5
Activity (CIS score 3–21) 5 1.25
Quality of life (EuroQol 5D score 1–3) 0.5 0.125
Quality of life (EuroQol VAS 1–100) 21 5.25
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providing 750 kcal, 67 g carbohydrates, 54 g protein and 32 g fat (of which 16 g 
monounsaturated fatty acids (MUFA)) a day and RDA recommendations in micronutrients. 
We believe that enabling the participants to have dinner with their family during the 
VLCD will improve compliance.
We have developed a protocol for the use of a VLCD in patients with type 2 diabetes, 
where we describe the different aspects of the treatment. Oral anti-diabetic agents (ex-
cept Metformin) and short-acting insulin analogues are discontinued, while the dosage 
of long-acting insulin analogues and biphasic mixtures is halved, to avoid severe hypo-
glycaemia. GLP-1 or DPP-4 inhibitors will be continued. During the VLCD and gradual 
transition to a normal diet, medication is adjusted by means of glucose self-control and 
frequent contact with diabetes nurses and dieticians. The dose of any antihypertensive 
medication is also adjusted during VLCD and follow-up, in consultation with the respon-
sible physician. Re-alimentation takes place by slowly reintroducing normal food in 12 
weeks’ time, until participants use a lightly energy restricted diet (1300 kcal a day), 
according to national dietary guidelines.
Phase 1: control group
Following the VLCD-period and gradual reintroduction of normal diet, the control group 
receives usual care, provided by the diabetes team of the out-patient diabetes clinic of 
the Erasmus Medical Centre. Usual care consists of a 3-monthly visit to the physician and 
diabetes nurse, including medical examinations. Dietary treatment is part of usual care 
by referral to a specialized dietician. Patients are free to make additional appointments 
with their dietician in- or outside the hospital and they can choose to follow whatever 
diet they would like during the follow-up period. Both the number of visits to a dietician 
and the dieting methods, products and duration of the diet are noted during the follow-up 
period of 2 years. Dieticians in our hospital are all trained in motivational interviewing 
to motivate the patients in changing their lifestyle. All members of the diabetic team 
encourage the patients to get enough exercise, but we do not refer to an exercise 
programme. Patients in need of psychological help (ie psychological disorder, clinical 
depression, major eating disorder) are referred to a clinical psychologist in- or outside 
the hospital. In our population, these referrals are rare. Nonetheless, the number of visits 
to a psychologist as well as to other caregivers will be noted during this trial. CBT or 
techniques of PST and PC are no part of usual care.
Phase 1: intervention group
After 8 weeks of VLCD, the participants allocated to the intervention group start with 
CPI in groups of up to 10 patients, in addition to the basic treatment for diabetes and 
obesity, focusing on (self) regulation of blood glucose and the prevention/reduction 
of complications, according to national guidelines. The CPI sessions are guided by a 
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trained psychologist/psychotherapist, with experience in diabetes care. Two psycholo-
gists (HB and AVTS) are involved in this study, so we can investigate the ‘therapist-effect’.
The first 10 weekly sessions consist of cognitive behaviour therapy, partly based on 
the method developed by Werrij and colleagues from the University of Maastricht (27). 
These CBT meetings are followed by 7 relapse prevention sessions. The aim of the first 
10 sessions is to restructure dysfunctional cognitions on lifestyle, weight and body per-
ception. Sessions 11–17 aim to prevent relapse by combining intervention techniques of 
CBT, PC and PST. Table 3 presents the treatment protocol in brief.
Table 3. Brief presentation of the treatment protocol
Weekly sessions  
Session 1 Introduction of the therapist and the group members
 Agreements on attendance, commitment, homework and privacy
 Setting realistic treatment goals
 Explaining the rationale of the cognitive treatment
 Introducing relevant concepts op CBT (situation, thoughts, emotions, behaviour) and the use 
of the diary
Sessions 2 – 4 Discussing rationale and the concepts of CBT
 Explaining unrealistic and automatic thoughts
 Identifying and challenging dysfunctional cognitions about eating, weight and shape (by 
Socratic dialogue)
 Homework: cognitive diaries
Sessions 5 – 8 Introducing the behavioural experiment
 Challenging dysfunctional cognitions by setting up a behavioural experiment
 Identifying and challenging ‘core beliefs’, the underlying self-schemas
 Homework: cognitive diaries and behavioural experiments
Sessions 9 – 10 Preparing for the oncoming ending of weekly sessions
 Identifying and challenging dysfunctional cognitions about relapse
 Introducing relapse prevention sessions
Relapse prevention sessions
Session 11 Challenging dysfunctional cognitions about relapse
 Setting goals for the long term
 Explaining Problem Solving Treatment and Proactive Coping
Session 12 – 16 Implementing PST and PC in an individual plan
Session 17 Preparing for treatment ending
 Challenging dysfunctional cognitions about treatment ending
 Personal reminder in difficult times
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After session 1, the structure of each session is as follows:
– time for questions following the previous session
– discussing home-assignments
– explaining and practicing of cognitive (behavioural) techniques
– discussing new home-assignments
– summary and evaluation of the session (by completing the Session Rating Scale)
In sessions 1–5 dysfunctional cognitions about eating, weight and shape are identified 
and challenged. Also exercise will be included in the sessions. Cognitive diaries are 
introduced and participants are encouraged to use these diaries at home to record per-
sonal critical situations and dysfunctional thoughts. They also score the credibility of their 
dysfunctional thoughts (0-100%). Furthermore, the validity of the dysfunctional thoughts 
is tested and alternative thoughts are generated. Guided by examples of the group, the 
group is acting as a research team, investigating the validity of dysfunctional cognitions 
and creating alternative and more realistic thoughts. The new thoughts are again scored 
on credibility (0-100%). Methods used for testing the validity of a person’s thoughts 
are the Socratic dialogue and behavioural experiments. Behavioural experiments are 
set up during the session, carried out at home, and discussed in the next session. The 
underlying schemas (‘core beliefs’) are explored during sessions 6–10. The validity of 
self-schemas is tested in the same way as the other dysfunctional thoughts and recorded 
in the diary. Subsequently, 7 relapse prevention meetings are held to stabilize behaviour 
change, with increasing intervals until the end of the study (2 years). During these relapse 
prevention meetings, the acquired techniques will be repeated. In addition, techniques of 
Problem Solving Therapy are used to help participants coping with everyday problems 
they encounter while implementing their lifestyle changes. Based on individually set 
goals, experienced problems are identified and possible solutions will be put forward 
in a group brainstorm session. The participant will choose the most appropriate solu-
tion and creates and carries out an implementation plan. In this plan, the participant 
formulates the solution as a SMART (Specific, Measurable, Attainable, Realistic, Timely) 
goal and considers which steps should be taken to achieve this goal. Subsequently, the 
participants will be encouraged to identify barriers that may arise while trying to achieve 
their goals. Under guidance of the psychologist, activities will be defined which can be 
undertaken to prevent the occurrence or diminish the effect of these potentially threats 
(Proactive Coping).In following relapse prevention sessions, the implementation plan 
is evaluated and new (sub) problems are chosen to tackle. By linking Problem Solving 
Therapy to Proactive Coping and cognitive restructuring of (relapse) thoughts, we hope 
to have created a powerful intervention to provide participants skills to prevent and cope 
with relapse in their behaviour.
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outcome assessment
Outcome measurements (see below) are assessed at baseline (before start VLCD), and 
again at 4 months (after VLCD and 10 CPI sessions), 1 year, 1 ½ years and 2 years. 
Demographic variables are assessed at baseline by use of a self-administered ques-
tionnaire, which is checked during the intake interview with the investigator. All other 
secondary outcomes are assessed at baseline, after 4 months, 1 year, 1 ½ years and 2 
years, using self-administered questionnaires, except of the Session Rating Scale, which 
is filled in after every CPI session. Data are managed by use of the trial management 
system ‘EXPeRT Clinical’ of OmniComm, USA.
Primary outcome
The primary endpoint with respect to the efficacy of CPI is the differential course of 
weight (kg) between both study groups, measured at 8 weeks and at 2 years follow-up. 
Weight is measured to the nearest 0.1 kg, after removal of shoes using a Seca 888 
compact digital flat scale.
Secondary outcomes
1. Anthropometric measurements: Height is measured to the nearest 0.5 cm without 
shoes using a Seca stadiometer. Body Mass Index is calculated as weight divided 
by height squared (BMI = weight (kg)/height (m)2). Waist circumference (cm) is 
measured at the level midway between the lowest rib margin and the aliac crest. 
Hip circumference is measured at the widest point over the buttocks. Both waist- and 
hip circumference are measured by the nearest 0.5 cm, using a tape-measure. 
Subsequently, waist-hip ratio (WHR) is calculated.
2. Cardiovascular risk profile by use of the UKPDS risk engine (49):
a.  Systolic and diastolic blood pressure (mmHg) are measured twice in upright position, 
while the patient had rested for at least 5 minutes with an Omron M4-I Intelli-sense 
device. The second value will be used.
b.  Blood samples are taken to asses total cholesterol, LDL-cholesterol, HDL-cholesterol 
and triglycerides (mmol/l), measured on a Roche Modular P 800, reagents used 
from Roche, methods used from Roche are Cholesterol Chod-pap, HDL-c plus 3rd 
generation, LDL-c plus 2nd generation and Triglycerides GPO-PAP.
3. Glycaemic control:
a.  HbA1c (mmol/mol), measured on a Menarini HA-8160, reversed-phase action 
exchange chromatography.
b.  HOMA-%S calculated by measuring fasting plasma glucose (mmol/l), (measured 
on a Roche Modular P 800, reagent used from Roche, method used from Roche is 
Glucose Hexokinase) and fasting insulin (mmol/l)
c.  Glucose lowering medication (insulin (IU/day) and antidiabetic agents (mg/day))
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4. Psychological measurements
a.  Anxiety and depression are measured by the Hospital Anxiety and Depression 
Scale (HADS) (50,51). The HADS consists of a 7-item Anxiety scale and a 7-item 
Depression Scale. The items are scored from 0 to 3 and the range of scores is 
0 – 21. A score between 0 and 7 excludes depression/anxiety. A score of 8–10 
indicates a possible depression/anxiety. A score of 11–21 is indicative of a prob-
able depression/anxiety.
b.  Somatic symptoms are measured by the VOEG-13 (‘Vragenlijst Onderzoek Ervaren 
Gezondheid’) (52), a Dutch 13-item questionnaire used to measure the health of a 
population, often used in social science research. The items consist of somatic symp-
toms like headache, nervousness and lethargy and respondents indicate whether 
they have these symptoms or not. A higher score indicates more somatic symptoms 
and a worse perceived health.
c.  Fatigue is measured by the Checklist Individual Strength (CIS) (53) which quantifies 
subjective fatigue and related behavioural aspects. The CIS consists of 20 state-
ments for which the respondent has to indicate on a 7-point scale to what extent 
the particular statement applies to him or her (1 = Yes, that is true; to 7 = No, that 
is not true). The statements refer to four fatigue aspects: (1) subjective fatigue (2) 
reduced motivation (3) reduced activity and (4) reduced concentration. For the CIS 
a cut-off point of >76 has been established [54).. People with a score above this 
cut-off point are at an increased risk of long-term sickness absence.
d.  Self-esteem is measured by the Rosenberg Self-Esteem Scale (RSE) (55). The RSE 
is a 10-item questionnaire that measures global self-esteem. Items are scored on a 
4-point scale. A higher score indicates a more positive self-esteem. Scores below 
21 indicate low self-esteem.
e.  Eating disorders are measured by the Eating Disorder Examination-Questionnaire 
(EDE-Q) (56), a 36 item questionnaire that measures concerns about shape, weight 
and eating, restraint and binge eating. Subscale scores for restraint and shape, 
weight and eating concern range between 0–6. A higher score indicates more 
severe eating psychopathology. Because binge eating cannot be measured reli-
ably by the EDE-Q, we use a questionnaire composed by Werrij, et al (28). for 
diagnosing binge eating disorder (BED), based on the DSM-IV criteria for BED. BED 
is diagnosed when respondents report eating binges twice a week or more.
f.  Session rating. How the participants value the sessions is measured by the Session 
Rating Scale (SRS) (57). The SRS is an ultra-brief alliance measure designed specifi-
cally for every session clinical use. The SRS consists of four 10-cm visual analogue 
scales (relationship scale, goals and topic scale, approach or method scale, overall 
evaluation scale), with instructions to place a hash mark on a line (continuum) with 
negative responses depicted on the left and positive responses indicated on the 
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right. Based on a total possible score of 40, any score lower than 36 overall, or 9 
on any scale, could be a source of concern and therefore prudent to invite the client 
to comment.
5. Lifestyle
a.  We developed a lifestyle questionnaire on diet history, smoking, drinking habits, 
drug use and hours sleep.
b.  Physical activity is measured using the SQUASH (Short Questionnaire to Assess 
Health Enhancing Physical Activity) (58). The SQUASH collects days per week, 
average time per day, and effort for physical activities such as commuting activities, 
leisure time and sport activities, household activities, and activities at work or school. 
Total minutes of activity are calculated for each question by multiplying frequency 
(days per week) by duration (minutes per day). Activity scores for separate questions 
are calculated by multiplying total minutes of activity by an intensity score (range 
1–9). The total activity score is calculated by taking the sum of the activity scores for 
the separate questions.
6. Cost-effectiveness
a.  Quality of life is measured by the EuroQol (EQ-5D) (59,60). The EQ-5D is 5-item 
self-report questionnaire on which participants report if they experience any 
problems in mobility, self-care, usual activities, pain and anxiety/depression. Each 
dimension has 3 levels: no problems, some problems and severe problems. The 
scores on the three dimensions can be combined into one co called ‘utility’ score, 
which represents the societal value of quality of life. The utility score has a range 
from 1.00 (the value of health without health problems) till 0.00 (the value of health 
problems as bad a death). This societal value of quality of life is used as input for so 
called Quality Adjusted Life Years (QALY) analysis, as the societal perspective is the 
preferred perspective in health economics. The EuroQol instrument contains also the 
EQ-VAS, a vertical visual analogue scale with the anchors best imaginable health 
(score of 100) and worst imaginable health (score of 0). This EQ--VAS represents 
the patient’s perspective of quality of life.
b.  Costs are measured by the Trimbos/iMTA Questionnaire for Costs associated with 
Psychiatric Illness (TiC-P) (61). The TiC-P measures direct medical costs due to health-
care utilization during the past four weeks. Also, it registers the indirect non-medical 
costs due to productivity loss during the past two weeks.
Patient follow-up and compliance
Follow-up measurements will take place combined with evaluation group meetings. For 
patients in both groups, follow-up visits to the physician, diabetes nurse and dietician 
are registered. A common limitation of weight loss studies is a selective loss to follow-up: 
higher drop-out rates occur among patients, who do not achieve their weight loss goals. 
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We want to tackle this problem by use of incentives to keep all patients in the trial: 
motivating phone calls of the researcher, little gifts during the program, etc. Furthermore, 
we will perform a follow-up and analysis of the drop-outs after completion of the study 
and compare completers and drop-outs at base-line. For this purpose, the drop-outs will 
be interviewed by a medical student, who is not involved in the study. Compliance to the 
intervention is assessed by registration of the attendance to the CPI sessions: participants 
are considered non-compliant when they are absent on more than 8 sessions. Since we 
expect that the treatment will be less effective when more than 8 sessions are missed, 
this non-compliant participants will be considered drop-outs. We have conducted a pilot 
study to improve our research protocol. We will not perform interim analyses and we will 
not define stopping rules, since the intervention has no serious side-effects.
Data/results pilot study
In order to test the protocol we conducted a pilot study, in which we included 13 patients 
to assess the study design and logistic pathways of the VLCD-period and the first 10 
weeks of CPI. In this pilot study, we found that the protocol was feasible and that no 
Table 4. baseline characteristics pilot group
 Baseline (n=13)  
Sex (%) Males 25%
Females 75%
Age (y)  49.5
Insulin dependent (%) Insulin dependent 75%
Non-insulin dependent 25%
Table 5. Outcome measurements pilot group
 Baseline (n=13) T1 = 4 months (n=13) 95%CI
Weight (kg) 114.8 106.0*** [5.2-12.4).
Waist circumference (cm) 121.4 113.7** [3.2-12.2).
Systolic BP (mmHg) 144.6 127.9* [1.1-32.2).
Diastolic BP (mmHg) 86.1 78.0 [−0.4-16.7).
Total cholesterol (mmol/l) 5.0 4.5 [−0.2-1.3).
HDL cholesterol (mmol/l) 1.7 1.3 [−0.3-1.3).
LDL cholesterol (mmol/l) 2.6 2.5 [−0.3-0.5).
Triglycerides (mmol/l) 3.6 2.6 [−1.1-3.0).
HbA1c (mmol/mol) 66.3 66.6 [−9.8-9.1).
Insulin (IU) 82.3 32.3* [7.3-94.7).
Depression score (HAD) 
>8 = (sub)clinical
5.7 4.6 [−1.5-3.7).
Paired samples T-test *p<0.05 **p<0.01 ***p<0.001
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major changes had to be done. The only change we made was in the lay-out of the 
questionnaires, making them better understandable to our participants. Results of this pilot 
study (baseline and T=4 months) are shown below (Table 4 and 5).
statistical analyses
All analyses will be conducted according to the intention-to-treat as well as the on-
treatment principle. We consider participants on-treatment when they miss less than 8 
sessions CPI. At baseline, comparability between the control- and intervention group will 
be assessed to test the success of the randomization. As measures of central tendency 
for numerical data we will use the mean (in case of normal distribution) and median 
values (in case of non-normal distribution), with respectively the standard deviation 
and interquartile range as measures of dispersion. Mixed modelling, also known as 
random effect modelling, multilevel or hierarchical linear regression analyses will be 
applied for longitudinal analyses of the data. Mixed modelling can efficiently handle 
data with missing and unbalanced time-points. It corrects for bias when absence of data 
is dependent on characteristics that are present in the models (missing at random, MAR) 
(62). There will be two levels in the models. The patients constitute the upper level, their 
repeated measures the lower level. First, for each outcome variable a saturated model 
will be postulated, with the primary or secondary outcomes as dependent variables. 
The saturated models will include treatment group, time, quadratic time, logarithm of 
time and all treatment-time interactions as fixed effects. The deviance statistic (63) using 
restricted maximum likelihood (64) will be applied to determine the covariance structure. 
Next, using Wald tests, the saturated models will be reduced by eliminating insignificant 
fixed effects. The significance of the difference between the saturated models and the 
parsimonious final models will be determined with the deviance statistics using ordinary 
likelihood.
Discussion
To our knowledge, this trial is the first randomized controlled trial to test the effects of an 
integrated multi-model cognitive group therapy in the battle against weight regain after 
a successful weight loss intervention (VLCD) in patients with type 2 diabetes. Weight 
regain is common in the obese population in general, but even more pronounced in the 
diabetes type 2 population, and with more devastating effects on their health outcomes. 
The strength of this study is the combined psychological intervention (CPI) of cognitive 
restructuring, problem solving treatment and proactive coping, which will provide power-
ful tools to the participants for maintaining behavioural change and improving health 
outcomes. We expect that adding CPI to a VLCD will be effective in maintaining weight 
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loss, improving lifestyle and, as a result, leading to improved glycaemic control and a 
reduction of cardiovascular risk.
We expect that a number of factors may influence the treatment effect, therefore we 
will also examine potential determinants of weight maintenance, such as depression, 
anxiety, self-esteem, fatigue, somatic symptoms, eating disorders and lifestyle. Apart 
from being predictive for the success of the intervention, these factors may be changed 
by the treatment itself and therefore will be followed over time as secondary outcome 
measurements.
It is expected that if the intervention is successful, it will also be cost effective since the 
costs of group counselling are relatively low and the expected reduction of medication, 
prevention or delay of complications and a reduction of hospital admissions are consid-
ered major cost savings. If the therapy is indeed effective, a formal cost effectiveness 
analysis will be performed.
Few studies have implemented interventions to sustain weight loss for longer than 18 
months. In this study, we opt for a follow-up period of 2 years, enabling predictions on 
long-term behavioural change and weight maintenance. During the follow-up period, 
participants will have relapse-prevention group meetings with increasing intervals to 
stabilize behaviour. It is known that the effect of an intervention reduces when the contact 
with the therapist stops, and one can therefore expect that the participants experience 
a relapse in their behaviour after the follow-up period. The last session op CPI will be 
at 1,5 years after randomization, leaving the participants 6 months ‘to themselves’. 
Obviously, our patients remain under supervision of the healthcare team after completion 
of the study and will be encouraged to continue their good habits. Nevertheless, after 5 
years, we will try to repeat the assessment of the main outcome variables to determine 
the long-term effect.
Limitations
This trial is explanatory in design in relation to the measures of process but pragmatic in 
terms of the comparison with usual care rather than a specified alternative group. We 
chose this design to enable analysis of an additional intervention on top of usual care 
in a population already receiving multiple interventions. The pragmatic approach and 
planned economic analysis aim to facilitate implementation of the intervention when 
successful, but this design does not identify the optimal psychological therapy.
If the intervention is successful, it cannot be ascertained which of the 3 therapies 
involved determined the success. However, each of the treatments has been studied 
separately and is more or less proven effective in achieving weight reduction and 
maintenance (20,26,28-32,34-36,40). We expect that a diet with a combination of 
several forms of cognitive behaviour therapy together will have a greater impact than the 
individual factors.
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Clearly the assumption is that the overlap of effects of the different types of interventions 
is negligible. This is not necessarily true. Hence, the present study is designed to study 
the effect of a combination therapy, but cannot identify the optimal combination of 
interventions.
Another limitation is the comparison to usual care only. One could argue that the 
participants in the intervention group may benefit from the attention they get, and not 
necessarily from the CPI. In our study design, it is impossible to distinguish between 
the effect of attention and the effect of the intervention itself. Our choice to compare 
our intervention on top of usual care with usual care only, is based on the fact that this 
kind of comparative effectiveness design has more clinical relevance. Such design is a 
necessary condition for a cost effectiveness analysis, as cost effectiveness is measured in 
relation to the dominant alternative treatment strategy. Moreover, the individual interven-
tions have been shown effective in comparison with other psychological interventions, 
exercise or placebo as a control (27,35,40,65).
We are aware of the fact that our population is not generalizable to the entire group 
of overweight patients with type 2 diabetes.
One can speculate that patients, who agree to participate in the study and are able 
to achieve a 5% weight reduction in 8 weeks, are expected to be more motivated then 
patients, who refuse to participate or who fail to lose sufficient weight. Randomization 
will distribute this selection bias equally to the CPI and the control group. Nonetheless, 
our findings will solely be applicable to patients, who are motivated to reduce their body 
weight.
Our hospital is a tertiary referral centre and as a result the patients often have end 
stage disease with multiple complications. Due to this selection, motivation, compliance 
and treatment outcome are expected to be low, potentially resulting in underestimation 
of the effect. However, GP’s will also be able to refer their eligible patients directly to the 
trial. Those patients often have less severe disease and complications.
Insufficient command of the Dutch language is an exclusion criterion of this investiga-
tion, because the cognitive training is given in Dutch and the workbook and homework 
assignments must be understood and carried out in Dutch as well. In this way, a part of 
the immigrant population is excluded and the study population will not reflect the entire 
diabetic population of the Erasmus MC.
We will use incentives (motivating phone calls, little booklets etc.) to minimize drop-out. 
This effect will be the same for the control group and the intervention group, not affecting 
the results. However, it will have an effect on the generalizability of the study because 
the less motivated participants are more likely to remain in the study where they would 
normally drop-out.
We are aware of the impact, especially on the control group, of the large measure-
ment burden due to all the psychological questionnaires. We will discuss this with the 
115
Design of the Prevention Of WEight Regain in diabetes type 2 (POWER) trial
participants beforehand and expect that they find 5 times 30 minutes of completing 
questionnaires is acceptable in the light of the weight loss intervention they will receive.
future implementation
If this intervention proves to be effective and cost-effective, we will promote implementa-
tion into diabetes care.
In the present study, we use a VLCD because it leads to quick and substantial weight 
loss, but off course the multi-model cognitive therapy can be combined with any weight 
loss intervention (i.e. low calorie diet, low carbohydrate diet, exercise), to sustain the 
effect.
The study will start in 2010 and the inclusion of patients will take approximately 3 
years. After the follow-up period of 2 years, we expect the results to become available 
in 2015.
abbreviations
BMI, Body Mass Index; CBT, Cognitive Behaviour Therapy; PST, Problem Solving 
Therapy; PC, Proactive coping; CPI, Combined Psychological Intervention; VLCD, Very 
Low Calorie Diet; LDL, Low Density Lipoprotein; HDL, High Density Lipoprotein
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absTracT
objective
Weight loss programs for adults with type 2 diabetes are not effective in the long term 
due to regain of weight. Our aim was to determine the efficacy of cognitive behavioral 
group therapy (CBGT) in preventing weight regain after a very low-calorie diet (VLCD) in 
obese adults with type 2 diabetes.
research design and methods
We randomized 158 obese adults (BMI 36.3 [32.5-40.0]) with type 2 diabetes, who 
achieved ≥5% weight loss with an 8-week VLCD, to usual care or CBGT (17 group 
sessions) to prevent weight regain, on top of usual care. The primary outcomes were the 
between-group differences after two years in (1) body weight and (2) weight regain. 
Secondary outcomes were HbA1c, insulin dose, plasma lipids, depression, anxiety, self-
esteem, quality of life, fatigue, physical activity, eating disorders and related cognitions.
results
The difference in body weight at two years was -1.2 [95% CI -7.7-5.3] kg (P=0.7). 
Weight regain was 4.7 [95% CI 3.0-6.3] kg for the control group and 4.0 [95% CI 2.3-
5.6] kg for the CBGT group, with a between-group difference of -0.7 [95% CI -3.1-1.6] 
kg (P=0.6). None of the secondary outcomes differed between the two groups.
conclusions
CBGT after diet-induced weight loss did not prevent weight regain, and did not improve 
cardiovascular risk factors and the psychological wellbeing in obese adults with type 2 
diabetes. Our results suggest that there is no scientific justification for offering CBGT to 
optimize the long term effect of weight loss dieting in this patient group.
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inTroDucTion
Lifestyle interventions that reduce weight improve a number of cardiovascular disease 
risk factors in adults with type 2 diabetes (1, 2), but studies on hard endpoints have 
been disappointing. In the Look AHEAD trial, an intensive lifestyle intervention did not 
result in an effect on cardiovascular outcomes (3). Weight regain during follow-up in a 
substantial proportion of the participants has contributed to this unforeseen outcome (4, 
5). Obviously, non-invasive weight loss interventions require strategies that prevent regain 
of body weight to achieve clinically relevant effects.
Cognitive behavioral group therapy (CBGT) has been shown effective in weight 
management and weight loss maintenance after dieting in obese adults without type 2 
diabetes (6, 7). CBGT is a psychological intervention aimed at changing dysfunctional 
thoughts about self-image and behavior into more realistic, helpful thoughts, hereby 
facilitating long term behavioral change. In type 2 diabetes, only two observational 
studies have been conducted reporting favorable effects on weight loss of CBGT as part 
of weight loss programs (8, 9). The effect of CBGT on maintenance of weight loss has 
not been investigated in patients with type 2 diabetes.
The primary objective of the present study was to determine the efficacy of CBGT on 
maintaining weight during two years after diet-induced weight loss in overweight and 
obese adults with type 2 diabetes. The secondary objectives were to evaluate the effects 
of CBGT on cardiovascular risk factors and psychological wellbeing.
research DesiGn anD MeThoDs
study design
The protocol of the ‘Prevention Of Weight Regain’ (POWER) trial has been published 
previously (10). This study was a parallel-group, randomized clinical trial, conducted 
between March 2010 and May 2015, and was approved by the Medical Ethics 
Committee (MEC-2009-143/NL26508.078.09) in compliance with the Helsinki Dec-
laration (2008). All participants provided written informed consent.
study Population
Overweight and obese (BMI>27 kg/m²) patients with type 2 diabetes aged 18-75 
years were recruited from the outpatient diabetes clinic of the Erasmus MC. Our hospital 
is a tertiary referral center, but patients with severe comorbidity were excluded for this 
trial. Some of the eligible patients were referred by their GPs specifically for participation 
in our trial. Exclusion criteria were: pregnancy; lactation; inadequate understanding 
of the Dutch language (spoken and written); severe psychiatric problems; significant 
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cardiac arrhythmias; unstable angina; decompensated congestive heart failure; carci-
nomas; major organ system failure; untreated hypothyroidism; end-stage renal disease; 
myocardial infarction, cerebrovascular accident or major surgery during the previous 3 
months. Of the subjects who met the criteria but declined to participate, we recorded 
age, sex and ethnic origin.
Weight loss dieting
After collection of baseline data, participants started with a very low-calorie diet (VLCD) 
of approximately 750 kcal/day for 8 weeks. Blocks of twenty participants started with 
the diet concomitantly. The daily diet consisted of 2 diabetes-specific meal replacements 
(Glucerna SR, Abbott Nutrition B.V.) plus 75 grams of lean meat, 150 ml of skimmed 
milk, and low-carbohydrate vegetables ad libitum. To reduce the risk of hypoglycemia, 
doses of sulfonylurea derivates and insulin were reduced at the start of the dietary inter-
vention. After 8 weeks the diet was changed into a low-calorie diet of 1100-1300 kcal/
day, gradually increasing the intake during the following 12 weeks. From then on, the 
participants used a diet based on national health recommendations, aiming at weight 
maintenance. During the entire study, 60 minutes of moderately intensive daily exercise 
was recommended, and antidiabetic medication and insulin doses were adjusted by 
the responsible physician based on plasma glucose levels. Other medication remained 
unchanged.
Randomization and Masking
After 8 weeks of the VLCD, the participants who lost >5% of bodyweight were randomly 
assigned to either the usual care group or the CBGT group with an allocation ratio of 
1:1. The block randomization was stratified to weight loss: categories 5-7.5%, 7.5-10% 
and >10%. The participants, CBGT therapists and primary researcher (KAB) were not 
blinded for the intervention, whereas the medical team at the outpatient clinic was. 
Participants were not allowed to talk to their medical team about the CBGT sessions. The 
treatment of diabetes and its complications (according to the national guidelines) was not 
influenced by the allocation of the participants. Blinded medical assistants conducted the 
measurements (weight, waist circumference, blood pressure) and all statistical analyses 
were conducted by two researchers independently.
Control group: usual care
The control group received the usual care for diabetes regulation and cardiovascular 
risk management in our tertiary medical referral center. This consisted of scheduled visits 
every 3-6 months (often on separate occasions) to the internist and diabetes nurse, plus 
referral to a dietitian or psychologist when indicated. Additionally, during the diet period 
the participants using insulin frequently contacted the diabetes nurse by mail or telephone 
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to optimally adjust their insulin dose according to their glucose levels. The increased 
attention (during additional visits) given to the CBGT group was not compensated for in 
the control group.
Intervention group: cognitive behavioral group therapy (CBGT) added to usual care
After randomization, participants allocated to the intervention group started with CBGT 
with up to 10 participants per group. The first 10 sessions were weekly; these were 
followed by two fortnightly sessions, two monthly sessions, two 3-monthly sessions, and 
the last session took place 18 months after randomization. The CBGT sessions were 
given by a trained psychologist/psychotherapist (HB or AVTS) experienced in CBGT as 
well as in diabetes care.
The aim of the first 10 sessions, including 1 partner-session, was to restructure dys-
functional cognitions on lifestyle, weight and body perception, based on the method 
developed by Werrij and colleagues at the University of Maastricht (11). Sessions 11-17 
were aimed at preventing relapse by combining intervention techniques of Cognitive 
Behavioral Therapy (CBT) with pro-active coping and problem solving therapy (12-14). 
A detailed description of the intervention has been published previously (10). The CBGT 
was given on top of usual care.
outcome Measures
All primary and secondary outcome variables were pre-specified an described in more 
detail in the study protocol (10). Outcome variables were assessed at baseline, at ran-
domization after eight weeks of VLCD (primary outcome only), and at 12 weeks (after 
the weekly CBGT sessions were finished), 52 weeks, 78 weeks and 104 weeks after 
randomization.
The primary endpoints were the differences between the study groups in body weight 
(kg) after two years of follow-up and in weight regain (kg) from randomization to two 
years. Weight was measured to the nearest 0.1 kg after removal of shoes, using a Seca 
888 compact digital flat scale.
Secondary outcomes (all defined as between-group differences) were as follows: 
change in weight (kg) from baseline to two years of follow-up; two year estimates 
and change from baseline to two years in waist circumference (cm); systolic blood 
pressure (mmHg); total cholesterol (mmol/l), LDL-cholesterol (mmol/l), HDL cholesterol 
(mmol/l), triglycerides (mmol/l) and HbA1c (%/mmol/mol), all measured via routine 
laboratory techniques; insulin dose (IU/day); depression and anxiety (Hospital Anxiety 
and Depression Scale (HADS) (15, 16)); self-esteem (Rosenberg Self-Esteem Scale (RSE) 
(17)); quality of life (EuroQol EQ-5D (18, 19)); fatigue (Checklist Individual Strength (CIS) 
(20, 21)); physical activity (Short Questionnaire to Assess Health Enhancing Physical 
Activity (SQUASH) (22)); eating disorders (Eating Disorder Examination-Questionnaire 
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(EDE-Q) (23)) and related cognitions (EDE-Q sub scores eating restraint, eating concern, 
weight concern and shape concern, score range 0-6). In addition to the predefined 
outcome variables, we recorded the number of visits to physicians and paramedics at 
the diabetes out-patient clinic. We managed our data using the trial management system 
OpenClinica (Waltham, MA).
sample size
To base the sample size calculation on realistic eight-week weight loss data, an inde-
pendent statistician carried out a blinded power-calculation after the first 75 partici-
pants completed the eight-week VLCD period, as was described in the protocol (10). 
Sample size was calculated with SPSS 17.0, using the mixed-model ANOVA procedure 
described by Aberson (24). Alpha was set at 0.05, power at 0.80 and the baseline-end 
correlation at 0.90. A clinically relevant difference between the treatment groups was 
set at 5% weight loss (25). This calculation yielded a necessity of 52 patients in each 
group. Anticipating a dropout rate of 25%, we aimed for a total sample size of 140. 
We also conducted a post-hoc power calculation. With an alpha of 0.05 and the true 
baseline-end correlation of 0.94, the power was 0.998 for the intention-to-treat analysis 
and 0.969 for the per-protocol analysis.
statistical analyses
Normality of the data and homogeneity of variances were tested using the Shapiro-Wilk 
test and Levene’s test. Variables at baseline were expressed as number with percent-
age, mean with standard deviation or median with inter-quartile range. The difference 
between the control and intervention group at baseline was tested with a Chi-Square 
test, an independent samples t-test or a Mann-Whitney U test, depending on normality 
of the data. Linear mixed modelling was applied for the analyses of the between-group 
differences of the 2-year course of the primary and secondary outcomes. This method 
efficiently handles data with missing and unbalanced time-points, and corrects for se-
lective dropout when missing is conditionally on variables incorporated in the model 
(missing at random) (26). The models included three levels: group membership as highest 
level, patients as intermediate level and their repeated measures as lower level. The 
need of the upper (group membership) level was determined with the deviance statistic 
(27). The fixed parts of the models included allocation arm, sex, linear, quadratic and 
logarithmic time effects and the interactions of allocation and sex with the time effects. 
Variance components matrices were applied for the covariance structures. All analyses 
were conducted according to the intention-to-treat and the per-protocol principle. Treat-
ment was considered per-protocol when participants attended at least 9 CBGT sessions 
(10). Per-protocol analyses were restricted to the usual care group and the compliant 
participants in the CBGT group. The difference in number of visits to the outpatient clinic 
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during the study was analyzed using a Mann-Whitney U test. Results with p-values <0.05 
were considered statistically significant. Analyses were carried out using IBM SPSS 21.0.
resuLTs
Patient characteristics
Of the 296 patients who were assessed from March 2010 until May 2013, 276 were 
eligible to participate in our study and 206 gave written informed consent (Figure 1). 
Individuals who declined to participate were older (56.1 ± 10.3 years vs. 53.0 ± 10.8 
years, P = 0.05) and more often male (61% vs. 43%, p=0.008) than those willing to 
participate in the study. The main reasons for refusal to participate were work-related 
and lack of time.
296  Assessed for eligibility 
90 Excluded: 
     20 Not meeting inclusion 
           criteria 
     70 Refused to participate 
206 started with 8 weeks of 
VLCD 
48 Excluded: 
<5% weight loss 
83 Assigned to receive CBGT 
      50 compliant 
            2 lost to follow-up* 
      33 non-compliant 
            12 lost to follow-up* 
75 Assigned to receive usual care 
      75 Received usual care as assigned 
            8 lost to follow-up* 
 
 
83 Included in primary analysis (intention- 
      to-treat) 
50 included in per-protocol analysis 
 
75 Included in primary analysis (intention- 
      to-treat) 
75 included in per-protocol analysis 
 
158 Randomized 
(stratified block 
randomization) 
figure 1. Study flow-chart
*Reasons for lost to follow-up: 3 got pregnant, 2 moved to other country, 2 moved to other hospital, 3 un-
derwent bariatric surgery, 2 were diagnosed with carcinoma, 5 did no longer want to participate, 5 did no 
longer respond to invitation
BMI = body mass index; VLCD = very low-calorie diet; CBGT = cognitive behavioral group therapy
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After the 8-week very low-calorie diet, 158 participants (77%) had lost ≥5 % of their 
bodyweight and were randomized to either the intervention (n=83) or the control group 
(n=75). Baseline characteristics of the participants that did and did not achieve ≥5 % 
weight loss are compared in supplemental table S1. The excluded individuals had signifi-
cantly higher baseline levels of HbA1c (8.5 (7.6-10.0)%; 69.5 (59.3-86.3) mmol/mol 
vs. 7.6 (7.0-8.5)%; 60.0 (53.0-69.0) mmol/mol, P = 0.001) and a higher anxiety 
score (8.0 (4.0-11.0) vs. 6.0 (3.0-9.0), P = 0.038) than the included participants.
Baseline characteristics did not significantly differ between the control and interven-
tion group (Table 1), except for the eating disorder score (EDE-Q; P = 0.021). Eight 
participants in the control group and 14 in the intervention group were lost to follow-up 
at different time points during the study (P = 0.358) (Figure 1). Those participants were 
kept in the analyses as data with missing time points.
The average numbers of usual care visits to the outpatient diabetes clinic during 2 
years were similar in the CBGT and the control group: 12.0 (8.0-15.0) vs. 13.0 (8.0-
17.0), respectively, P = 0.495. In addition to the visits for the usual care, the participants 
in the intervention group attended a median of 9.0 (5.0-14.0) CBGT sessions. Thirty-
three participants missed more than 8 sessions and were considered non-compliant. 
Non-compliant participants attended a median of 4.0 (0.0-7.0) CBGT sessions, while 
compliant participants attended 14.0 (11.0-15.3) CBGT sessions. Non-compliant par-
ticipants were significantly younger than compliant participants (49.0 (38.5-55.5) vs. 
56.0 (49.5-63.0) years; P = 0.004). The main reasons mentioned for non-compliance 
were health problems and lack of time (work related). Twenty % of the participants in the 
CBGT group and 12% of the participants in the control group reported consulting an 
external psychologist (P = 0.187), with a median number of 3.5 (2.0-5.8) visits in the 
CBGT group and 4.0 (1.0-8.5) visits in the control group during two years (P = 0.978).
Weight change during the trial
During the initial 8-week of dieting a weight loss of 10.0 [95% CI 9.1-10.9] kg was 
observed in the control group while the CBGT group lost 9.2 [95% CI 8.4-10.0] kg. 
After 2-year of follow-up weight loss was 5.3 [95% CI 3.5-7.2] kg and 5.2 [95% CI 
3.4-7.1] kg, respectively. Overall, 38.6% of the participants still had a weight loss of 
≥5% after two years of follow-up, including 17.7% whose weight loss remained ≥10%. 
During the 2-year follow-up, 19.0% of the participants managed to fully maintain their 
lost weight. These percentages were similar in both study arms: χ²=0.161, P = 0.688; 
χ²=0.307, P = 0.580; and χ²=0.077, P = 0.781, respectively.
Primary outcome
We did not find a significant difference in body weight between the CBGT and control 
group at two years of follow-up (intention-to-treat analysis, table 2). The between-group 
129
Efficacy of cognitive behavioral group therapy to prevent weight regain after dieting in T2D: the POWER trial.
difference was -1.2 [95% CI -7.7-5.3] kg (P = 0.717). In the per-protocol analysis the 
between-group difference was -3.8 [95% CI -11.5-3.8] kg (P = 0.323). Weight regain 
during follow-up was 4.7 [95% CI 3.0-6.3] kg for the control group and 4.0 [95% 
CI 2.3-5.6] kg for the CBGT group, with a between-group difference of -0.7 [95% CI 
Table 1. Baseline participant characteristics
Characteristic* Control (n=75) CBGT (n=83)
Age (y) 55.2±9.3
range 32-73
52.3±11.3
Range 28-74
Female (No. (%)) 44 (58.7) 44 (53.0)
Caucasian (No. (%)) 45 (60.0) 42 (50.6)
Low education (No. (%)) 25 (33.3) 21 (25.3)
Employed (No. (%)) 24 (32.0) 36 (43.4)
Employment (days/week) 0 (0-3.3) 0 (0-5)
Years after diagnosis T2D 10.0 (3.0-15.0) 8.0 (3.5-16.0)
Weight (kg) 106.7±22.5 105.5±19.3
BMI (kg/m²) 35.7 (32.9-40.9) 36.7 (31.7-39.4)
Waist circumference (cm) 120.4±12.9 119.4±14.2
Systolic blood pressure (mmHg) 145.0±20.9 138.6±18.6
Diastolic blood pressure (mmHg) 81.0±10.5 80.2±10.7
HbA1c (%) 7.7 (7.1-8.4) 7.5 (6.9-8.7)
HbA1c (mmol/mol) 61.0 (53.8-68.3) 58.0 (51.5-72.0)
Fasting glucose (mmol/l) 8.7 (6.9-10.5) 8.2 (6.8-10.8)
Total cholesterol (mmol/l) 4.4 (3.7-5.1) 4.5 (3.9-5.2)
LDL cholesterol (mmol/l) 2.5 (2.0-3.0) 2.6 (2.2-3.1)
HDL cholesterol (mmol/l) 1.2 (1.0-1.4) 1.1 (1.0-1.3)
Triglycerides (mmol/l) 1.7 (1.3-2.4) 2.0 (1.3-2.7)
Insulin users (No. (%)) 49 (65.3) 52 (63.4)
Insulin dose among users (IU/day) 100.1±42.2 95.7±54.9
Statin users (No. (%)) 50 (69.4) 59 (74.7)
Clinical depression
(No. (%) with HADS score >10)
12 (16.4) 15 (18.8)
Clinical anxiety disorder (No. (%) with HADS score >10) 12 (16.4) 16 (20.0)
Self-esteem (RSE score) 32.0 (28.0-35.0) 32.5 (27.0-35.0)
Quality of life (EQ5D score) 0.78 (0.57-0.84) 0.81 (0.65-1.0)
Fatigue (CIS sub score 1) 37.0 (27.3-47.8) 36.5 (28.0-47.8)
Eating disorder (EDE-Q score) 1.9±1.0 2.4±1.2
Physical activity (SQUASH score) 2350 (1260-5355) 3495 (1440-5978)
*Data are mean±SD, median (interquartile range) or number (%).
CBGT = cognitive behavioral group therapy group; T2D = type 2 diabetes; BMI = body mass index; HbA1c 
= glycated hemoglobin; LDL = low-density lipoprotein; HDL = high-density lipoprotein
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-3.1-1.6] kg (P = 0.556) in the intention-to-treat analysis and -0.6 [95% CI -3.3-2.0] kg 
(P = 0.635) in the per-protocol analysis. The deviance statistic of the linear mixed model 
indicated that a three-level model with a third upper ‘group’ level was not significantly 
better than a two-level model with time and allocation (χ²(1)=1.189; P = 0.28). In supple-
mental table S2 we show the estimates of the linear mixed model for weight during the 
study (intention-to-treat). These results indicate that there is no allocation effect and also 
no allocation-time interaction. We found no interaction of sex with time and allocation 
(data not shown).
Table 2. Differences in outcome variables after two years of follow-up between the Cognitive Behavioral 
Group Therapy group (CBGT) and the control group (intention-to-treat)
Outcome variables* Control CBGT Between-group difference
Primary outcomes    
Weight (kg) 101.4 [96.7, 106.1] 100.2 [95.8, 104.7] -1.2 [-7.7, 5.3]
Weight regain# (kg) 4.7 [3.0, 6.3] 4.0 [2.3, 5.6] -0.7 [-3.1, 1.6]
    
Secondary outcomes    
Waist circumference (cm) 116.0 [112.7, 119.2] 115.0 [111.9, 118.1] -1.0 [-5.4, 3.5]
Systolic blood pressure 
(mmHg)
140.0 [135.4, 144.7] 139.2 [134.8, 143.7] -0.8 [-7.3, 5.6]
HbA1c (%) 8.1 [7.7, 8.5] 8.0 [7.6, 8.4] -0.1 [-0.6, 0.5]
HbA1c (mmol/mol) 64.9 [60.6, 69.1] 64.0 [59.8, 68.1] -0.9 [-6.8, 5.0]
Insulin dose (IU) 43.5 [26.9, 60.1] 40.4 [24.3, 56.6] -3.1 [-26.3, 20.2]
Total cholesterol (mmol/l) 4.20 [3.90, 4.50] 4.48 [4.19, 4.77] 0.29 [-0.13, 0.70]
LDL cholesterol (mmol/l) 2.34 [2.10, 2.58] 2.65 [2.42, 2.88] 0.31 [-0.03, 0.64]
HDL cholesterol (mmol/l) 1.24 [1.16, 1.32] 1.22 [1.14, 1.30] -0.02 [-0.13, 0.10]
Triglycerides (mmol/l) 2.08 [1.50, 2.66] 2.29 [1.73, 2.84] 0.21 [-0.60, 1.01]
Depression (HADS) 5.3 [4.2, 6.3] 5.5 [4.5, 6.6] 0.3 [-1.2, 1.8]
Anxiety (HADS) 5.3 [4.1, 6.4] 6.1 [4.9, 7.2] 0.8 [-0.8, 2.4]
Self-esteem (RSE) 31.1 [29.1, 33.1] 29.9 [27.9, 31.9] -1.2 [-4.0, 1.7]
Quality of life (EQ5D) 0.69 [0.62, 0.76] 0.69 [0.63, 0.76] 0.01 [-0.09, 0.10]
Fatigue (CIS) 31.2 [27.9, 34.5] 33.4 [30.2, 36.7] 2.2 [-2.4, 6.9]
Eating disorders (EDE-Q) 1.70 [1.39, 2.01] 2.11 [1.80, 2.41] 0.41 [-0.02, 0.84]
Physical activity 
(SQUASH)
4176 [2160, 6191] 5453 [3427, 7480] 1278 [-1580, 4136]
*Estimates after two years of follow-up and between group difference [95% CI] and #change from random-
ization to two years [95%CI] and between group difference [95% CI]; all analyzed via linear mixed model 
procedure. HbA1c = glycated hemoglobin; LDL = low-density lipoprotein; HDL = high-density lipoprotein
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secondary outcomes
Change in weight from baseline to two years was not significantly different between 
the two groups (intention-to-treat: 0.1 [95% CI -2.5-2.7] kg (P = 0.951) Figure 2A; 
per-protocol: -0.8 [95% CI -3.7-2.2] kg, P = 0.613, Figure 2B). None of the other 
secondary outcomes was significantly different between the intervention and control 
group at two years (Table 2). Also, the change from baseline was not different between 
the two groups for any of the secondary outcome variables (data not shown). At two 
years of follow-up, both the CBGT and the control group had a significantly lower 
waist circumference, insulin dose, depression score and fatigue score than at baseline 
(P< 0.05). In addition, the EDE-Q subscale scores on weight concern and shape concern 
significantly improved during the two years of follow-up for both groups (P< 0.01).
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figure 2. Estimates of weight from baseline to two years of follow-up in cognitive behavioral group 
therapy (CBGT) and control group: (A) intention-to-treat; (B) per-protocol.
*p-value of between-group difference in weight from baseline to two years of follow-up, analyzed by mixed 
modelling procedure
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concLusions
In this randomized controlled trial, CBGT did not reduce the problem of regaining weight 
following a successful diet-induced weight reduction in overweight and obese adults 
with type 2 diabetes. Moreover, the secondary outcomes were not different between 
the intervention and control group, while the average waist circumference, insulin dose, 
depression score and fatigue score remained significantly lower during follow-up after 
the very-low calorie diet for both groups.
Weight regain usually occurs in the first year after weight loss (4, 28-30). In line, the 
participants of both groups showed a gradual regain of weight during the two years 
of follow-up. In a post-hoc analysis of the Look AHEAD trial, a sustained weight loss of 
≥10% was associated with a 21% decrease in the incidence of cardiovascular disease, 
indicating that increasing the magnitude of long term weight loss potentially could lead 
to a positive effect on hard endpoints (5). In our trial, only 18% of the participants 
maintained a weight loss of ≥10% in both the CBGT and the control group. Clearly, 
CBGT did not improve the magnitude of the sustained weight loss. In the Look AHEAD 
trial (4), 17% of the participants in the control group and 27% of the participants in the 
intervention group maintained a weight loss of ≥10% after 8 years of follow-up. This 
long term preservation of weight loss in the intervention group was more impressive than 
in our study, probably because of the increase in physical activity. Physical activity has 
been shown to produce small but significant benefits to the maintenance of weight loss 
(31). In our study, physical activity did not differ between the groups during the 2-years 
of follow-up.
The rate of non-compliance with the CBGT intervention in our study was 40%, which is 
similar to 35-50% non-compliance reported in other CBT studies (32). Non-compliance 
may have diminished the effect of the CBGT. However, analyses restricted to the compli-
ant group did not show an effect of CBGT on weight at 2 years nor at any intermediate 
time point. Notably, post-hoc power calculations showed that we included a sufficient 
number of participants for the intention-to-treat as well as the per-protocol analysis en-
abling detection of relatively small differences (Table 2 of reference (10)).
In obese individuals with type 2 diabetes, two observational studies have been con-
ducted that showed favorable effects of combining CBGT with diet and/or exercise on 
long term weight loss (8, 9). Since CBGT was part of an intensive, combined interven-
tion including diet and exercise in these studies, no conclusions can be drawn on the 
effectiveness of CBGT itself. Our randomized controlled trial does not support an effect 
of CBGT as suggested by the two observational studies.
In obese adults without type 2 diabetes, positive effects of CBGT on weight loss and 
weight loss maintenance have been described, and this treatment option has been incorpo-
rated in international obesity guidelines (6, 7, 11, 33). Our intervention was based on the 
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protocol of Werrij et. al. (11). They found that in obese non-diabetic individuals CBGT was 
superior to increasing physical activity in maintaining diet-induced weight loss. In addition 
to methodological considerations, our trial differs from these previous studies in a number 
of ways: the follow-up of our study was substantially longer and we restricted our study fully 
to participants with diabetes. Our results are in concordance with a randomized controlled 
trial that had a follow-up period of three years, in which CBGT did not improve weight loss 
maintenance in obese individuals without type 2 diabetes, despite improvements in cogni-
tion scores (34). We did not find an effect of CBGT on the cognition scores of concern 
about weight and shape, possibly indicating that the usual care in our tertiary referral 
center is already comprehensive and gives little window for CBGT for further improvement. 
Nevertheless, weight regain occurred in both groups, similarly to what has been shown by 
Cooper et al. in obese individuals without diabetes (34).
A recent meta-analysis showed that CB(G)T reduces depressive symptoms in persons 
with diabetes (35). We found no effect of CBGT on the depression scale that is part of 
the HADS. However, our CBGT was specifically designed for and aimed at maintenance 
of body weight loss and not at alleviating depression.
It could be argued that individual CBT is more effective than CBGT. Conversely, in 
obesity research one-to-one therapy has been shown equally (36) or even less effective 
(37) than group therapy in achieving weight loss and reducing attrition. Another potential 
weakness of our study could be that the contrast in treatment between our two study 
groups was diminished by psychological treatment outside the study. This is, however, 
unlikely as the self-reported psychological consultation outside the study was similar for 
both groups. Furthermore, it is also unlikely that the absence of an effect of CBGT could 
be attributed to the therapists, as they were both very experienced with CBGT, and we 
found no difference in results between them (data not shown).
Strengths of our study include the randomized, controlled design and the relatively long 
follow-up period. Participants were referred to a single tertiary center, therefore our find-
ings may not be generalizable to the entire population of overweight and obese patients 
with type 2 diabetes. Obviously, our findings are exclusively applicable to patients, who 
are motivated and able to lose 5% or more of their body weight by dieting. Finally, our 
trial had a pragmatic design, not compensating for the increased attention received by 
the CBGT group. Despite greater attention, there was no difference in outcomes between 
both arms, thus strengthening our conclusions.
We conclude that in overweight and obese patients with type 2 diabetes, who were 
able to lose a clinically relevant amount of body weight on a very low-calorie diet, CBGT 
is not more effective in maintaining long term weight loss than usual care alone. Future 
research should elucidate whether CBGT is effective in subgroups of patients with type 
2 diabetes and whether tailoring the CBGT program to individual needs improves its 
effectiveness in maintaining weight loss.
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suPPLeMenTaL TabLes
supplemental table s1. Baseline characteristics excluded vs. included participants
characteristic* excluded 
participants† (n=48)
included participants 
(n=158)
p-value‡
Age (y, range) 50.6 (25-70) 53.7 (28-74) 0.141
Female (No. (%)) 30 (62.5) 88 (55.7) 0.404
Caucasian (No. (%)) 25 (52.1) 87 (55.1) 0.717
Low education (No. (%)) 14 (29.2) 46 (29.1) 0.497
Years after diagnosis T2D 8.0 (2.5-13.0) 9.0 (3.0-15.0) 0.414
Weight (kg) 106.9±16.9 106.1±20.8 0.806
HbA1c (%) 8.5 (7.6-10.0) 7.6 (7.0-8.5) 0.001
HbA1c (mmol/mol) 69.5 (59.3-86.3) 60.0 (53.0-69.0) 0.001
Fasting glucose (mmol/l) 10.1 (8.3-13.0) 8.4 (6.8-10.6) <0.001
LDL cholesterol (mmol/l) 2.6 (2.0-3.5) 2.6 (2.1-3.1) 0.706
Insulin users (No. (%)) 25 (52.1) 101 (63.9) 0.456
Insulin dose among users (IU/day) 111.1±61.6 97.8±49.0 0.258
Depression score (HADS) 7.0 (4.0-11.0) 7.0 (4.0-9.0) 0.395
Anxiety score (HADS) 8.0 (4.0-11.0) 6.0 (3.0-9.0) 0.038
Quality of life (EQ5D score) 0.81 (0.69-0.84) 0.78 (0.65-0.84) 0.320
Eating disorder (EDE-Q score) 2.1±1.3 2.2±1.1 0.946
Physical activity (SQUASH score) 4200 (1440-8405) 2940 (1350-5775) 0.327
*Data are mean±SD, median (interquartile range) or number (%).†Participants were excluded when they lost 
<5% of body weight during the 8-week phase-in very low-calorie diet. ‡Between-group differences were ana-
lysed using a Pearson Chi-Square test, an independent samples t-test or a Mann-Whitney U test, depending 
on normality of the data.
CBGT = cognitive behavioral group therapy group; T2D = type 2 diabetes; BMI = body mass index; HbA1c 
= glycated hemoglobin; LDL = low-density lipoprotein; HDL = high-density lipoprotein.
supplemental table s2. Linear mixed model of weight course from baseline to two years of follow-up 
and allocation to group (ITT)
Parameter estimate 95%ci p-value
Intercept 106.769 102.327, 111.211 <0.001
Time 0.361 0.293, 0.429 <0.001
Quadratic time -0.001 -0.002, -0.001 <0.001
Logarithmic time -5.818 -6.400, -5.237 <0.001
Allocation -1.274 -7.403, 4.855 0.682
Time*allocation -0.033 -0.127, 0.061 0.491
Quadratic time*allocation 0.000 -0.001, 0.001 0.720
Logarithmic 
time*allocation
0.473 -0.331, 1.278 0.248
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General Discussion
The primary aim of my thesis was to determine the effectiveness of cognitive behavioral 
group therapy (CBGT) in maintaining weight during 2 years of follow-up after weight 
loss via a very low-calorie diet (VLCD) in overweight and obese adults with type 2 
diabetes (T2D). The secondary objectives were to establish which participants benefit 
most from a VLCD, and to evaluate the short-term effect of a VLCD on conventional and 
non-conventional cardiovascular risk factors.
In this chapter, the main findings of the current thesis are discussed in a broader 
perspective and some methodological issues are addressed. Further, the implications of 
our findings for clinical practice and views for future research are outlined.
quick answers to the research questions
– Cognitive behavioral group therapy did not result in better 2-year weight main-
tenance after weight loss via a very low-calorie diet, compared to usual care 
only.
– Cognitive behavioral group therapy did not result in better 2-year outcomes on 
cardiovascular risk factors and psychological wellbeing, compared to usual 
care only.
– Short term diet-induced weight loss was predicted by the baseline variables 
fasting glucose, insulin dose, waist-to-hip ratio, anxiety and numb feeling in 
extremities (related to neuropathy).
– A short-term very low-calorie diet improved glycemic control, lipid profile, sLR11 
level and levels of biomarkers of endothelial dysfunction and inflammation, 
while reducing the need for insulin.
– Diet-induced weight loss increased Lp(a) levels in overweight and obese adults 
with and without type 2 diabetes; an effect that was absent after weight loss 
via bariatric surgery in obese adults without type 2 diabetes.
– After 2 years of follow-up, despite weight regain, a very low-calorie diet still 
resulted in a clinically relevant decrease in weight, need for insulin, depression 
score and fatigue score.
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overvieW anD inTerPreTaTion of Main finDinGs
Weight loss maintenance
What was already known on cognitive behavioral group therapy 
for weight loss maintenance?
– In non-diabetic obese adults, cognitive behavior group therapy is effective in 
achieving weight loss when combined with diet and/or exercise, and also in 
enhancing weight loss maintenance.
– In 2 observational studies in obese adults with type 2 diabetes, cognitive 
behavioral group therapy led to weight loss when combined with diet and/or 
exercise.
What knowledge is added by this thesis?
– In our randomized controlled trial, cognitive behavioral group therapy did not 
result in better weight loss maintenance after diet-induced weight loss in obese 
adults with type 2 diabetes.
Since being overweight or obese is particularly detrimental for individuals with type 2 
diabetes (T2D), increasing morbidity and mortality, weight loss is a cornerstone of treat-
ment (1-4). Diet-induced weight loss induces various beneficial effects in these persons, 
such as improved glycemic control, lipid profile and blood pressure (5). Unfortunately, 
from clinical care experience and past research it is known that weight regain after 
successful weight loss is a common problem in people with obesity (6-9). As described 
in the introduction of this thesis, both behavioral and physiological challenges should be 
tackled in order to succeed in maintaining weight loss.
Cognitive behavioral therapy for weight loss maintenance
In order to achieve weight loss maintenance, a sustained (long-term) change in be-
havior is needed. Behavioral modification techniques like goal setting, self-monitoring, 
stimulus control, portion control, changing the environment, problem solving and relapse 
prevention have been intensively studied and shown more or less effective in improving 
weight loss maintenance in the obese population (10). There is evidence suggesting that 
cognitive change precedes and produces behavior change, and that therefore cognitive 
skills like cognitive restructuring and problem-solving techniques should be incorporated 
in weight loss programs in order to achieve long-term weight loss maintenance (10, 
11). Cognitive behavioral group therapy (CBGT) for non-diabetic obese individuals has 
been shown to facilitate weight loss as well as weight loss maintenance (10, 12-16). 
However, not all studies have shown positive results of CBGT. Cooper et al. (11, 17) 
were strong advocates of a more cognitive approach to weight loss management, 
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but showed negative results of a cognitive behavioral therapy (CBT) intervention (24 
individually delivered sessions over 44 weeks, with 3 years of follow-up) for weight loss 
in obese individuals (18). Only two observational studies reported the effect of CBGT 
as part of dietary weight loss interventions in T2D: i.) in a prospective cohort study, a 
diet plus CBGT resulted in weight loss and improved metabolic control after four years 
of follow-up; ii.) in a retrospective cohort study, an intervention combining diet, exercise, 
intensive medication adjustments, group education and CBGT led to weight reduction 
and maintenance for one year (19, 20). Until now, the effect of CBGT on weight loss 
maintenance has not been studied in a randomized controlled manner in persons with 
T2D. In chapter 7, we showed in a randomized controlled trial in overweight and obese 
adults with T2D, that CGBT on top of usual care did not perform better than usual care 
only in preventing regain of weight during 2 years of follow-up, after participants lost ≥5% 
of weight via a VLCD (figure 1A). Moreover, we did not find any significant difference 
between the CBGT and the usual care group for the secondary outcome measures at any 
time point during the trial, despite the CBGT group receiving more attention as indicated 
by the higher number of visits to the outpatient clinic. Even in compliant participants, 
who actually followed most of the CBGT sessions (predefined in the protocol), no effect 
on weight during 2 years of follow-up was seen as compared to usual care (figure 1B).
Those new findings are in contrast with most of the literature on CBGT. The CBGT 
method we used was adapted from the method used by Werrij et al. (13). They found 
that CBGT performed significantly better than exercise on maintaining weight loss in 
obese persons without T2D after 1 year of follow-up (13). The CBGT group in our study 
improved in the cognition scores weight concern and shape concern, in concordance 
with the studies of Cooper et.al. and Werrij et.al.. These improvements did not result 
in better long term weight maintenance in our trial and in the study of Cooper et.al. in 
obese non-diabetic persons, but they did result in better weight loss maintenance in the 
study of Werrij et.al.. What could explain this difference in result between their and our 
trial? The dietary intervention we used as a phase-in period to achieve weight loss was a 
VLCD, while Werrij et. al. used a LCD. Then again, well-designed trials provide evidence 
that use of a VLCD or LCD does not differentially influence weight regain or maintenance 
(21, 22). Another difference was that our follow-up was twice as long. However, we 
did not find an effect of the CBGT at any intermediate time point. This leaves us with a 
very important difference between the two studies: the difference in study population. 
Could overweight T2D adults be metabolically different from non-diabetic overweight 
adults? Unfortunately, no literature exists comparing persons with and without diabetes in 
their ability to maintain weight loss or their metabolic response to weight loss dieting, so 
future studies are warranted focusing on these differences. In my study, the participants 
in the CBGT group tended to blame their antidiabetic medication and medical condition 
(diabetes complications) rather than their own behavior for their overweight and inability 
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to maintain weight loss. These external factors could play a role in weight loss and 
weight loss maintenance. However, in the intervention (CBGT) group, the presence of 
diabetic complications was not correlated with long term weight loss. Also the baseline 
insulin dose or change in insulin dose was not correlated with long term weight loss. We 
found that older participants, male participants and participants who initially lost the most 
weight, were more likely to maintain their weight loss. Yet, these correlations were found 
for both the CBGT and the control group. Another explanation for the lack of effect of the 
CBGT could be the large heterogeneity in educational background of the participants 
in the CBGT group. In order to master all the techniques of CBT, a basic knowledge on 
behavior and a minimum intellectual capability may be needed. Nonetheless, we did 
not find a correlation between educational level and long-term weight loss in the CBGT 
group. So unfortunately, we did not find any clues to identify subgroups for which CBGT 
could be helpful in maintaining weight loss. Of course, the sample size may have limited 
subgroup analysis.

	

	
 

   	 
 







	

	
 

   	 
 









	


figure 1. Estimates of weight from baseline to two years of follow-up in cognitive behavioural group 
therapy (CBGT) and control group: (A) intention-to-treat; (B) per-protocol.
*p-value of between-group difference in weight from baseline to two years of follow-up, analysed by mixed 
modelling procedure
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In weight maintenance research several limitations have been identified (23):
1. Few studies report the number of participants successful in maintaining a significantly 
lower body weight, a highly relevant outcome parameter.
2. Most studies lack a control group.
3. The rate of loss to follow-up is high, falsely inflating the reported mean weight loss.
4. Follow-up is generally short (i.e. <1 year)
In our trial, we tried to avoid abovementioned shortcomings by reporting the percentage 
of participants successful in maintaining weight: 39% of the participants achieved a 
(generally considered) clinically relevant weight loss of ≥5%, while 18% maintained a 
weight loss of ≥10% after 2 years of follow-up. Secondly, we chose for a pragmatic 
randomized controlled design, comparing CBGT plus usual care to usual care only. With 
this design, we were able to draw conclusions about the effectiveness of the intervention, 
relevant for the clinician. Thirdly, we experienced a rather low rate of loss to follow-up: 
22 participants (14%) dropped out of the study during follow-up (at various time points), 
but were kept in the analyses as data with missing time points. Unlike statistical methods 
most often used in weight maintenance trials (Repeated Measures ANOVA), the method 
we used (linear mixed modeling) provides unbiased estimates of at random missing data 
points, and no cases will be ‘lost’ (24). The latter is also in line with the intention-to-treat 
principle. Fourthly, our follow-up period was 2 years, which is considered a medium 
length follow-up, where most regain in weight is believed to have taken place. Finally, 
previous studies often randomized prior to weight loss, focusing on long term weight loss, 
making it impossible to draw conclusions about weight regain after initial weight loss. 
In our trial, we have chosen for a design where participants were randomized after a 
period of weight loss in order to study weight regain, answering a to our opinion more 
important question.
To conclude, CBGT as performed in our study, did not solve the problem of weight 
regain after diet in overweight and obese T2D adults. How the long-term effectiveness 
of weight loss dieting can be enhanced in this patient group remains to be established. 
In the following paragraphs, we elaborate on other potentially effective strategies for 
weight loss maintenance.
Promising psychological interventions for weight loss maintenance
Some other promising psychological interventions for weight loss (maintenance) have 
been identified, for example cue exposure therapy. It has been shown that successful 
weight loss maintainers differ from obese people in their cognitive responses to high-
calorie food cues (25). In cue exposure therapy, obese individuals are repeatedly 
exposed to cues associated with food, like the sight, smell, taste of palatable food or a 
situation in which overeating typically occurs. When these cues are not followed by the 
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actual eating, the responses on appetite associated with these cues can extinguish. An 
RCT is underway which aims to determine the effect of a cue exposure therapy on weight 
loss and short term weight maintenance (26). Another promising therapy is executive 
functioning training in obese individuals. Eating behavior and ability to lose and maintain 
weight has been associated with individual differences in executive functioning, like 
planning ability and inhibitory control. Internal disinhibition has been associated with 
poorer weight loss maintenance (27). In small short-term studies, executive functioning 
training has been shown to increase weight loss and weight loss maintenance (28-30). 
Future studies should focus on the effect of these psychological interventions on long term 
weight loss maintenance in overweight and obese adults with and without T2D.
Changing diet composition for weight loss maintenance
As described in the introduction of this thesis, weight loss triggers several physical 
adaptations in the body, promoting appetite and decreasing energy expenditure. 
Counteracting these responses via long-term changes in diet and exercise could assist 
in achieving weight loss maintenance. Johansson et. al. conducted a meta-analysis of 
randomized controlled trials focusing on strategies for weight loss maintenance after a 
(very) low-calorie diet. In figure 2, the results of this meta-analysis are shown. For illustra-
tive purposes, I added the data of the POWER trial to the graph. The authors concluded 
that the prolonged use of meal replacements and high-protein diets were associated with 
improved weight loss maintenance (31). The largest trial on the effect of different dietary 
patterns on weight loss maintenance is the Diogenes study (32). A total of 773 obese 
participants, who lost at least 8% of their body weight via a VLCD, were randomized to 
one of the five ad libitum weight maintenance diets: a low-protein and low-glycemic-index 
diet, a low-protein and high-glycemic-index diet, a high-protein and low-glycemic-index 
diet, a high-protein and high-glycemic-index diet, or a control diet. After 26 weeks, the 
high-protein and low-glycemic-index diet resulted in the best weight loss maintenance. 
Moreover, the compliance with this diet intervention was highest. In concordance with 
these findings, different studies have shown that a weight loss maintenance diet with a 
minimum of 30% of energy intake derived from protein, limits the drop in resting and total 
energy expenditure normally seen after weight loss (33, 34). Apparently, the physical 
adaptations to weight loss can partly be antagonized by diet composition, although 
the effect size is only modest. Unfortunately, persons with T2D were underrepresented 
in these trials, so the results could and should not be generalized and future studies are 
required to analyze persons with T2D separately. In the weight maintenance phase of the 
POWER trial, we slowly reintroduced a diet which contained approximately 15 energy% 
of protein and 60 energy% of carbohydrates. We encouraged the use of unprocessed 
products high in fiber to reduce the glycemic-index. Nonetheless, we should consider the 
results of the Diogenes trial when implementing the POWER diet program into clinical 
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care in order to enhance weight loss maintenance. As mentioned, long-term effectiveness 
in individuals with T2D still needs to be studied. Alternatively, repeated VLCD may be an 
effective strategy for weight loss maintenance. There is some evidence that intermittent 
VLCD periods are benefi cial for weight loss and weight loss maintenance. In patients 
with T2D, a regimen of 5 consecutive days of VLCD every 5 weeks improved weight 
loss and HbA1c compared to standard behavioral therapy (35). Also in a 50-week 
diet study, T2D patients lost more weight and had better glycemic control during an 
intermittent VLCD regimen than during a continuous LCD, although these benefi ts were 
largely due to the fi rst 12-week VLCD period (36). Long term RCT’s studying the effect of 
repeated VLCD periods on weight loss maintenance in T2D are warranted.
Exercise for weight loss maintenance
One of the biological adaptions to weight loss is the decrease in energy expenditure, 
which has been shown to persist over time, predisposing to weight regain (37). Theo-
retically, increased physical activity is needed to counteract this adaptive decrease in 
energy expenditure and to prevent the loss in fat free mass (22). The effect of exercise 
on initial weight loss is only modest, but the importance of exercise in weight loss 
maintenance has been shown repeatedly (38). Relatively high doses of physical activity 
are needed in order to achieve long-term weight loss success. Individuals who engaged 
in regular physical activity of approximately 300 min/week were far more likely to 
0.1kg 
P=0.95 
CBGT 
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figure 2. Overview of changes in body weight during the rapid weight-loss phase and the weight-loss 
maintenance period in 20 randomized controlled trials that evaluated different anti-obesity drug, diet, and 
exercise weight-loss maintenance strategies after an initial very-low-calorie diet or low-calorie diet (<1000 
kcal/d). The dashed lines represent the POWER study (black is CBGT and gray is control), gray lines 
represent the control subjects in each subcategory weights and p-values refl ect differences with the control 
subjects. (Adapted from: Johansson et al Am J Clin Nutr 2014 Jan;99(1):14-23).
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maintain 10% weight loss for more than 1 year (39, 40). In our POWER trial, we 
recommended 60 minutes of physical activity daily (420 min/week), in concordance 
with national recommendations for weight loss. In all study meetings, we promoted 
the engagement in regular physical activity and we encouraged personal goal setting. 
Despite our recommendations, no increase in physical activity was seen during the 2 
years of follow-up. Perhaps this was related to the absence of an integrated exercise 
program. Indeed, some participants mentioned a wish for more support in achieving 
their exercise goals during the evaluation of the program. In children with obesity, the 
incorporation of active video gaming (for example Nintendo Wii) was more effective in 
increasing physical activity and reducing weight compared to following a weight loss 
program without active gaming (41). Whether active video gaming is also a suitable 
intervention for obese adults with T2D remains to be investigated. Nonetheless, in future 
weight maintenance programs, the possibility of a more structured exercise support in the 
weight maintenance phase should be explored.
Drug therapy for weight loss maintenance
In the earlier discussed meta-analysis of the effect of weight loss maintenance strategies 
after a V(LCD), the use of the anti-obesity drugs Orlistat and Sibutramine has been shown 
effective in maintaining weight (31) (figure 1). Sibutramine has been retracted from 
the European market due to cardiovascular side-effects. Another drug that facilitates 
weight loss is the glucagon-like peptide-1 receptor agonist (GLP-1 RA). In two random-
ized controlled trials, a GLP-1 RA has been shown to improve weight maintenance after 
diet-induced weight loss (42, 43). Moreover, a GLP-1 RA diminished the decrease in 
plasma leptin levels upon diet-induced weight loss, possibly leading to a decreased 
craving for food (43). Interestingly, there seems to be a ceiling on the weight loss effect 
of a GLP-1 RA, regardless whether it is used for weight loss or weight loss maintenance 
and the weight loss is maintained only during the prolonged use of a GLP-1 RA (44). 
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new class of oral antidiabetic 
drugs. Inhibiting SGLT2 decreases reabsorption of glucose and sodium in the kidney 
which results in increased diuresis and enhanced glucose (energy) loss with subsequent 
reduction in blood glucose and body weight (45). The effect of SGLT2 inhibitors on long 
term weight loss or weight loss maintenance has not yet been investigated.
New technologies for weight loss maintenance
In this era of rapid technological improvements, it is logical that numerous promising 
new devices have been developed to facilitate people in maintaining weight loss. Many 
technology-based weight loss interventions have been conducted in the last decade 
using for example e-mail, interactive websites, mobile phones or wearable devices. 
However, results were mixed and technology-based interventions did not perform better 
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than non-technology-based interventions in maintaining weight loss (46, 47). In a large 
RCT in overweight young adults, the addition of a wearable device (and accompanying 
web interface) to monitor diet and physical activity to a standard behavioral intervention, 
resulted in less weight loss over 24 months compared to usual care only. The authors 
concluded that devices that monitor and provide feedback on physical activity and diet 
may not offer an advantage over standard behavioral weight loss approaches (48). Also 
in another RCT, social and mobile technologies did not facilitate sustained reductions in 
weight among young adults (49). Again, these studies have been conducted in non-T2D 
populations, but technology-based interventions alone do not seem to hold promise for 
long-term weight management. Though, combining technology based interventions with 
traditional face-to-face care may provide additional benefit in weight loss and deserves 
further study.
a very low-calorie diet for weight loss
What was already known on vLcD induced weight loss?
– A very low-calorie diet is effective in producing short term weight loss in obese 
adults with and without type 2 diabetes.
What knowledge is added by this thesis?
– After 2 years of follow-up, a very low-calorie is still effective in producing a 
clinically relevant weight loss in obese adults with type 2 diabetes, which is 
accompanied by improvements in waist circumference, fatigue and depression 
score, and need for insulin.
In our Prevention Of Weight Regain (POWER) trial we used a very low-calorie diet 
(VLCD) to induce weight loss, as the phase-in to the randomized controlled trial. We 
intended to achieve a large initial weight loss in our participants, to create a big window 
for differences in weight regain to occur between the intervention and control group 
during follow-up. In previous research, VLCDs have been shown effective in producing 
short term weight loss in adults with T2D. In the meta-analysis of Tsai et. al., participants 
(with and without T2D) who were prescribed a VLCD for a mean of 12.7 weeks, lost 
16.1 ± 1.6% of their bodyweight, while participants on a low-calorie diet (LCD) lost 
9.7 ± 2.4% of bodyweight, in line with the difference in energy deficit (p=0.0001 for 
between group difference) (50). Recently, a meta-analysis has been conducted on the 
effectiveness of VLCDs in adults with T2D (51). The authors identified 9 studies and 
showed that VLCD’s led to greater weight loss after 6 months compared to usual care 
(between-group difference -8.5 kg (95%CI -15.6 to -1.3; p=0.02) and also compared 
to an LCD (between-group difference -5.7 kg (95%CI -11.1 to -0.35; p=0.04).
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In chapter 2 we presented the short term results on weight. The short-term weight loss 
achieved in the phase-in of our trial seems modest compared to literature, with 7.8±4.6 
kg (95%CI 7.2-8.5; p<0.001), but this was after only 8 weeks of dieting, while the 
mean duration of the interventions in previous studies was 13 weeks. Moreover, we 
prescribed a VLCD of 750 kcal per day while others used 450-600 kcal per day. 
We chose for this less stringent regimen as it allowed our participants to use a low-fat, 
low-carbohydrate dinner along with their family. There is not much evidence on long term 
efficacy of VLCDs with regard to weight loss in adults with T2D. In 1 RCT, a 24-week 
VLCD resulted in a weight loss of 13.4±9.7% after 1-year follow-up, which decreased 
to 6.8±7.6% after a follow-up of 2 years (36). In line with these results, we showed 
that our participants maintained an average weight loss of 5.1±6.2% (95%CI 4.0-6.1) 
after 2 years of follow-up. However, our results are biased by the design of our long-
term follow-up trial, since we only included participants with an initial weight loss of at 
least 5%. Nevertheless, this amount of weight loss was accompanied by a lower waist 
circumference, lower score on fatigue and depression, and an improved insulin sensitivity 
illustrated by a reduced need for insulin.
One argument against ‘crash’ diets like a VLCD is that it’s believed to result in more 
weight regain thereafter. Is rapidly lost weight also more quickly regained? This research 
question was studied in two recent randomized controlled trials (21, 22). In the study of 
Purcell et al. (21), 200 obese participants were randomized to either rapid weight loss 
dieting during 12 weeks or gradual weight loss dieting during 36 weeks. 81% of the 
participants in the rapid weight loss group and 50% of the participants of the gradual 
weight loss group achieved 12.5% weight loss. The participants of both groups who lost 
at least 12.5% of weight were subsequently placed on the same weight maintenance 
diet. After 144 weeks, there was no difference between the two groups in weight 
regain: both groups regained around 70% of their lost weight. The study of Vink et 
al. (22) showed similar results, comparing a 5-week VLCD (rapid weight loss) with a 
12-week low-calorie diet (LCD, slow weight loss). Both groups experienced the same 
amount of weight loss and regain of weight during the following 9 months. In addition, 
no difference in food cravings was reported in an RCT comparing a 20-week LCD with a 
20-week VLCD. These findings do not support the common belief that restricting intake of 
certain foods leads to increased craving for these foods, or that the magnitude of weight 
loss is related to food cravings (52).
In conclusion, we and others have shown that VLCDs are effective in producing weight 
loss in overweight individuals with T2D. Secondly, weight regain following a short term 
VLCD is similar to that following a (more traditional) LCD.
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effect diet-induced weight loss on cardiovascular disease risk 
factors
What was already known on the effect of weight loss dieting on 
cardiovascular disease risk factors?
– In obese adults with type 2 diabetes, diet-induced weight loss results in im-
proved classical cardiovascular disease risk factors, as well as in improved 
biomarkers for endothelial dysfunction and inflammation.
What knowledge is added by this thesis?
– The diet-induced improvements in biomarkers for endothelial dysfunction and 
inflammation was independent of cardioprotective medication and the duration 
of type 2 diabetes.
– Diet-induced weight loss decreased the new cardiovascular disease risk factor 
sLR11, and this reduction was associated with improvements in lipid profile and 
the glycemic state.
– Another emerging cardiovascular risk factor Lp(a) increased during short term 
weight loss via diet in obese adults with and without type 2 diabetes, while it 
was unaffected by weight loss via bariatric surgery.
– After 2 years of follow-up, this effect on Lp(a) had waned off.
In chapter 3, we showed that besides a favorable effect on weight, our VLCD interven-
tion also led to significant improvements in glycemic control and lipid profile, and a 
large decrease in the need for insulin, which is in concordance with previous studies in 
individuals with T2D (53). We additionally showed that after 4 months of weight loss 
dieting, markers of endothelial dysfunction and inflammation were significantly lower 
than before start of the diet, which is in line with previous studies as well (54-57). These 
markers have been associated with vascular complications and mortality in individuals 
with T2D, suggesting that weight loss dieting has attenuated their risk of developing 
cardiovascular disease (58-63). Until now it was unknown whether diet-induced weight 
loss still has an effect on vascular function in T2D adults, who are on (maximum) car-
dioprotective medical treatment, and whether recently diagnosed patients benefit more 
compared to patients with a long history of T2D. It is possible that in a late stage of 
disease many pathological changes to the vasculature have become irreversible (64). 
Here, we added to the existing evidence by showing that the positive effects of weight 
loss dieting were not influenced by the use of cardioprotective drugs, nor by the duration 
of T2D. This findings suggests that individuals on intensive medical treatment or with a 
long history of T2D still benefit from a weight loss intervention similar to newly diagnosed 
patients. A limitation of these findings is that biomarkers were measured after only 4 
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months of dieting. After 2 years of follow-up, measurement of the biomarkers could have 
been repeated in a non-random subset of participants only, because participants who 
lost <5% of their weight after the first diet phase were excluded from further participation. 
Therefore, we do not have long-term data. Another limitation is our use of surrogate 
markers of endothelial dysfunction and inflammation to study CVD risk. The extent of 
the short-term reduction in the biomarkers, such as hs-CRP and sICAM-1, that we found 
is in line with previous observations (54-56). In two studies, this diet-induced reduction 
in CRP and sICAM-1 was accompanied by a significant improvement in flow-mediated 
dilatation, a functional test for endothelial dysfunction (55, 65). This indicates that the 
reduction we found in markers of endothelial dysfunction and inflammation may be 
clinically relevant to our participants.
Furthermore, we showed for the first time that VLCD-induced weight loss led to a 
decrease in soluble LDL receptor relative sLR11, which is a novel CVD risk factor in 
overweight and obese adults with T2D (chapter 4). This decrease was associated with 
a simultaneous improvement in lipid profile (non-HDL cholesterol) and glycemic control 
(HbA1c). High sLR11 levels have been associated with vascular complications in adults 
with type 2 diabetes (66-68). Whether the decrease in sLR11 we found leads to less 
diabetic complications still needs to be investigated.
In contrast to the diet-induced improvements of various cardiovascular risk factors we 
found that Lp(a), an independent risk factor for cardiovascular disease in T2D (69-74), in-
creased with diet-induced weight loss (chapter 5). The Lp(a) levels increased significantly 
after 4 months of weight loss dieting in 3 independent cohorts of overweight individuals 
with and without T2D. This increase in Lp(a) could potentially reduce the positive effects 
of weight loss dieting on CVD risk. In a subset of our overweight T2D participants, we 
observed that the Lp(a) levels returned almost to baseline values 2 years after the diet 
intervention, suggesting that the initial increase in Lp(a) upon diet was an acute effect that 
waned off after a longer period of a normal diet. The long-term change in Lp(a) was not 
associated with weight loss or regain during follow-up, implying that other factors associ-
ated with the diet have been of influence. It has been shown previously that in healthy 
subjects, the dietary fat content affected the Lp(a) levels: diets high in total and saturated 
fat lowered Lp(a) levels, while diets high in unsaturated fatty acids increased Lp(a) levels 
(75-77). The VLCD we used in our trial was low in total fat content (33 gram/day) and 
relatively high in unsaturated fatty acids with 17 grams/day. Low-fat diets may increase 
Lp(a) levels via an altered metabolism of Lp(a) particles. However, more studies are 
needed to clarify this mechanism Hypothetically, a diet low in carbohydrates and high 
in fat could lead to a lowering of Lp(a) levels, while still producing weight loss and the 
accompanied benefits on CVD risk. This should be investigated in future clinical trials in 
overweight individuals with and without T2D. The effect of Lp(a) on CVD has only been 
studied in observational designs and via Mendelian randomisation (78). Evidence from 
153
General Discussion
genetic studies support a causal relation between Lp(a) and CVD (79, 80), however, 
evidence from randomised controlled trials is currently lacking. Hence, clinical studies 
addressing the effect of Lp(a) change (upon diet) on hard clinical endpoints are needed. 
Recently, new Lp(a) lowering drugs became available. A pooled analysis of individual 
participant data taken from PCSK9 inhibitor trials has shown that both alirocumab and 
evolocumab could lead to a reduction of Lp(a) by up to 25–30% (81). Additionally, 
antisense oligonucleotides targeting apolipoprotein(a) might be promising as inhibitors of 
Lp(a) synthesis (82). Long-term follow-up studies are required to establish whether adding 
an Lp(a)-lowering agent to a dietary intervention will improve long-term CVD outcome in 
obese individuals with and without type 2 diabetes.
In summary, short term effects of weight loss dieting are quite positive with regard to 
improving classical CVD risk factors, sLR11 and markers of endothelial dysfunction and 
inflammation, with the possible exception of the short-term increase in Lp(a). Future studies 
are needed to establish the long-term effect of weight loss dieting on these biomarkers 
and their associations with cardiovascular end points, in order to show clinical relevance. 
Moreover, future studies should focus on elucidating the underlying mechanisms.
Predicting short term weight loss
What was already known on predicting weight loss?
– Many predictors of weight loss have been identified for obese adults without 
type 2 diabetes, but these predictors have not been studied in individuals with 
type 2 diabetes, and diabetes-specific variables have not been included in 
previous research in this field.
What knowledge is added by this thesis?
– Successful short term diet-induced weight loss was predicted by the baseline 
variables fasting glucose, insulin dose, waist-to-hip ratio, anxiety and numb 
feeling in extremities (related to neuropathy).
– 3 out of these 5 predictors are diabetes-related, suggesting that considering 
diabetes specific characteristics is of importance in achieving successful weight 
loss in type 2 diabetes.
An alternative approach to the problem of weight regain is focusing on (pre-treatment) 
predictors of weight loss success. Personalized medicine is the ultimate goal for the treat-
ment of obesity. Ideally clinicians should have a screening tool to select individuals for 
an intervention based on simple measurable baseline variables, in order to offer the best 
and most cost-effective treatment to their patients with obesity and T2D. Another option 
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is to screen and evaluate the treatment response of individuals after a certain amount of 
time, to be able to direct them to alternative approaches when indicated.
In our POWER trial, the effect of a VLCD on weight showed a marked variability: the 
initial weight change during the 8-week phase-in diet ranged from -21.3% to +1.0%. 
In participants who initially achieved 5% weight loss, weight change at 2 years of 
follow-up varied even more: from -28.3% to +11.5%. Apparently, there are responders 
and non-responders as well as sustainers and non-sustainers (23). Also in literature this 
large heterogeneity in weight loss successes has been described (9). Since fairly all re-
search in predicting weight loss has been carried out in obese persons without T2D, we 
developed a prediction model for short-term weight loss in persons with T2D. In chapter 
2, we showed that successful short term VLCD-induced weight loss was predicted by the 
baseline variables fasting glucose, insulin dose, waist-to-hip ratio, anxiety and numb feel-
ing in extremities (related to neuropathy). Interestingly, 3 out of those 5 predictors were 
diabetes related. The predictors previously identified in obese adults without diabetes 
were not associated with weight loss in our T2D group. This suggests that the diabetes 
status is of importance in the ability of achieving weight loss. Whether these predictors 
are specific for VLCD-induced weight loss or represent predictors of weight loss induced 
by any type of diet is unknown. Theoretically, the predictors we found are able to predict 
short-term weight loss for any diet with a large enough energy deficit in obese T2D 
patients, however, more studies are needed to prove this.
In our study, only 25% of the variance in short-term weight loss was explained by our 
model, which is comparable to previous research in the field of obesity (83). Apparently, 
the most important factors that explain the variance of weight loss are unknown. Many 
different factors contribute to weight loss success, each accounting only for a small pro-
portion of the variance. Previous studies in the field of obesity reported obviously positive 
predictors of weight loss, like initial body weight, male gender, resting metabolic rate, 
self-efficacy, initial/early weight loss, social support, self-monitoring, physical activity, 
etc. (83). The main difficulty to predict success of weight loss strategies is heterogeneity 
of the treatments for weight control, the populations studied, and of the predicting vari-
ables. Another problem is that certain predictors (such as weight and coping strategies) 
change over time and can be pre-treatment predictors but also process predictors.
A common problem in prediction research is that underpowered studies generate false 
negatives (Type II error). On the other hand, tests that have many predictors and set the 
significance cut-off at the usual 5% may generate large series of false positive predic-
tors (Type I errors). It has been shown that a minimum of 2 subjects per variable are 
required in order to adequately estimate the regression coefficients of the model (84). 
With approximately 10 subjects per variable, we have reduced the chance of overfitting 
the model. Additionally, we used statistical techniques (bootstrapping) to improve the 
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precision of our results. However, replication in another independent cohort is clearly 
necessary to further substantiate our findings.
Predicting long term weight loss
Predictors of short-term weight loss and weight loss maintenance may be different. Again, 
most work in this field has been done in the obese population without T2D (39, 85-88).
In our POWER trial, 61 of the 158 participants (39%) maintained a weight loss of 
5% or more, while 28 participants (18%) maintained a weight loss of 10% or more 
for 2 years. This result is biased by the design of our long-term follow-up trial, since 
we only included participants with an initial weight loss of at least 5%. Nonetheless, 
this percentage of successful long term weight loss is consistent with previous research 
in obese adults with and without T2D (89). In a post-hoc analysis, we found that age 
and sex were predictors of weight loss after 2 years of follow-up compared to baseline 
(r=-0.306, p<0.001 and r=0.237, p=0.007): older, male participants achieved more 
weight loss. We also found that initial weight loss (after 8 weeks of VLCD) was strongly 
associated with long term weight loss (r=0.453, p<0.001). In a multivariate regres-
sion analysis, only initial weight loss remained associated with long-term weight loss 
(β=0.324, p=0.023), which is consistent with literature (88, 90). In the Look AHEAD 
trial with persons having T2D, age was a predictor of weight loss at 8 years of follow-up 
after an intensive lifestyle intervention: the oldest participants (65-76 years) lost more 
weight than the younger individuals (89). In line with our trial, big initial weight loss 
was a predictor of long-term weight loss in the Look AHEAD trial (90). Interestingly, 
participants with a high initial weight loss but full regain of weight during follow-up, still 
had better HbA1c values after 4 years than those with less or no initial weight loss. The 
authors suggest a positive legacy effect of having achieved a larger initial weight loss, 
even if it is (partially) regained, and conclude that a large initial weight loss should be 
encouraged in adults with T2D (90).
Using the long-term data of the POWER trial, I have developed a prediction model for 
2-year weight loss success (defined as ≥3% of bodyweight). In previous research, cut-off 
values of 3% and 5% long term weight loss have been used to discriminate between 
responders and non-responders (23, 91, 92). In this prediction model, successful long 
term weight loss was predicted by initial (short term) weight loss, initial reduction in insulin 
need, age and presence of eye problems (0.78 (95%CI 0.69-0.87) post-test likelihood 
of predicting successful long term weight loss). Ideally, the combination of our prediction 
model for short-term (initial) weight loss should be combined with this model for long-term 
weight loss and tested prospectively on the prediction of long-term weight maintenance 
after diet in overweight and obese persons with T2D.
Future research should focus on identifying pre-treatment, in-treatment and process-
predictors of weight loss and maintenance in adults with T2D, since virtually all research 
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has been done with non-diabetic persons with obesity. Moreover, research programs 
should be developed to reach the goal of matching treatments to the individuals’ needs to 
improve success at weight loss maintenance instead of a ‘one size fits all’ approach. We 
also need to recognize that people may need different things at different points in their 
treatment cycle. What might help them in the weight loss phase may be quite different 
from what is helpful in the maintenance phase (83, 93).
cLinicaL iMPLicaTions
My results indicate that there is no scientific justification to offer overweight and obese 
adults with T2D CBGT, as performed in my studies, on top of usual care in order to 
optimize the effect of weight loss dieting. Although CBGT can have positive effects 
on depressive symptoms and eating disorders in individuals with T2D (94-96), at this 
moment clinicians should not offer this expensive treatment to their T2D patients for 
weight loss maintenance. Future studies should focus on the possibility that certain T2D 
subgroups could benefit from CBGT or a modified CBGT for weight loss maintenance. 
Despite weight regain, the diet intervention used in our trial was quite successful: almost 
40% of the participants initially lost 5% or more of their bodyweight and maintained this 
weight loss for 2 years. Moreover, the waist circumference, need of insulin, depression 
score and fatigue score was on average lower at 2 years compared to baseline. For this 
reason, I started an implementation project with the help of the Dutch Diabetes Research 
Foundation, to implement the study diet intervention into the usual care of the diabetes 
team of the Erasmus Medical Center (POWER 2.0). We found that the POWER 2.0 
program was effective in reducing weight, improving glycemic control and reducing the 
need of insulin in 77 overweight and obese adults with T2D, after 1 year of follow-up. In 
figure 2, the effect of the POWER 2.0 program is shown on weight, HbA1c, and insulin 
dose. These results are comparable to the effects of the POWER trial. Moreover, the 
program was successfully integrated in the usual care of the diabetes team of the Erasmus 
MC. Subsequently, we conducted a pilot study to determine the effect and feasibility 
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figure 3. Results of the POWER 2.0 implementation trial
Shown are means with 95% confidence interval.
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of implementing the diet intervention in a primary care setting (‘Huisartsen Onder Een 
Dak’ (HOED), Overschie). In this explorative pilot study in 10 participants, we found 
that the POWER 2.0 program was effective in reducing weight and can be successfully 
implemented in the primary setting as well. A second group of participants already 
started with the program, showing the intention of HOED Overschie to incorporate this 
treatment option into their usual diabetes care.
To further improve the long term effectiveness of weight loss dieting in overweight and 
obese adults with T2D, it is important to acknowledge that weight loss maintenance 
is influenced by many factors, like diet and exercise behavior, psychological factors, 
culture, environment, biological adaptions to weight loss, etc. Targeting to change only 
one factor (behavior) like we did in our trial appears to be insufficient. Perhaps different 
strategies must be combined to combat all the drivers behind weight regain, and prefer-
ably studied in pragmatic clinical trials in the future.
stop the rise in obesity and type 2 diabetes: prevention
In this thesis, I studied the effect of diet and CBGT in a group of people with obesity and 
T2D. Worldwide, this group is steadily growing. From the Rotterdam Study we learned 
that nowadays 1 out of 3 adults aged 45 years will develop T2D. Moreover, having a 
higher BMI has been shown to increase this lifetime risk even more (97). Needless to say 
that this puts a heavy burden on our future healthcare system. One of the most important 
reasons for the obesity and obesity-related T2D pandemic is the present-day obesogenic 
environment, making it extremely difficult to choose for and maintain a healthy lifestyle. 
Obviously, people bear individual responsibility for their health, but environmental factors 
can encourage or undermine the ability of people to act in their own self-interest. Obesity 
has been called the “Cholera of the 21st century” (Tom Farley, 2001). The cholera 
epidemic was successfully combatted 150 years ago by environmental changes. In the 
same way, we have to fight the obesity epidemic via broad environmental modifications 
(98). Additionally, it is of great importance to educate people about nutrition, starting 
with our children. During their school career, primary school children only receive 7-8 
hours of nutrition education. To create a generation with a positive mind set and sufficient 
knowledge on healthy lifestyle, we need to offer our children more and better ‘lifestyle’ 
education. Fortunately, the Dutch government has recently taken action on improving 
nutrition education and I have recently co-authored a book about healthy food for chil-
dren (99). Hopefully, with these initiatives we can halt the rise in (childhood) obesity and 
obesity-related T2D in the near future.
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concLusion
With the research presented in this thesis I showed that a short term very low-calorie 
diet has sustainable effects on weight, insulin need and psychological wellbeing in 
persons with obesity-related T2D, although regain of weight occurred in the majority 
of people. To solve this problem of weight regain, a psychological intervention like 
cognitive behavioral group therapy is not sufficient. Now, we face the challenge of 
inventing new strategies, hypothetically combining dietary-, drug-, behavioral- and 
environmental interventions, to improve the long term effectiveness of weight loss 
dieting. With the ultimate goal of curing obesity-related T2D and preventing its 
complications in the near future.
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Summary
suMMary
Over the past decades, both the prevalence of obesity and type 2 diabetes (T2D) 
have been increasing dramatically, with devastating consequences for the health related 
quality of life of the affected individuals and for society. Overweight and obesity increase 
cardiovascular morbidity and mortality in patients with T2D. Weight loss improves sev-
eral cardiovascular disease risk factors and is therefore a cornerstone in the treatment 
of obesity related T2D. However, the effect of weight loss dieting is highly variable 
between individuals and subsequent weight regain is a substantial problem in the dietary 
treatment of obese adults with or without T2D.
A prediction model of weight loss may assist in selecting those individuals that would 
respond best to a weight loss diet, hereby improving cost-effectiveness of the treatment 
and preventing patient distress upon failure. In Chapter 2, we examined which physi-
ological and psychological variables predict weight loss induced by a short-term very 
low-calorie diet (VLCD). In 192 overweight or obese adults with T2D, who underwent 
an eight-week VLCD, we found that successful weight loss (i.e. ≥5%) was predicted fairly 
well by five baseline parameters, which were predominantly diabetes related. These 
data enabled us to develop a prediction model of diet-induced weight loss in T2D. 
I propose to test this prediction model in future prospective diet intervention studies in 
patients with T2D.
When obese persons with T2D lose weight, several conventional cardiovascular 
disease risk factors, like hyperlipidemia and hyperglycemia, improve dramatically. In 
chapter 3, I showed that diet-induced weight loss also led to a reduction in biomarkers of 
endothelial dysfunction and inflammation within four months of dieting. This positive effect 
was independent of medication frequently prescribed to T2D patients, such as statins, 
ACE inhibitors and metformin, and also independent of T2D history. The conclusion is 
that even on intensive medical drug treatment as well as after a long history of T2D, 
vascular health of these patients may still benefit from diet-induced weight reduction.
New candidate biomarkers for cardiovascular disease risk have recently emerged, 
such as increased plasma levels of soluble low density lipoprotein receptor-relative with 
11 ligand-binding repeats (sLR11) and lipoprotein(a) [Lp(a)]. In the research reported 
in chapter 4, we determined the effect of diet-induced weight loss on plasma sLR11 
levels in overweight and obese individuals with T2D. Weight loss dieting resulted in a 
reduction in plasma sLR11 levels that was associated with improvements in lipid profile 
and the glycemic state. In chapter 5, I examined the effect of weight loss via diet and 
bariatric surgery on lipoprotein(a) [Lp(a)] levels in overweight and obese individuals 
with and without T2D. In three independent cohorts of overweight and obese subjects 
with or without T2D, weight loss upon four months of dieting was accompanied by an 
increase in Lp(a) levels, while conventional cardiovascular disease risk factors improved. 
170
Appendix
This increase in Lp(a) levels may potentially antagonize the beneficial cardio-metabolic 
effects of diet-induced weight reduction. This increase in Lp(a) after weight loss was 
not observed upon bariatric surgery-induced weight loss. In a subset of the participants 
with T2D, the Lp(a) levels had returned almost to baseline levels two years after the diet 
intervention, suggesting that the initial increase in Lp(a) upon diet was an acute effect that 
waned off after a longer period of a normal diet.
Weight regain after successful weight loss dieting is a universal problem, also for 
patients with T2D. This may well lead to loss of the potential benefits on cardiovascu-
lar disease risk achieved by short-term weight loss. In obese individuals without T2D, 
cognitive behavioral group therapy (CBGT) has been shown effective in weight loss 
maintenance. Therefore, I hypothesized that CBGT would prevent weight regain after 
diet-induced weight loss in obese individuals with T2D. To test this, we performed the 
Prevention Of Weight Regain (POWER) trial, a single center, parallel-group, randomized 
controlled trial (chapter 6). The results of this trial are reported in chapter 7. Contrary to 
my expectations, CBGT after VLCD-induced weight loss did not prevent weight regain 
when given on top of usual care during 2 years of follow-up. Moreover, CBGT had no 
effect on cardiovascular disease risk factors and psychological wellbeing compared to 
usual care exclusively. Two years after finishing the VLCD, participants still had a better 
diabetes control than before, illustrated by a reduced need for insulin. However, this 
proved to be true for both the CBGT and the control group. Our results indicate that there 
is no scientific justification to offer CBGT on top of the usual care, provided in a tertiary 
referral center, to obese patients with T2D for weight loss maintenance after dieting.
In chapter 8, we reviewed our findings in a broader perspective and elaborated on 
the methodological aspects and potential clinical implications. Since CBGT did not solve 
the problem of weight regain after successful weight loss, we discussed other strategies 
to improve the effect of weight loss dieting and maintenance in T2D. Additionally we 
discussed the use of prediction models for short-term weight loss as well as for weight loss 
maintenance, to select those individuals that will benefit most of a diet intervention. In this 
chapter, I also described the implementation in our usual care of the very low-calorie diet 
intervention used in the POWER trial. I found that the POWER 2.0 program was effective 
in reducing weight, improving glycemic control and reducing the need of insulin in 77 
overweight and obese adults with T2D, after 1 year of follow-up. Moreover, the POWER 
2.0 program was successfully implemented in a primary care setting in a small pilot study 
and shown effective in reducing weight. Finally, I discuss directions for future research to 
identify pre-treatment and in-process predictors of weight loss and maintenance, and on 
new strategies for long term weight loss maintenance in obese patients with T2D.
To conclude, with the research presented in my thesis, I showed that a short term VLCD 
has sustainable effects on weight and diabetes control in persons with obesity-related 
T2D, although regain of weight occurred in the majority of people. To solve this problem 
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of weight regain, a psychological intervention like CBGT appeared not effective. Now, 
we face the challenge of designing new strategies to improve the long term effectiveness 
of weight loss dieting, with the ultimate goal of reversing obesity-related T2D and prevent 
its complications.
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Samenvatting
saMenvaTTinG
Het aantal mensen met obesitas en type 2 diabetes (T2D) is de afgelopen decennia sterk 
toegenomen. Dit heeft negatieve gevolgen voor zowel het individu als voor onze maat-
schappij. Mensen met T2D die overgewicht of obesitas hebben, overlijden eerder aan 
cardiovasculaire ziekten in vergelijking met mensen die een gezond gewicht hebben. 
Gewichtsverlies leidt tot verbetering van het cardiovasculaire risico profiel en is daarom 
een belangrijk onderdeel van de behandeling van mensen met aan obesitas-gerelateerde 
T2D. Helaas verschilt het effect van een energiebeperkt dieet op het gewicht sterk tussen 
individuen. Bovendien neemt het gewicht vaak snel weer toe na een aanvankelijk suc-
cesvolle dieetbehandeling: het zogenoemde ‘jojo-effect’.
Idealiter zouden zorgverleners vooraf mensen willen selecteren met de grootste kans 
om succesvol af te vallen. Hiermee zou namelijk de kosteneffectiviteit van de dieet-
behandeling vergroot kunnen worden én zou de patiënt de negatieve gevoelens, die 
gepaard gaan met falen van het dieet, bespaard blijven. In hoofdstuk 2 hebben wij 
onderzocht welke fysiologische en psychologische variabelen voorspellend zijn voor 
succesvol gewichtsverlies (≥5 %) bij mensen met obesitas en T2D. Bij 192 mensen 
die gedurende acht weken een zeer laag calorisch dieet (very low-calorie diet, VLCD) 
volgden, werd succesvol gewichtsverlies redelijk goed voorspeld door vijf variabelen, 
die voornamelijk gerelateerd zijn aan diabetes. Met deze gegevens hebben wij een 
predictiemodel ontwikkeld. Dit predictiemodel zou in toekomstige prospectieve dieet 
interventie studies verder uitgetest moeten worden bij mensen met T2D.
Gewichtsverlies leidt bij mensen met obesitas en T2D tot verbetering van conventionele 
cardiovasculaire risico factoren, zoals hyperlipidemie en hyperglycemie. In hoofdstuk 3 
hebben wij laten zien dat een gewichtsreducerend dieet gedurende vier maanden ook 
leidt tot verlaging van biomarkers voor endothele dysfunctie (schade aan de vaatwand) 
en systemische inflammatie (ontsteking). Dit positieve effect was onafhankelijk van het 
gebruik van cardioprotectieve medicatie, zoals statines, ACE inhibitoren en metformine. 
Ook was dit effect onafhankelijk van hoe lang mensen al T2D hadden. Onze conclusie 
is dat de gezondheid van de vaten van obese mensen met T2D verbetert door gewichts-
reductie, ook al gebruiken zij daarvoor al medicatie en hebben zij al vele jaren T2D.
Verhoogde plasmaconcentraties van ‘soluble low density lipoprotein receptor-relative 
with 11 ligand-binding repeats’ (sLR11) en lipoproteine(a) [Lp(a)] zijn recentelijk geïden-
tificeerd als onafhankelijke biomarkers voor het cardiovasculair risico. In het onderzoek 
dat beschreven wordt in hoofdstuk 4 hebben wij het effect onderzocht van gewichtsver-
lies door dieet op de hoeveelheid sLR11 in het bloed bij mensen met obesitas en T2D. 
Het gewichtsreducerende dieet leidde tot verlaging van sLR11. De mate waarmee sLR11 
verminderde was geassocieerd met verbeteringen van het lipiden profiel en de diabetes 
regulatie. Het gunstige effect van het dieet werkt dus deels via verlaging van het sLR11.
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In het onderzoek gepresenteerd in Hoofdstuk 5 is het effect van gewichtsverlies op 
de hoeveelheid Lp(a) in het bloed bestudeerd bij obese mensen met en zonder T2D. In 
drie onafhankelijke onderzoeksgroepen resulteerde een gewichtsreducerend dieet in een 
onverwachte stijging van Lp(a), terwijl de klassieke cardiovasculaire risicofactoren juist 
verbeterden. Deze stijging in het Lp(a) niveau zou potentieel het gunstige cardio-metabole 
effect van een gewichtsreducerend dieet kunnen verminderen. Bij mensen die gewicht 
verloren door middel van bariatrische chirurgie werd geen Lp(a) stijging waargenomen. 
In een subgroep van mensen met T2D heb ik het Lp(a) niveau ook twee jaar na het dieet 
kunnen meten: toen was de Lp(a) spiegel weer vrijwel gelijk aan het niveau van vóór 
het dieet. Dit suggereert dat de Lp(a) stijging een acute reactie is op het dieet, die weer 
verdwijnt gedurende een periode met normale voeding.
Weer zwaarder worden na succesvol afvallen is een universeel probleem, ook 
voor mensen met T2D. Hierdoor worden potentiele voordelen van gewichtsverlies op 
de lange termijn teniet gedaan. Uit studies bij mensen met obesitas, zonder T2D, is 
gebleken dat cognitieve groeps-gedragstherapie (‘cognitive behavioral group therapy’, 
CBGT) effectief is in het bereiken en behouden van gewichtsverlies. Mijn hypothese was 
dat CBGT ook bij obese mensen met T2D terugval in gewicht na succesvol gewichts-
verlies kan voorkómen. Om deze hypothese te testen heb ik de ‘Prevention Of Weight 
Regain (POWER) trial’ opgezet: een gerandomiseerde, gecontroleerde studie met paral-
lelle groepen, uitgevoerd in één onderzoekscentrum (hoofdstuk 6). De resultaten van 
dit onderzoek zijn beschreven in hoofdstuk 7. Anders dan verwacht, voegde CBGT 
niets toe aan de gebruikelijke behandeling om de terugval in gewicht na een VLCD te 
voorkomen. Ook vonden wij geen extra effect van CBGT op risicofactoren voor hart- en 
vaatziekten of psychisch welbevinden bovenop dat van de gebruikelijke zorg. Twee 
jaar na het VLCD hadden de deelnemers in zowel de CBGT als de controle groep nog 
steeds minder insuline nodig en hadden zij minder last van depressieve gevoelens en 
vermoeidheid. Ik concludeer daarom dat er wetenschappelijk gezien geen reden is 
obese mensen met T2D voor behoud van hun gewichtsverlies CBGT aan te bieden, 
bovenop de gebruikelijke derdelijnszorg.
In hoofdstuk 8 bediscussieer ik mijn bevindingen en plaats deze in een breder perspec-
tief. Daarnaast ga ik in op methodologische aspecten van de in dit proefschrift beschre-
ven studies en van soortgelijke studies, en bespreek ik potentiele klinische implicaties. 
Aangezien CBGT het probleem van terugval in gewicht niet heeft opgelost, zijn duidelijk 
andere strategieën nodig om het langetermijneffect van gewichtreducerende diëten 
verbeteren. Daarnaast wordt het gebruik van predictiemodellen voor gewichtsverlies en 
gewichtsbehoud besproken. Verder beschrijf ik in dit hoofdstuk dat implementatie van 
het VLCD dieetprogramma (POWER 2.0) als onderdeel van de behandeling door het 
diabetesteam van het Erasmus MC, vergelijkbare gunstige effecten heeft als in onze 
klinische studie. Ook hebben we in een pilotstudie het POWER 2.0 dieetprogramma 
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in de eerstelijnszorg geïmplementeerd, met goed effect op gewicht. Tot slot bespreek 
ik welke richting toekomstig onderzoek op zou moeten gaan met betrekking tot het 
identificeren van voorspellers van gewichtsverlies en het behoud daarvan, en het ontwik-
kelen van nieuwe strategieën voor het behoud van gewichtsverlies op de lange termijn 
voor mensen met obesitas en T2D.
Concluderend blijkt uit het in mijn proefschrift gepresenteerde onderzoek, dat een kort 
durend ‘very low-calorie diet’ blijvend gunstige effecten heeft op gewicht en insuline 
behoefte bij mensen met obesitas en T2D, alhoewel bij het merendeel van de mensen 
het gewicht weer toenam. Met een cognitieve groepstherapie gericht op gedragsveran-
dering wordt de terugval in gewicht niet voorkomen. Er zullen dus nieuwe strategieën 
ontwikkeld moeten worden om het lange termijn effect van gewichtsreducerende diëten 
te verbeteren. Het ultieme doel is om daarmee de diabetes controle bij obesitas-gerela-
teerde T2D te verbeteren en complicaties te voorkomen of te verminderen.
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summary of PhD training and teaching activities
Name: Kirsten A.C. Berk
Erasmus MC Department: Internal Medicine
Research School: COEUR
PhD period: 2010 – 2017
Promotor(s): Prof.dr. E.J.G. Sijbrands and Prof.dr. J.J. van Busschbach
Supervisor(s): dr. A.J.M. Verhoeven and dr. M.T. Mulder
1. PhD training
 year Workload
(hours/ecTs)
General academic skills   
-  Biomedical English Writing and Communication 2012 4
-  Research Integrity 2012 1
-  BROK course + recertification 2012 + 2016 1.5
research skills   
-  Principles of Research in medicine and Epidemiology 2008 0.7
-  Introduction to Public Health 2008 0.7
-  Methods of clinical research 2010 0.7
-  Clinical trials 2010 0.7
-  Courses for the quantitative researcher 2010 1.4
-  Biostatistics for clinicians 2012 1.0
-  Regression analyses for clinicians 2012 1.9
-  Repeated measurements in clinical studies 2012 1.9
-  Quality of life measurements 2012 0.9
in-depth courses (e.g. research school, Medical Training)   
-  Seminar: glucose metabolism and vascular disease (prof dr E. 
Sijbrands)
2012 0.4
-  Coeur lecture: HDL’s Protein Cargo: Friend or Foe in 
Cardioprotection? (prof dr J.W. Heijnecke)
2013 0.1
-  Coeur seminar: gender differences in cardiovascular disease’ (prof J. 
Roos)
2013 0.4
-  Coeur debate: ‘cardiovascular controversies’ 2014 0.4
-  Coeur lecture: ‘Science update on tea and cardiovascular health’ (dr 
R. Draijer)
2015 0.1
Total ECTS courses:  17.8 ECTS
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 year Workload
(hours/ecTs)
oral presentations and chairmanship   
-  National Diabetes Day: ‘modedieten bij diabetes’ 2010 0.3
-  Diabetes and Nutrition Organization jubilee symposium, chair and 
organisation
2010 0.3
-  Researchmeeting Internal Medicine Antwerp (3x poster presentation, 
1x oral presentation)
2010,2014, 
2015,2016
1.2
-  Vascular Rounds: ‘diet as a cure for diabetes type 2’ 2011 0.3
-  NESPEN:‘cognitive behavioural therapy in DM2 and overweight’ 2011 0.3
-  National Insulin Congress: ‘VLCD bij insuline afhankelijke diabetes’ 2011 0.3
-  Annual Dutch Diabetes Research Meeting 2013: ‘effect VLCD 
induced weight loss on sLR11 levels in diabetes’
2013 0.3
-  Big 5 congress: ‘Gewichtsbeheersing in de praktijk’ 2013 0.3
-  Research meeting Antwerp: oral presentation ‘effect VLCD induced 
weight loss on sLR11 levels in diabetes’
2014 0.3
-  National Diabetes Day: ‘resultaten POWER-onderzoek’ 2014 0.3
-  Annual Dutch Diabetes Research Meeting 2014: ‘effect VLCD 
induced weight loss on endothelial markers and inflammation in T2D’
2014 0.3
-  Langerhans diabetes congress: ‘diabetesdiëtist anno 2015’ 2015 0.3
-  National diabetes congress: ‘goede voeding bij diabetes type 2’ 2015 0.3
-  Annual Dutch Diabetes Research Meeting 2015: ‘No effect of 
cognitive behavioral therapy on weight maintenance in T2D: results 
of the POWER-trial’
2015 0.3
-  Internal Medicine Research meeting: ‘Effect of weight loss via diet 
and bariatric surgery on Lp(a) levels’
2016 0.3
-  Annual Dutch Diabetes Research Meeting 2016: ‘Effect of weight 
loss on Lp(a) levels in obese subjects with and without T2D’
2016 0.3
-  ‘Voeding Nederland 2016’ congress: chair session ‘metabolomics in 
nutrition’
2016 0.3
-  ‘Studiedag diabetes voor diëtisten’: chair 2017 0.3
international conferences   
-  EASD Vienna 2009 1
-  ISA Amsterdam 2015 1
-  EASD Lissabon 2017 1
Total ECTS congresses and presentations:  9.3 ECTS
   
seminars and workshops   
-  PRISMA course VUMC 2009 0.8
-  Coeur PhD day (organisation) 2012-2014 0.9
-  PhD retreat: life after PhD 2012 0.8
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 year Workload
(hours/ecTs)
Didactic skills   
-  Teach the Teacher I (Desiderius school) 2014 0.8
-  Workshop ‘tentamen vragen maken’ (Desiderius school) 2014 0.2
-  Workshop ‘individuele begeleiding’ (Desiderius school) 2014 0.2
-  Workshop ‘omgaan met groepen’ (Desiderius school) 2014 0.2
-  Workshop ‘feedback geven’ (Desiderius school) 2014 0.2
-  University Teaching Qualification (portfolio) 2016 0.6
Total ECTS seminars and workshops  4.7 ECTS
   
2. Teaching activities
 year Workload 
(hours/ecTs)
Lecturing   
-  Ba1C1 ZO ‘behandeling en preventie van overgewicht en obesitas’ 2010 t/m 2017 2.1
-  Minor department of medical psychology week 9 ‘diabetes’ 2010 t/m 2015 1.5
-  Post HBO dietetiek ‘Voeding en diabetes’ HAN, 4 times per year 2013 t/m 2017 3.0
-  Post HBO POH ‘Diet in Chronic vascular risk management’ 2013, 2014 0.6
-  Keuzevak Ba3 ‘Effectieve bestanddelen van psychotherapie in het 
ziekenhuis’
2014, 2015 0.6
-  Education of AIO’s: ‘Voeding bij diabetes’ 2014 0.3
supervising Master’s theses   
-  Fabiana Kopra, master student psychology, university of Tilburg: 
‘non-compliance with cognitive behavioural therapy in patient with 
diabetes type 2 and overweight’ oct 2013-May 2014
2013 1
-  Thonke Oudshoorn, master student geneeskunde, university of 
Utrecht: ‘Effect of weight loss on endothelial function in overweight 
type 2 diabetic patients’ feb 2014-jun 2014
2014 0.6
-  Edith van der Kraan, bachelor student Voeding&dietetiek, HvA: 
‘evaluation of the implementation of a very low calorie diet in the 
usual care of patients with type 2 diabetes and overweight’ sept 
2015-feb 2016
2015 1
-  Supervising AIO (Mardin Licona) in research project: ‘the effect 
of monomeric and oligomeric flavanols in the dietary treatment of 
patients with diabetes type 2 and microalbuminuria’
2014 t/m 2017 1.2
Total ECTS teaching  11.9 ECTS
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 year Workload
(hours/ecTs)
other   
-  Chair Diabetes and Nutrition Organization – member NDF 2009 t/m 2012 600 hours
-  Member of PhD committee Coeur research school – organization 
Coeur day may 2013 + may 2014
2012 t/m 2014 1.2
-  Program committee ‘nationale diabetesdag 2014’ Nederlandse 
Diabetes federatie
2014 0.3
-  Wetenschapsdagen organization committee 2015-2017 0.9
-  Member NIV guideline committee:’richtlijn behandeling diabetes 
mellitus type 2’
2015-2017 0.9
Total ECTS other:  3.3 ECTS + 600 
hours
   
Total:   48.2 ECTS
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Kirsten Berk was born on the 7th of April 1981 in 
Aalsmeer, The Netherlands. She graduated cum 
laude from secondary school (Alkwin Kollege, Uit-
hoorn) in 1999. She then started studying Nutrition 
and Dietetics at the Amsterdam University of applied 
sciences (HvA), and graduated cum laude in 2003. 
From 2003 she worked as a registered dietitian 
at the department of Internal Medicine, Leiden 
University Medical Center, where she specialized in the field of nutrition and diabetes. 
From 2006 onwards she worked as a registered dietitian at the diabetes team of the 
department of Internal Medicine of the Erasmus Medical Center. From 2009 to 2012 
she was chairwoman of the Diabetes and Nutrition Organization (member of the Dutch 
Diabetes Federation), an organization of dietitians specialized in diabetes. In 2010 
she received a research grant of the Erasmus MC program ‘Zorgonderzoek’ and started 
working part-time on the research presented in this thesis (supervised by Prof.dr. Eric 
Sijbrands and Prof.dr. Jan van Busschbach); in the meantime she continued working 
as a dietitian in the diabetes team. In 2014 she obtained the Diabetes Research Foun-
dation grant ‘Innovatieonderzoek’, to study the implementation of the very low-calorie 
diet intervention into daily practice of the Erasmus MC. In the same year she received 
sponsorship for the FLAVA trial, aimed to study the effect of monomeric and oligomeric 
flavanols on microalbuminuria in patients with type 2 diabetes. She currently supervises 
the researcher appointed to this project. She was member of the PhD committee of the 
research school COEUR for three years, and in that capacity helped organizing the 
yearly Coeur Research Day. During her whole professional career, she was involved in 
teaching both health care professionals and students, and has been invited as a guest 
speaker for many national congresses in the field of nutrition and diabetes. In 2016 she 
obtained her University Basic Teaching Qualification at the Erasmus Desiderius school. 
From 2016 onwards she is member of the ‘Nederlandse Internisten Vereniging’ commit-
tee for the development of the clinical guideline for the glucose lowering treatment of 
patients with T2D. Moreover, she writes opinion papers and blogs for national nutrition 
platforms. In 2016, she co-authored a children’s book about healthy nutrition and lifestyle 
(www.boeketenstijd.nl). She also has an active family life: she is married and has two 
daughters. She will continue working as a dietitian at the diabetes team and start as a 
post doc researcher at the department of Internal Medicine, in the field of nutrition and 
diabetes.
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acknoWLeDGMenTs (DankWoorD)
Promoveren is als een onervaren kok een driesterren maaltijd bereiden voor de koningin, 
onder tijdsdruk uiteraard. Gaandeweg het koken krijg je er wat meer handigheid in en 
zowaar plezier, maar op sommige momenten heb je de neiging om je misbaksels de prul-
lenbak in te gooien... Het voordeel van een promotie traject boven een deelname aan 
Masterchef, is de enorme hoeveelheid hulp en steun die ik gehad heb van iedereen die 
erbij betrokken was. Graag voer ik u langs alle gangen van mijn ‘driesterren maaltijd’, 
onderwijl mijn dank uitsprekend aan een ieder die zijn of haar bijdrage heeft geleverd. 
voorgerecht 
Waarom ben ik hier aan begonnen? Zo’n 14 jaar geleden is mijn interesse in de 
wetenschap aangewakkerd door mijn toenmalige afstudeerbegeleiders Peter Weijs en 
Gerdien Melis, tijdens een onderzoeksstage op de intensive care van het VUMC. Toch 
nog 7 jaar later zat ik met een onderzoek idee aan tafel bij Aart Bootsma en Adriaan van 
‘t Spijker. Wat wilde ik met dit idee, wilde ik misschien promoveren? Ik beantwoordde 
positief, zonder enige voorkennis over wat een dergelijk traject zou inhouden. Aart en 
Adriaan, heel erg bedankt voor het geven van vertrouwen, en het planten van het idee 
dat ik ooit een onderzoeker zou kunnen worden. Wat volgde was het schrijven van 
een onderzoeksvoorstel, het aanschrijven van subsidieverstrekkers en het indienen van 
het protocol bij de medisch ethische commissie, zoveel werk voordat er ook maar 1 
metaforische hap gegeten kon worden…
Eric Sijbrands nam al snel de pollepel over van Aart, toen het diabetesteam onder zijn 
hoede kwam. Eric, je was co-promotor en promotor in één. Letterlijk, doordat je na je 
inauguratie het promotorschap overnam van Ernst Kuipers. Maar ook figuurlijk doordat 
je zowel de dagelijkse zorg als de eind verantwoordelijkheid van mijn onderzoekswerk 
op je nam. Daarnaast heb je, ook niet geheel onbelangrijk, zorg gedragen voor het 
ontwikkelen van mijn smaak op het gebied van Rotterdamse (Italiaanse) traiteurs. Eric, je 
bent een visionair die het grote geheel blijft zien. Je kon me op belangrijke momenten 
stimuleren door wat peper op bepaalde plaatsen te stoppen, maar ook door me te 
complimenteren als een tussengerecht redelijk te eten was. Het was een gouden greep 
om mij op een bepaald moment op het lab te planten, ver buiten mij comfort zone. 
Adrie Verhoeven en Monique Mulder hebben me er thuis laten voelen. Monique, ik 
heb bewondering voor de rust die je uitstraalt en je gave om allerlei dwarsverbanden 
te leggen. Ik heb daarvan geprofiteerd door te mogen samenwerken met binnenlandse 
en buitenlandse onderzoekers uit jouw netwerk. Een metafoor voor jouw manier van 
werken zijn de vele etentjes bij jou thuis aan de grote keukentafel, met een mengelmoes 
aan culturen en smaken. Adrie, jij was en bent mijn wetenschappelijke geweten. Niets 
‘quick and dirty’, jij hebt vrijwel ieder woord in dit proefschrift opgepakt, tegen het licht 
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gehouden en met de nodige droge humor van commentaar voorzien. Blijkbaar kun je als 
man van god toch een advocaat van de duivel zijn… Je bent een geboren educator en 
ik heb dan ook veel en graag van je geleerd: experimenteren met nieuwe ingrediënten 
waar ik nog nooit van had gehoord, creatief met hypotheses en samenhang. Achter 
dit team staat natuurlijk Edith Padberg, als een rots in de branding. Jij laat je, zoals 
je zelf zegt, niet zo gauw gek maken door alle dynamiek van de sectie vasculaire 
geneeskunde. Al met al een team waar menig sterren kok zijn vingers bij aflikt!
hoofdgerecht
De belangrijkste gang is uiteraard het daadwerkelijk uitvoeren van het onderzoek zelf. 
Het allerleukste aan dit onderzoek was voor mij het begeleiden en motiveren van de 
deelnemers. Aan iedereen die deel heeft genomen: heel erg bedankt voor uw hulp aan 
de wetenschap. Alle gezelligheid en waardering hebben me altijd goed gedaan! 
Natuurlijk kon het hoofdgerecht niet worden geserveerd zonder alle hulp en steun 
vanuit mijn eigen team: het diabetesteam. Ik ben trots op ons gezellige, multiculti team 
waarin de zorg voor onze patiënten altijd centraal staat! Mijn lieve dietetiek collega’s 
Maaike en Holger: jullie hebben mij altijd gesteund in mijn onderzoek ambities. Onze 
wandelingetjes in het park samen met Bo hebben me regelmatig geholpen om weer 
even te ‘aarden’. En bij de Starbucks hebben ze gelukkig niet alleen overgewaardeerde 
koffie, maar ook thee en koekjes! Bedankt alle diabetesverpleegkundigen (Bo, Elvia, 
Marianne, Zuzana, Jelena, Sofia, Anelida, Elly, Sijda, Liesbeth, Xiomara, Majorie) 
voor het beoordelen van al die duizenden bloedglucose dagcurves van mijn ‘POWER-
patiënten’ en voor jullie collegialiteit. Bedankt dames van de balie en de prikpost 
Inwendige Geneeskunde (o.a. Linda, Simone, Patricia, Eveline, Trudy, Marjolein, 
Sita, Ursula), voor het beantwoorden van alle vragen en het oplossen van problemen 
(alweer het labformulier vergeten??). Joy, heel erg bedankt voor het met zoveel passie 
en enthousiasme includeren van deelnemers, wie kan er nu nee zeggen tegen jou? 
Bedankt Behiye, Mandy, Jeanine, Annet en alle arts-assistenten, voor jullie betrokkenheid 
bij mijn onderzoek en het doorsturen van mogelijke deelnemers. Bedankt Elina (praktijk 
EetZo) en mensen van HOED Overschie, voor jullie tijd, energie en enthousiasme bij het 
uitvoeren en evalueren van de pilot studie. Bedankt Joke, Mieke en Arjen, voor jullie altijd 
oprechte belangstelling en het creëren van de randvoorwaarden om dit project te kunnen 
uitvoeren (en het geven van het laatste zetje). 
Lange tijd was de afdeling medische psychologie mijn tweede ‘keuken’, mede dankzij 
Adriaan. Adriaan, bedankt voor de tijd en energie die je in de begeleiding van ‘mijn’ 
patiënten hebt gestoken. In de flex-kamer van de afdeling medische psychologie, met 
steeds wisselend maar altijd interessant gezelschap, was het vaak een dolle boel. Ik heb 
goede herinneringen aan de afdelingsuitjes en het Sinterklaas-ruil-spel waarin iedereen 
ineens die foeilelijke theepot moest hebben… En dat alles onder bezielende leiding 
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van Jan Passchier en later Jan van Busschbach. ‘Tweede’ Jan, je bent wat later in mijn 
‘onderzoeksteam’ gestapt als mede-promotor, maar hebt altijd een glimlach op mijn 
gezicht gebracht met je relativerende breedsprakigheid. Je gevleugelde uitspraak; ‘het 
is af wanneer het af is’ heeft menig gestreste PhD student doen kalmeren, mijzelf incluis. 
Bedankt voor alle, soms bijna filosofische, gesprekken. En dan mijn paranimf Hanneke 
Buijks, in de loop van de jaren ben je naast een collega ook een lieve vriendin geworden, 
waar ik alles bij kwijt kon en kan. De combinatie van je talent om de menselijke geest te 
analyseren en je inlevingsvermogen en bevlogenheid maakt je een goede psycholoog, 
fijne vriendin en een prachtig mens! Een andere reden waardoor ik nog steeds vaak en 
graag naar het Na-gebouw loop zijn mijn afspraken met Reinier: ik heb zoveel geleerd 
van het samen met jou perfectioneren van syntaxen, als ware het recepten voor culinaire 
hoogstandjes. En Hetty, altijd vol energie en gezelligheid, bedankt dat ik gebruik mocht 
maken van jouw grote organisatietalent! Daarnaast wil ik alle studenten (o.a. Sara, 
Jolien, Eva, Thonke, Marloes, Willian, Albert, Edith) bedanken die zich belangeloos 
hebben ingezet voor mijn onderzoek.
Halverwege het koken van keuken switchen lijkt het recept voor een catastrofe, maar 
niets is minder waar:  toen ik verhuisde naar het lab van vasculaire geneeskunde voelde 
ik me meteen op mijn plek. Ik ben geen echte ‘labrat’ geworden (alleen bloed afdraaien 
telt niet echt mee natuurlijk), maar ben blij dat ik een klein steentje bij heb mogen dragen 
aan het goede werk van onder andere Leonie, Jeanette en Frank. Hier ook weer veel 
lol&lekker eten. Van moeders’ dolma’s (met omkeer-ritueel!) en zelfgebrouwen limoncello 
tot borrelen met een bijpassende taart bij het vieren van een artikel of posterprijs. And re-
member: no alcohol in the tiramisu! Bedankt promovendames: Reyhana, Mardin, Sandra 
en Roosmarijn, jullie hebben mijn PhD tijd gekruid met gezelligheid en soms gedeelde 
smart. En wie drinkt er nou champagne in Blijdorp?? Ik niet natuurlijk. Bedankt Anton, 
alleen al praten over wijn gaf ontspanning, en ik ben nog steeds van de omgekeerde 
smileys zoals je ziet (-;. Reyhana, fijn dat jij mijn andere paranimf wilde zijn! Je bent nu 
alweer bezig met een nieuw leven: een baan als huisarts in Nijmegen in verband met je 
opleiding, een kindje en een nieuw huis. Ook jij bent een echte vriendin geworden: ik 
mis nu al onze gezellige gesprekken over werk, kinderen, mode en natuurlijk eten. We 
hebben samen lekker gesleuteld aan artikelen, syntaxen en figuren (ok, soms werden we 
gillend gek), maar met een fantastisch eindresultaat, dat uiteraard gevierd werd op de 
enige goede manier: shoppen en eten!
To all my co-authors: it has been a privilege to work together with experts from within 
the Erasmus MC and from all around the world: Leiden, Zeist, Innsbruck, Vienna, Sakura. 
Special thanks to Wim Dik of the department of Immunology, Herman van Wietmarschen, 
Ruud Boessen and Linette Pellis of TNO Zeist, Hanno Pijl and Mirjam Lips of the Leiden 
University Medical Center, Hideaki Bujo and Meizi Jiang of the Toho University, Sakura 
Medical Center, Wolfgang Schneider of the Medical University of Vienna and Florian 
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Kronenberg and Gertraud Erhart of the Medical University of Innsbruck. Thank you so 
much for all your time, effort and knowledge! Together we conducted some very nice 
research, and I hope we will continue our collaboration.
En dan ligt daar het proefschrift, klaar om opgediend te worden. Een moment waarop 
lang is gewacht. Een goed moment om ook even aandacht te besteden aan het schilderij 
dat gebruikt is voor de cover. Het is gemaakt door Jasper, een kunstenaar van galerie 
de Brugspin in mijn woonplaats Ter Aar; een plek waar mensen met een verstandelijke 
beperking enorm mooie dingen maken. De kubistische voorstelling is een ‘remake’ van 
het werk ‘still life with almonds’ van Maurice de Vlaminck (1907). Met de toegevoegde 
insulinepen symboliseert het de continue aandacht die iemand met diabetes moet heb-
ben voor de afstemming tussen voeding en medicatie. Diabetes lijkt soms een ‘milde’ 
ziekte, maar de energie die het kost om de bloedglucose waarde iedere dag, bij iedere 
hap en stap, goed te reguleren moet niet onderschat worden. 
Bedankt ook leden van de leescommissie: Liesbeth van Rossum, je bent voor mij hét 
voorbeeld van een ‘powervrouw’, die bereikt wat ze wil bereiken. Je bent een voor-
vechter van het belang van voeding als onderdeel van de medische behandeling, wat 
mij natuurlijk nauw aan het hart ligt. Bedankt voor de fijne (en hopelijk ook toekomstige) 
samenwerking. Hanno Pijl, jij was de eerste internist die, toen ik in een grijs verleden in 
het LUMC werkte, mee wilde kijken met mijn spreekuur om te weten welk dieetadvies ik 
aan onze patiënten meegaf. Deze voedings-minded instelling ben je gelukkig nooit kwijt 
geraakt! Oscar Franco, you once inspired me with your personal story about how you 
became what you are today, and with your statement ‘always say yes and then learn to 
say no’. The latter I still need to practice… 
Toetje
Het lekkerste heb ik voor het laatst bewaard. Wie mij wat beter kent weet: hoe zoeter 
hoe beter... Lieve familie en vrienden, heel erg bedankt voor het meelezen, meeleven 
en soms lekker meezeuren. Petra, Monique, Maike en José, jullie zijn al heel lang mijn 
meest dierbare vriendinnen en ik ben blij dat ik zulke mooie mensen om me heen heb! 
Lieve papa en mama, voor jullie is het denk ik niet altijd makkelijk geweest om me te 
zien stressen over zaken waar jullie me niet mee konden helpen. Maar de sterke basis 
en de positieve instelling (het komt altijd weer goed, op welke manier dan ook) die jullie 
me hebben meegegeven, helpen me in alles wat ik doe. Mama, vroeger bij de triatlon 
wedstrijden stond je altijd als meest trouwe supporter aan de kant, vaak met appeltaart. 
Hoe de wedstrijd ook ging, dat maakte voor jou niet uit! Nu sporten we gezellig samen 
en sta je nog steeds altijd voor mij en ons klaar, vaak met appeltaart... (-; Bedankt voor 
het vertrouwen en de emmers liefde die je geeft. Papa, van jou heb ik mijn perfectionis-
tische aard en gedisciplineerdheid geërfd, wat soms een last is, maar ook zorgt dat we 
geen uitdagingen uit de weg gaan en dat heeft me wel gebracht waar ik nu ben. Van 
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jouw rustige diplomatie kan ik nog veel leren! Lieve Birgit, Sander en Jochen, jullie staan 
als mede-wetenschappers nog het dichtst bij mijn werk, maar er ver genoeg van af om er 
met frisse blik tegenaan te kunnen kijken en met brede interesse lekker te kunnen sparren. 
Bedankt voor het meedenken en het leveren van commentaar, soms op de achterkant van 
een kindertekening… Het grote aantal kleine Berkjes dat wij bij elkaar geproduceerd 
hebben biedt altijd voldoende positieve afleiding: voor mij geen mindfulness training, 
een gezellig familiefeestje en ik ben weer helemaal down to earth!
Lieve Frits, Liv, Wende en Tjes: wat een genot om na een dag hard werken thuis te 
komen bij mijn eigen lieverds. Om dan tijdens de (uiteraard gezonde, zelf gekookte) 
maaltijd weer met beide voeten op de grond gezet te worden door opmerkingen als: 
‘dat lust ik niet hoor, dat ziet er echt te vies uit om te eten!’ Jullie zorgden er voor dat ik 
altijd wist waar mijn prioriteit lag. Woensdagmiddag en het weekend is voor ons gezin 
en dan wordt er niet gewerkt! Een regel waar ik me toch (bijna) altijd aan heb kunnen 
houden…  Lieve Frits, bedankt voor je liefde en geduld, en gelukkig was er badminton… 
Als ik een voedingsmetafoor (wees gerust, bijna de laatste) zou moeten toepassen op 
jullie dan is dat: chocola, meer heb je niet nodig! Ik hoop dat we elkaar nog heel veel 
jaren gelukkig mogen maken, ik houd van jullie!
En nu is het klaar. Klaar om op te dienen. Aangezien menigeen direct doorbladert 
naar het dankwoord zou ik eenieder toch willen aansporen om hier en daar iets te 
proeven. Eet smakelijk! 
Kirsten, 2017

